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Abstract 
The effect of a 0,2 µm air venting in-line filter on the 
incidence of post-infusion phlebitis was studied in a 
prospective, controlled, observer-blind investigation of 132 
infusions. The filters were changed daily and the infusions 
were allowed to continue until no longer required, or until 
there was a reason for discontinuation. Microbiological 
evaluation of filters, skin at the site of cannulation 
immediately prior to removal of cannulae, and cannula tips 
was performed. Particle size analyses of the commonly used 
intravenous infusion fluids and medicines was also carried 
out. 
The incidence of phlebitis was significantly reduced by the 
inclusion of the filter in-line. The efficacy of the filter 
in reducing phlebitis was most pronounced when intravenous 
antimicrobial agents, especially the cephalosporins, were 
administered. 
Micro-organisms were isolated from 13% (28/209) of filters 
which originated from 31% (16/32) of infusions with filters 
in-line. A relationship could not be established between 
the number of filters used per infusion or the number of 
intravenous additives to the infusion system. Phlebitis was 
not associated with microbial contamination of cannula tips. 
Medicines for intravenous administration, especially the 
powders 
heavily 
to be reconstituted prior to administration, were 
contaminated with particulate matter prior to 
filtration. 
iv 
Abbreviations and codes 
~/,1",1?;3 Duration of in-line filter period 
j.-:· ... ,;'.·.· .. :/::~,-.:~·,::,I Duration of control period; no end-line· filter 
Key to alcohol intake 
1 Total abstainer 
2 Moderate or social drinker ie one who drinks on social 
occasions, or with meals, but rarely to excess 
3 Sporadic excessive drinker ie one who drinks excessively 
on festive occasions 
4 Heavy social drinker ie one who habitually drinks 
heavily, primarily on social occasions, and suffers 
frequent episodes of intoxication 
5 Alcoholic ie one who has developed a disease called 
alcoholism 
6 Indeterminate 
Based on page 8 of Alcoholism. The total treatment approach 
(113) 
Key to smoking 
1 Total abstainer 
2 0 - 9 cigarettes daily 
3 10-19 cigarettes daily 
4 20-39 cigarettes daily 
5 over 40 cigarettes daily 
6 Indeterminate 





































dextrose 5% solution in water 
dextrose 5% solution in normal saline 
2'-Deoxycoformycin 
erythrocyte sedimentation rate 
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millimetre per hour 
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WBC white blood cell count 
Active ingredients of proprietary products 
Codi~ 
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= Acetylsalicylic acid 
Codeine phosphate 
Calcium carbonate 
Anhydrous citric acid 








Moduretic@ = Arniloride hydrochloride 5mg 
Hydrochlorothiazide 





Solphyllin® = Etofylline 10mg+ Theophylline 80mg/ 15 ml 
vii 
Infusion fluids 
Ma intelyte ® = Dextrose 10% 
Na+ 35 millimoles/litre 
K + 25 " " 
Mg++ 2, 5 " " 
Cl - 65 " " 
Plasmolyte s® = Na+ 130 millimoles/litre 
K+ 4 " n 
Mg++ 1,5 " n 
c1- 109 n n 
HC03 28 n n 




INTRODUCTION and LITERATURE REVIEW 
1.1 Introduction 
The cholera epidemic of 1832 in Scotland heralded the 
clinical use of crystalloid solutions for intravenous 
infusion therapy (1). Dr T Latta, in order to rehydrate the 
cholera victims, " ••• resolved to throw the fluid immediately 
into the circulation." No adverse effects were recorded, 
but Dr Latta warned " ••• the vein should be treated with much 
delicacy to avoid phlebitis." 
Since then many probiems associated with intravenous 
infusion therapy have been recognised, the most frequent 
being phlebitis, which is reported to occur in 0,9-1¢~% of 
' patients receiving intravenous infusions. This wide 
variation in the reported incidence of phlebitis depends to 
some degree on the criteria used for assessment, and the 
duration of cannulation. Catheter sepsis, pyrogenic 
reactions and septicaemia may also develop and complicate 





is pri::narily a physicochemical 
by phlebitogenic substances 
administered intravenously, and mechanical irritation by the 
cannula. However, it can also be produced by microbial (2) 
and particulate contamination (3,4) of the intravenous 
fluid, and by infection of the cannula tip or cannula wound 
(5,6). 
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If microbial and particulate contamination of intravenous 
fluids does lead to phlebitis and other complications, then 
it would be reasonable to propose that final in-line filters 
may reduce the incidence of complications due to intravenous 
infusion therapy. 
1.2 Literature review 
1.2.1 Incidence of phlebitis 
The overall incidence of phlebitis reported in the 
literature varies from 0.9 to 100%. 
incidence of phlebitis of 0,9%, 
Bogen (6) reported an 
when the cannula was in 
place for less chan 12 hours, 2,9% when in place for 12 to 
36 hours, and 37% when the cannula remained in place for 36 
to 72 hours; phlebitis was recorded when inflammation was 
noted along the course of the infused vein. Frazer et al. 
(7) reported an incidence of phlebitis of 57% within 2,47 
days, as judged by erythema and tenderness; the incidence of 
phlebitis increased from 4,3% after 24 hours of infusion to 
100% after 5 days. Smallman et al. (8) found an incidence 
of phlebitis of 100% within 3,4 days, as judged by the 
presence of tenderness, erythema, oedema or warmth. 
Gough and Woodruff (9) reported a statistically significant 
variation (p < 0,01) in phlebitis between two surveys, 
undertaken by them in the same wards, but separated by an 
interval of 1 month. In the first survey, 42% of patients 
(61/147) developed phlebitis and in the second 22% (21/94). 
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The authors gave no criteria for the assessment of 
phlebitis, and were unable to explain this variation. The 
surveys also showed that the incidence of phlebitis 
increased with the duration of cannulation. In the second 
survey the mean time the cannulae remained in situ, without 
phlebitis developing, was 1,64 days as compared to 2,55 days 
for patients developing phlebitis. Cannulae left in situ 
for 48 hours or less carried a lower risk of phlebitis than 
those left in situ for over 48 hours (p < 0,01). 
Other studies also show that the risk of phlebitis 
developing increases with duration of infusion. 
Sexton and Gravney (10) found that 12/136 (9%) cannulations 
resulted in phlebitis. Only 2,5% of patients, with a 
duration of cannulation of 24 hours or less, developed 
phlebitis whereas 50% developed phlebitis, when the duration 
of cannulation was over 72 hours. The mean duration of 
cannulation was 25,3 hours, for patients not developing 
phlebitis, and 86,2 hours for those developing phlebitis. 
Phlebitis was recorded if two or more of the following signs 
were present at the cannulation site: erythema, tenderness, 
warmth, oedema, induration and purulence. 
Brown (11) reported an incidence of 8% phlebitis on the 
first day of his study and 18% on the second day, with an 
overall incidence of 27% (43/158 infusions); 69% of cases of 
phlebitis appeared within 48 hours. 
Bartz ( 12) reported an overall incidence of phlebitis of 
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36,7% (11/30 infusions) and that 6/7 patients, with a 
duration of infusion over 36 hours, developed phlebitis. 
The mean duration of infusion for patients, who did not 
develop phlebitis, was 21,36 ± 13,78 hours whereas for those 
developing phlebitis it was 36,97 ± 28,69 hours. 
In a study of 11 patients, over 65 years of age with septic 
phlebitis, the cannulae had been in situ over 48 hours, and 
the duration of cannulation ranged from 2 to 11 days (13). 
Hessov (14) in 1981 concluded, from a survey of 7 other 
published papers, that the incidence of phlebitis was 12-34% 
after 24 hours and 36-65% after 48 hours. One of these 7 
papers (15) reported a phlebitis rate of 70% when the 
duration of cannulation exceeded 72 hours, and that 
thrombophlebitis was significantly more common in infusions 
of 36-72 hours duration than in infusions of less than 36 
hours duration (an incidence of 52% and 18%, respectively). 
1.2.2 Clinical studies on in-line filters 
Clinical studies published to date have evaluated filters 
included in peripheral lines primarily for their ability to 
reduce the incidence of phlebitis. Four papers (3,16,17,18) 
have also investigated their efficacy in preventing changes 
in parameters such as temperature, respiratory rate, pulse 
rate, blood pressure, 
blood cell count 
hospitalization. 
erythrocyte sedimentation rate, white 
and reduction in duration of 
The first published 




on the clinical use of in-line 
Dudrick in 1969 (19), was 
uncontrolled and gave no criteria for the assessment of 
phlebitis or other complications of intravenous therapy. 
The authors state " No systemic signs of bacteremia, 
septicemia, or local signs of phlebitis were observed ••• " 
following the use of 0,45 µm filters left in-line for 72 
hours. This study was important because it demonstrated 
that final in-line filters would remove microbial 
contaminants from infusion systems. 
Ryan et al. (16), in a non-blind study of 100 postoperative 
patients at the Kentucky Medical Center, found that a 0,45 
µm filter in-line for 72 hours reduced the incidence of 
phlebitis from 45% in the nonfilter group to 2%. Phlebitis 
was recorded if erythema, induration and a palpable venous 
cord were present. Temperature, respiratory rate, pulse 
rate and diastolic pressure were reported to be more normal 
in the filter group. 
Three further papers from the above centre, one being a 
composite of the other two, also demonstrate a significant 
reduction in the incidence of phlebitis between the control 
and filter groups, in double-blind studies (3,20,21). In 
the study by DeLuca et al. (3), the incidence of phlebitis 
was reduced from 62% to 25% (over 72 hours) and, in the 
study by Maddox et al. (20), from 35% to 10% (over 48 hours) 
by an in-line filter. 
De Luca et al. ( 3) used a 0,45 µ m filter; phlebitis was 
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recorded as present if two of the following criteria were 
observed pain, tenderness, erythema, swelling or a 
palpable venous cord. The incidence of phlebitis was almost 
three times greater when the filter and set were changed 24 
hourly (32%), than when left unchanged for the 72 hours of 
the study (12%). Changes in temperature, respiratory rate, 
pulse rate, blood pressure, white blood cell count and 
erythrocyte sedimentation rate were monitored to determine 
if a systemic response to infusion phlebitis could be 
determined by these means. No significant differences in 
terms of vital signs were noted between the study groups, 
however, a significant rise in white cell count and an 
increase in sedimentation rate were observed in patients 
receiving unfiltered fluids. 
Maddox et al. (20) investigated the effects of a 0,22 µ m 
filter, as well as heparin and hydrocortisone, on the 
incidence of phlebitis in patients receiving cephalothin for 
48 hours. Sixty percent (12/20) of patients developed grade 
l+ phlebitis (pain at the intravenous site) in the control 
group and 20% (4/20) in the filter group; 35% (7/20) 
developed grade 2+ phlebitis (pain with erythema and/or 
swelling) in the control group compared to 10% (2/20) in the 
filter group. 
Rusho and Bair (18) demonstrated, in their double-blind 
study, that the phlebitis rate of a control group (27%) was 
significantly greater (p < 0,05) than that of a 0,45 µm 
filter group (6%), but not significantly different from that 
of a 5 µm filter group (22%). They also found that, for the 
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5 µ m and 0,45 µm filter groups, the duration of 
hospitalization was reduced by 3,4 and 3,3 days, 
respectively, from the control group's 13,6 days. All 
patients received cephalothin 2g 6 hourly and dextrose 5% in 
0,2% sodium chloride solution for 56 to 60 hours; filters 
were changed daily. Phlebitis was identified by pain, 
erythema and a hard and tender indurated vein. 
In contrast to Rusho and Bair (18), Evans et al. (22) found 
that a 5 µm filter significantly reduced the incidence of 
post-infusion phlebitis (p< 0,01). This was attributed to 
removal of particulate matter. Two of twenty-four patients 
(8%) developed phlebitis in the filter group, compared with 
14/25 (56%) in the control group. Phlebitis was recorded if 
two or more of the following criteria were met over the 72 
hour period of this double-blind study erythema, 
induration, heat, erythematous streak and discomfort. 
A recent study by Allcutt et al. (23) using a 0,2 µ m filter 
showed that, whilst the ultimate incidence of phlebitis was 
similar in the filter (48%: 49/101 infusions) and control 
groups (55%: 51/93 infusions), the filter significantly 
delayed the onset of phlebitis (p < 0,01). The incidence of 
phlebitis prior to 72 hours was 31% and 51% for the filter 
and control group, respectively. Phlebitis was recorded if 
inflammation was present. This study differs from others 
because no time limit was set on the length of infusion. 
Five published studies (17,24,25,26,27) show no advantage 
for ~,45 µm filters as regards post-infusion phlebitis. A 
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more recent double-blind study by Maddox et al. (28), using 
a 0,22 µm filter and larger numbers than in the previous 
study by Maddox et al. (20), confirms this lack of advantage 
for the filter group. 
Collin et al. (24) recorded phlebitis, if the vein was 
inflamed for a distance of over 2 cm from the site of 
cannulation, in 39% of patients receiving filtered solutions 
compared to 44% in the control group. Filters were changed 
at 48 hourly intervals, or when the filter blocked; 45/84 
filters required replacement in under 48 hours due to 
blockage. 
Swift et al. (17) found there was no statistically 
significant difference between patients with final filters 
and those in the control group, as regards the occurrence of 
phlebitis and changes in temperature, pulse rate and 
diastolic blood pressure. Filters were changed daily during 
the 72 hour study. 
O'Brien et al. (25), in a study of 48 patients over 48 
hours, found the incidence of phlebitis to be 42% in the 
filter group and 40% in the control group. The filters and 
cannulae were examined microbiologically after use, and 
found to be free of microbial contamination. 
In the study by Chamberland et al. (26), a total of 1~7 
infusions with filters (from 49 patients), and 84 infusions 
without filters (from 40 patients), gave a phlebitis rate of 
67% in the former group and 63% in the latter, as judged by 
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the presence of tenderness and/or oedema. 
Thayssen et al. 
using a 0,45 
phlebitis was 
(27), in their controlled double-blind study 
µm filter, found that the frequency of 
47% (27/57) in the filter group and 57% 
(33/58) in the control group. The average duration of 
infusion was 40 hours in the former and 39 hours in the 
latter group. The filters were not changed during the study 
period, and 7 of the 57 filters used became blocked. 
The incidence of post-infusion phlebitis in the filter group 
(38/95) and the control group (39/100) was also not 
significantly different in the recent study of Maddox et al. 
(28) using a 0,22 µm filter in-line. 
In another study, in which patients received total 
parenteral nutrition through in-line filters, the incidence 
of sepsis was four times greater than in the control group. 
This was attributed to the increased number of manipulations 
of the infusion system when filters blocked- (29). 
1.2.3 Microbial contamination 
Micro-organisms can cause serious infection if they are 
allowed to enter and proliferate in the intravenous cannula 
wound or intravenous fluid. In addition post-infusion 
phlebitis may be due to bacterial contamination of cannula 
tips (6,8). 
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1.2.3.l Contamination of cannulae 
Cannulae become contaminated when inserted under non-sterile 
conditions, when the wound site becomes infected, or when 
contaminated solutions are administered, see Figure 1.1 (5). 
Cannula-related infections derive mainly from the patient's 
own skin flora or from micro-organisms present on the hands 
of personnel inserting the cannula (30,31). 
Micro-organisms gain access to the tip of the cannula at the 
time of insertion, and subsequently by migration along the 
interface between the canr.ula and surrounding tissue (32). 
Once contaminated, the cannula and its adherent thrombus 
serve as an intravascular nidus for the dissemination of 
micro-organisms. 
The most common isolates from cannula tips have been 
Staphylococcus aureus, Staphylococcus epidermidis, 
Gram-negative bacilli (especially Enterobacter, Escherichia, 
Klebsiella, Pseudomonas and Serratia species), Enterococci 
and Candida (8,13,31,32,33). 
Cannula-related infections are frequently preceeded by, or 
associated with, phlebitis and can progress to suppurative 
phlebitis and systemic sepsis. 
Most studies have shown no correlation between phlebitis and 
a positive cannula culture for micro-organisms. For 
example, 47% of 135 patients developed phlebitis in Cheney 
- 11 -
Figure 1.1 
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and Lincoln's study, but only 9,7% had positive cannula tip 
cultures (34). In another study (35), 30% of 54 patients 
developed phlebitis and 40,7% of cannula cultures were 
positive, but there was no correlation between the two. 
Cannulae in situ for less than 48 hours were 
culture-negative, whereas 52% of those in situ for over 48 
hours were culture-positive. 
In the study by Collin et al. (24) on in-line filters, 55% 
(16/29) of the filter group had positive cannula tip 
cultures, as compared to 61% (14/23) in the control group. 
These investigators found no correlation between the 
presence of phlebitis and a positive cannula tip culture. 
Maddox et al. (28) also found that positive cannula tip 
cultures occurred as frequently in patients without 
as in those with filters. 
filters 
' 
Twenty one of 39 cannulae were contaminated in Baird and 
Doery's study (36); 19 with Gram-positive cocci, l with 
Gram-positive bacilli and l with both. Daily observations 
were made of the cannulation site in 21 patients; only 3 
patients experienced tenderness or inflammation at the 
cannulation site, but 9 had contaminated cannula tips. 
A prospective clinical study of 790 infusions by Band and 
Maki (37) also found no correlation between phlebitis and 
culture- positive cannula tips. An incidence of 40,2% 
phlebitis, 4,3% positive cannula cultures, and 0,63% cannula 
related septicaemias was reported. 
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Fuchs (38) reported that phlebitis, and other complications 
of intravenous infusion therapy, predisposed to a positive 
cannula tip culture. However, only 5,1% (5/99) cases of 
phlebitis were associated with a positive cannula culture, 
as compared to 3,5% (14/401) in cases with no phlebitis. 
Some published studies do indicate that phlebitis and other 
complications may be associated with contaminated cannulae. 
Maki et al. ( 3 9) found that cannula-related infection was 
associated with local inflammation. Of 250 cannulae 
cultured, 70,4% were culture-negative, 19,6% had a low level 
of contamination (ie they were culture-positive in broth 
culture or yielded 1-7 colonies on a plate culture) and 10% 
yielded significant growth on a plate cultur.e. Four of the 
25 cannulae in the latter group were associated with· 
septicaemia and 16/25 (64%) with local inflammation; in 
comparison, 13,3% (30/225) of the remaining cannulae were 
associated with local inflammation. 
Collins et al. (40) 
from patients with 
Collin et al. (15) 
reported that 43% of cannulae removed 
phlebitis were culture-positive, and 
that 61% of cannulae removed from 
patients with phlebitis were 
latter study 44% of cannulae, 
culture-positive. In the 
from patients not developing 
phlebitis, were culture-positive. 
Smallman et al. ( 8) in 1980 reported that phlebitis 
developed in 34,5% of cannulations, in which an aseptic 
technique was used for inserting the cannula, and that 50% 
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of cannulae were culture-positive. In contrast, phlebitis 
developed in 100% of cannulations in the control group and 
86% of cannulae were culture-positive. Staphylococcus 
epidermidis was most commonly cultured; Staphylococcus 
aureus, Micrococcus and Acinetobacter were also isolated. 
The duration of cannulation was 3,2 days in the former group 
and 3,4 days in the latter group. 
Published studies do however indicate that patients with a 
positive cannula culture have a significantly increased risk 
of septicaemia (5,32). From a survey of 33 papers by Maki 
et al. in 1973 (32), the percentage of positive cultures 
from cannulae was found to vary from 3,8 to 57%, with rates 
of associated sepsis ranging from zero to 8%. In a more 
recent survey, a sepsis rate of 0,5i (36/7618 infusions) was 
reported and 17,9% (543/3031) of cannulae were contaminated 
following peripheral percutaneous cannulation (41). 
Another survey of 916 cannulations (5) clearly demonstrated 
that the longer the duration of cannulation at one site, the 
higher the incidence of culture-positive cannula tips and 
associated septicaemia. On day one 11,2% of cannulae were 
culture-positive compared to 33,3% on day four; the 
incidence of septicaemia increased from zero on day l to 
2,9% on day 4. With cannulations exceeding 48 hours, the 
incidence of cannula-related septicaemia has ranged from 
0-8%, with an average of 2% (32). 
In 1958, Moncrief (42) reported 4 cases 




association between the incidence of complications and the 
duration of cannulation. 
Septic phlebitis is the most serious form of cannula-related 
infection (5,13,43) and occurs almost exclusively with 
plastic catheters left in situ for longer than 48 hours. 
The vein becomes an intravenous abscess discharging 
organisms into the bloodstream. 
The incidence of suppurative phlebitis following 
percutaneous cannulation has been estimated to be 0,2% (41). 
1.2.3.2 Contamination of infusion fluids 
Infections related to microbial contamination of the 
infusion fluid occur less commonly than cannula-related 
infections, 
(5,37,44). 
but often have more serious consequences 
Contamination of intravenous fluids can occur during 
manufacture, which is referred to as intrinsic 
contamination, or during administration to the patient, 
which is referred to as extrinsic contamination. 
contamination, arising before the fluid is 
Intrinsic 
used, is 
potentially more serious and has produced large scale 
epidemics of septicaemia, often resulting in death. 
Extrinsic contamination is usually seen on a smaller scale. 
The sources of contamination of infusion fluids have been 
illustrated by Maki, as shown in Figure 1.2 (5). 
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Figure 1.2 
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From a survey of world literature published between 1965 and 
1978, Maki (31) found that 33 out of 97 epidemics of 
hospital-acquired bacteraemia were due to infusion therapy. 
Twenty eight epidemics were traced to contaminated infusion 
fluids. Contamination of infusion fluids during manufacture 
was implicated in 7, and in-use contamination in the 
remaining 21 epidemics. 
The first reports of adverse 
infusion fluids appeared in 
reactions to contaminated 
1953. o ' Ha re et a 1 • ( 4 5 ) 
reported a fatal case of anaphylactic shock following the 
intravenous infusion of 10% m/v dextrose solution 
contaminated with Enterobacter aerogenes, and Michaels and 
Ruebner (46) attributed 2 cases of coliform septicaemia to 
contamjnated infusion fluid. The significance of these 
reports was not appreciated until the early 1970's, when 
other cases were published. 
In 1970, two reports implicated in-use contamination of 
infusion fluid with infection. Robertson (47) found two 
bottles of in-use dextrose in saline infusion fluid to be 
contaminated with fungi, one with Trichoderma and the other 
with Penicillium species, which they presumed to have gained 
access via cracks in the bottles. One patient developed 
transient fungaemia due to Trichoderma. 
Sack (48) reported 5 cases of septicaemia following 
infusions from a bottle containing succinylcholine in 5% 
dextrose solution and from which Klebsiella pneumoniae and 
Enterobacter cloacae were subsequently cultured. 
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Contamination via a crack in the bottle was hypothesised 
following a subsequent sixth case. 
Duma et al. in 1971 (49) reported 4 cases 
with in-use infusion fluid contaminated 
identical to those isolated from blood 
of septicaemia 
by organisms 







Serratia in the fourth. 
was Escherichia in two 
Klebsiella in the third and 
The widespread hazard of contaminated infusion fluids was 
first appreciated in the early 1970's when over 400 cases of 
Enterobacter septicaemia and 40 deaths, caused by intrinsic 
contamination of intravenous fluids, were reported from 25 
hospitals in the United States. Half of the patients 
developed infusion phlebitis; this suggests that phlebitis 
can be caused by contaminated infusion fluids. This 
epidemic was traced to intrinsic contamination of a newly 
introduced, elastomer-lined, screw-cap closure (2). 
Another epidemic began in 1971 in a London hospital. Forty 
patients developed infection from deionised water, 
containing Pseudomonas cepacia, which contaminated closures 
and bottles of infusion fluid when used in the rapid cooling 
autoclave (50). 
Other cases of septicaemia due to Enterobacter species 
occurred in 1972 in a hospital near Plymouth, England. Six 









Enterobacter agglomerans and Klebsiella aerogenes. 
Contamination was traced to faulty autoclaving equipment at 
the manufacturer's plant (51,52). 
In another outbreak, 5 patients developed sepsis from 
contaminated 5% dextrose in lactated Ringer's solution. 
Citrobacter freundii was recovered from the blood of 3 
patients, Enterobacter cloacae from the fourth and 
Enterobacter cloacae plus Enterobacter agglomerans from the 
fifth ( 3 2) • 
Infections due to contaminated infusion fluids are almost 
exclusively 
Klebsielleae 
due to Gram-negative bacilli, primarily 
tribe (Klebsiella, Enterobacter and Serratia 
species) although Citrobacter freundii and Pseudomonas 
cepacia have also been implicated in epidemics (31). These 
organisms are able to proliferate in dextrose-containing 
intravenous fluids; most other organisms die or are unable 
to proliferate in such fluids (30). 
Many studies have shown that even if an infusion fluid is 
sterile on arrival at the hospital ward it may become 
contaminated with micro-organisms 
Table 1.1 gives some documented 
during administration. 
examples of in-use 




Studies of in-use contamination rates and microbial contaminants present in 
intravenous infusions. 
Reference 
Wilmore & Dudrick 1969(19) 
Ceeb & :-latsios 1971 (53) 
Duma et al. 1971(49) 
Letcher et al. 
Myers 
Collin et al. 
D'Arcy & Woodside 
Hughes 
Lapage et al. 
Hanson & Shelley 
Maki et al. ---
:-lewman et al. 
Woods.:.de e1: al. 
Rus!Tlin et al. 
3and & ~aki 
aernicl< et a.:.. 
3uxt::>n et al. 






































































































































1.2.4 Particulate contamination 
Concern about the quantity of particulate matter in 
intravenous solutions, improvements in filtration techniques 
and the introduction of quantitative quality control 
regulations, in the British Pharmacopoeia 1973 (66), has led 
to a considerable reduction in the level of particulate 
matter in infusion solutions. 
However, the final solution entering the patient may be 
heavily contaminated with particulate matter introduced from 
the giving set, syringes, ampoules and intravenous additives 
(67 ,68). 
The clinical consequences of particulate matter are unclear, 
however, granulomas (69,70) and phlebitis (3,16) have been 
observed after the infusion of particles. It is thought 
that the degree of danger may depend upon the number and 
size of particles, the physical properties of the particle, 
the biological properties of the particle, the final 
location of the particle in the vascular system and the host 
response to the particle (71). As each particle has the 
potential to cause an adverse effect (72), the probability 
of an adverse reaction is proportional to the total number 
of particles introduced (71,72). 
Drews (73) was probably the first to realise the clinical 
implications of particulate 
found that patients with 
matter 
particles 
in solutions. Drews 
trapped behind a 
transplanted cornea experienced a visual haze and that the 
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irrigating solutions used during surgery contained from 435 
to 958 particles per millilitre, in the size range 5 to 300 
µm. Therefore, he recommended filtration of the solutions 
prior to use. 
1.2.4.1 Animal studies 
Dunn J74), in 1920, studied the effects of embolism of 
pulmonary arterioles following the intravenous 
administration of starch granules into animals. Large 
quantities decreased systemic arterial pressure, increased 
systemic venous pressure and produced death within 5-30 
minutes. Dunn believed that the starch granules remained in 
the lungs. 
Kittle et al. (75) produced pulmonary hypertension in dogs 
following the repeated 
particles of 50-400 µm. 
intravenous injection of carborundum 
The authors could not determine if 
the increased pulmonary artery pressure, after pulmonary 
embolization, was due to vascular obstruction or if an 
associated vasospasm 
particles required to 
had occurred. As 
produce pulmonary 
the quantity of 
hypertension was 
many times the quantity required to produce an acute lethal 
effect, this suggested that vasospasm might be partly 
responsible for death in acute embolization. 
Stehbens and Florey (76) found that the introduction of 
particulate matter into the blood stream led to 
agglutination of platelets, to which the particles adhered, 
and a reduction in the number of platelets circulating in 
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the blood stream. White and red blood cells also adhered to 
these masses, and formed thrombi which frequently blocked 
capillaries. 
Gesler et al. (77), in 1973, reported on the effects of 
injecting rats with varying quantities and sizes of inert 
polystyrene spheres. Thirteen 
8x10 6 particles/kg 40 µm 
respiration and died within 
of 18 rats injected with 
in size developed laboured 
3-5 minutes of injection; 
another rat injected with 4xl05 particles/kg 4 µmin size 
died within 3 minutes of injection. All other rats injected 
with polystyrene particles or control vehicle were 
unaffected. Particles of 4 µm were found in the lung, liver 
and spleen of test animals, whilst those of 10 µrn were found 
primarily in the lung, but also in the heart, liver, spleen, 
kidney, brain and pancreas. The authors concluded that 
nonreactive particles administered intravenously " ••• up to 
dosages that produced death were without clinical or tissue 
toxicity." 
Other investigators have reported the presence of particles 
in organs such as the brain, liver, heart, spleen and kidney 
(69,78,79). Glass beads, up to 390 µmin diameter, can pass 
through the pulmonary capillary bed and reach the systemic 
circulation via arteriovenous shunts in the lung (79). 
Dorris et al. (4) demonstrated that residues, obtained after 
filtration of 5% dextrose in water and sodium cephalothin 
solution, produced a reaction on the venous endothelium of 
rabbits. They noted venous congestion, perivenous 
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haemorrhage, and some necrosis 
particulate matter from dextrose 
following sodium cephalothin were 
after the infusion of 
solution. The changes 
more severe and included 
necrosis and degeneration of the vein wall. These authors 
also demonstrated, using dogs, that in-line filtration 
reduced the severity of the venous endothelial reaction to 
intravenous infusions. 
Animal studies have shown that microspheres larger than 7,5 
µmin diameter are localised in the capillary beds of the 
lungs during the first pass following intravenous 
administration, while microspheres smaller than 7,5 µm clear 
the lungs and accumulate primarily in the liver and spleen 
(77). If, however, a large particle bypasses the lungs, via 
arteriovenous shunts in the lung (80), it might occlude an 
arteriole in the brain, kidney or eye and cause injury 
(69,71). 
Several investigators have demonstrated that particulate 
matter in tissues leads to granuloma formation. 
Wartman et al. (81) reported in 1951 that, following the 
injection of filter paper fibres into rabbits, emboli became 
impacted in the pulmonary arteries or adhered to the intima. 
In one rabbit an embolus adhered to the endocardium of the 
right ventricle, resulting in an acute inflammatory response 
which subsided after a week. The filter paper fibres were 
surrounded by foreign body granulomas and became localized 
in either the vessel wall intima, media or adventitia. The 
granulomas frequently extended through the walls of the 
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arteries, and were found also in the lung or in perivascular 
sites. The authors interpreted this as indicating the 
existence of a mechanism for ridding the circulation of 
foreign material in the blood. 
Intravenous infusions in healthy rabbits resulted in the 
formation of capillary and arterial granulomas, containing 
fragments of cellulose fibres, in the lungs (69). The 
investigators estimated that for every 500 millilitres of 
intravenous fluid injected into each rabbit, there were 5000 
granulomas scattered throughout the lungs. 
Purkiss (82) injected cellulose fibres into 40 mice and 
saline into another 10 for control purposes. Granulomas 
were found in the lungs of all test mice, but not in the 
controls. 
La s k e r e t a 1 • (83) demonstrated, following peritoneal 
dialysis, the presence of particulate matter in inflamed 
peritoneal membranes of mice. The inflammation was 
prevented by filtration of the solutions through 0,22 or 
0,45 µm filters. 
1.2.4.2 Clinical significance of particulate matter 
Turco (84) concluded in 1973, in his review of the clinical 
significance of particulate matter, that "Although the 
biological effects of particulates injected into humans are 
still undefined ••• Particulate matter is ar. unwanted and 
unnecessary addition to medication therapy." 
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The clinical significance of particulate matter from 
intravenous solutions is still not clear. However, 
extrapolation from animal studies suggests that particles 
entering the systemic circulation may occlude a blood vessel 






occlusion, form granulomas, 
reaction or cause infusion 
Particles are potentially harmful to the eyes, lung and 
brain. The lung acts as a filter trap for the venous 
circulation, but it is possible for particles to pass 
through or bypass the pulmonary capillary bed and then block 
a small arteriole in the kidney, eye or brain (69,71). 
Liebow et al. (85) and Hales (80) have shown that 
arteriovenous shunts exist in the human lung. 
A 1966 United States Food and Drug Administration sponsored 
symposium concluded that particulate matter in parenteral 
drugs can result in pulmonary microemboli, thrombi or 
granulomas and reflex vasoconstriction in the lungs (86). 
The chemical composition of the particle may be critical. 
It may be biologically inert, or incite an inflammatory 
reaction or, even worse, a neoplastic response by the host. 
The particle could also be antigenic and sensitize the 
patient to a future allergic reaction (71,87). 
A foreign particle may initiate an inflammatory response in 
a blood vessel, and vascular granulomas caused by 
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particulate matter may also have deleterious effects on 
blood vessels and tissue (72,81,88). 
Information on the clinical effects of parenteral injection 
of particles is sparse. Pulmonary embolism has been 
reported in 5 to 14% of all autopsies (89). The embolism is 
usually caused by a blood clot, but may also be caused by 
foreign particles (90). 
Embolization of the lungs by particulate matter produces 
severe pulmonary hypertension, a fall in systemic blood 
pressure and death. Distension of the right cardiac 
chambers and engorgement of the peripheral veins develops, 
in conjunction with occlusion of the main pulmonary artery. 
It has been postulated that particulate embolism induces 
reflex pulmonary artery constriction, and this may explain 
the deaths of patients when pulmonary emboli block only a 
minor portion of the pulmonary artery bed (89). 
In a study (91) of 173 patients undergoing cardiac 
catheterization and/or surgery, 14 (8%) had fibre emboli in 
routine autopsy sections. Fibres were found in the 
pulmonary, renal, cerebral, and mesenteric arteries. The 
embolized fibre often resulted in narrowing or occlusion of 
the involved vessel. This study associated 3 cases of 
infarction with embolic fibres. In one patient multiple 
foci of cerebral necroses were present, associated with 
fibre emboli, within small cerebral vessels. In another 
patient long fibres were present within a thrombus that 
occluded a major pulmonary artery, resulting in pulmonary 
- 28 -
infarction. In the third case, fibres were present within a 
thrombus removed from the occluded radial artery of the 
patient, in whom ischaemia of the left hand developed 24 
hours after the artery had been cannulated. The hand was 
subsequently amputated for gangrene necrosis. 
Garvan and Gunner (69,70) examined postmortem sections of 
the lungs of terminally ill patients, who had received long 
term intravenous therapy. They found granulomas, similar to 
those in animals, and chronic fibrous pneumonitis; cellulose 
fibres and crystals were present in the fibrous tissue. 
Granulomas, caused by particles introduced into the cerebral 
circulation during angiography, were also observed in the 
brains of treated patients. 
Garvan and Gunner (69) quote the autopsy results of other 
investigators who found pulmonary vascular granulomas, due 
to fibres, in children. The only common denominator was 
that all the children had received intravenous therapy. 
These investigators also identified foreign particles lodged 
in the lungs of an infant who died after receiving 2700 
millilitres of intravenous fluid (70). 
It has been speculated that the adverse effect of 
particulate matter in intravenous solutions may be greater 
in patients who are hospitalized since they are often 
recumbent, with a resultant sluggish pulmonary circulation 
(72). In addition, these patients may be receiving therapy 
with corticosteroids or other agents which could so modify 
- 29 -
tissue response that a granulomatous process, which would 
otherwise be localized, could extend through the lungs (72). 
Woodhouse in 1980 (92) stated that phlebitis " ••• is an acute 
sterile inflammation without bacterial infection." Many 
clinical studies have failed to demonstrate any correlation 
between microbial contamination and the development of 
infusion phlebitis. This suggests that many cases of 
phlebitis may not be attributable to microbial infection. 
If microbial contamination of cannulae or infusion fluids 
were the primary cause of infusion phlebitis, concomitant 
administration of antibiotics might be expected to reduce 
its incidence. This is not the case. On the contrary, 
antibiotic therapy itself has been shown to cause infusion 
phlebitis (93,94). Studies have revealed the presence of 
subvisible particulate matter in many antibiotic 
preparations (4,95,96,97), and this may partially explain 
their ability to cause infusion phlebitis. 
1.2.4.3 Quantity and content of particulate contamination 
Particles maybe introduced into intravenous solutions during 
the manufacturing process, from the administration 
apparatus, or from drug additives. 
Draftz and Graf (98) in 1974 examined intravenous solutions 
of normal saline and 5% dextrose and found the main source 
of particles to be the rubber stopper. Flakes of lacquer 
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and salt crystals constituted 1-10% of the particles, and 
starch granules, glass, mica flakes and metal shavings less 
than 1%. The number of particles per litre, greater than 1 
µm in size, ranged from 6 000 to 77 000 for saline and 
10 000 to 32 000 for dextrose solution, whilst in the case 
of particles larger than 5 µm, the range was l 000 to 13 000 
and 2 000 to 6 000, respectively. Particles up to 100 µmin 
size were observed. 
Winding and Holma (99) reported in 1976 that more than 
250 000 particles in the size range 0,5-50 µm were present 
in l litre of infusion fluid. 
Pearse et al. (100) in 1982 reported particle counts, per 
litre of intravenous fluid, of 20 000 to 72 000 for 
particles over 2 µm, and 5 000 to 16 000 for particles over 
5 µm, using a Coulter Counter. These fluids, however, do 
comply with the British Pharmacopoeia 1980 (101) requirement 
that intravenous fluids should contain not more than 1 000 
particles per ml greater than 2 µm, and not more than 100 
particles per ml greater than 5 µm when using an apparatus 
such as the Coulter Counter. 
Myers (55), from a study using 0,45 µm end-line filters, 
estimated that a patient may receive between 100 000 and 2 
million particles greater than l µm during intravenous fluid 
therapy, depending on the number of bottles of fluid 
infused. The particles identified on the filters included 
fibres of paper, cotton and flax (400 µm in length), glass 
and plastic. 
- 31 -
Davis and Turco (67) reported in 1971 that 50-70% of 
infusion systems contained 
the particle count many fold. 
additives, which could increase 
Schroeder and DeLuca (97) 
estimated that a patient given intravenous therapy, 
including antibiotics, could receive with each litre of 
fluid 34 000 particles larger than 5 µm, l 400 particles 
larger than 10 µm and 500 particles larger than 25 µ m. 
I 11 urn e t a 1 • (10 2 ) found ad m i n i s t r a t i on s e ts to be a s e r i o us 
source of particulate contamination. Some particles 
released from the sets were larger than 100 µm. 
Mehrkens et al. ( 6 8 ) e s t i ma t e d th a t the to ta 1 numb e r o f 
particles a patient might receive, during 24 hours of 
infusion therapy, to be 1 920 504. The particulate matter 
was introduced from the following sources: 
Infusion solutions (3000 ml) 353 189 particles 
Additions of medicines 1 285 189 particles 
Ampoules 216 350 particles 
Latex fitment 24 776 particles 
Syringes 41 000 particles 
1 920 504 particles 
Pe a r s e e t a 1. ( l 0 0 ) i n 19 8 2 recommended , f o 11 ow i n g pa r t i c 1 e 
counts on intravenous medicines, that certain additives, 
especially powders requiring reconstitution, should be 
filtered during aseptic addition to intravenous fluids. 
These drugs included chloramphenicol, cephazolin, oxytocin, 
aminophylline and aminophylline in combination with 
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hydrocortisone. The particle counts of intravenous fluids, 
to which drugs had been added without prior filtration, are 
given in Table 1.2 (100). 
Table 1. 2 
Particle content of intravenous fluids to which drugs had 
been added without filtration, determined using a Coulter 
Counter 
Intravenous fluid Additive Particles/ml 
,2 µ m ~5 µm 
Dextrose 5% 100ml Chlorarnphenicol lg 1 075 23 
Dextrose 5% 100ml Erythromycin lg 213 36 
Dextrose 5% 500ml Naftidrofuryl 200mg 67 4 
Dextrose 5% 500ml oxytocin 10 IU 649 140 
Dextrose 5% 500ml Aminophylline 250mg 
+hydrocortisone 100mg 4 623 776 
Sodium chloride 0,9% 100ml Senzylpenicillin lmu 95 6 
Sodium chloride 0,9% 100ml Cephazolin lg 1 060 66 
Sodium chloride 0,9% 100ml Cimetidine 200mg 71 8 
Sodium chloride 0,9% 100ml Flucloxacillin 500mg 81 6 
Sod i urn chloride 0,9% 500ml Aminophylline 250mg l 630 237 
Sodium chloride 0,9% 500ml Aminophylline 250mg 10 364 2 812 
+hydrocortisone 100mg 
Sodium chloride 0,9% 500ml Heparin 5000 u 37 4 
Sodium chloride 0,9% 500ml Hydrocortisone 100mg 52 6 
Sodium chloride 0,9% 500ml ?arentrcvite 51 HJ 
:rom Pearse et al. ( 100) 
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1.3 Aims and scope of study 
This review of the literature clearly shows that, whilst 
every care may be taken during manufacture to ensure that 
the patient receives particle free, sterile intravenous 
infusion fluids and medicines, the possibility of 
contaminants entering the system during use and causing 
associated problems, is always present. 
This project was undertaken with the following aims: 
l To determine if the addition of an in-line filter to the 
infusion set reduces the incidence of phlebitis. This 
is deemed important because of the discrepancies between 
publishe~ reports and also because, in the majority of 
studies showing an advqntage for filters, the filters 
were not changed daily as is now recommended. 
2 To determine the level of microbial contamination of 
3 
infusion systems by culturing the filters and 
identifying the micro-organisms isolated. 
To determine, in view of the controversy in the 
literature, whether there is any correlation between 
phlebitis and culture-positive cannula tips and whether 
filters reduce the incidence of contamination of cannula 
tips. 
4 To determine particle counts in the commonly used 
intravenous infusion fl~ids and medicines, and to 
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establish whether there is any correlation between 
particulate contamination and phlebitis. 
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CHAPTER 2 
CLINICAL STUDY OF A 0,2 µm IN-LINE FILTER 
2.1 Aim 
This aspect of the investigation was aimed at determining 
whether the complications of intravenous infusion of fluids 
and additives might be reduced by the inclusion of a 0,2 µm 
air venting final filter in-line. The filter effectively 
removes microbial and particulate contaminants above 0.2 µm 
from intravenous fluids and additives. 
2.2 Location 
The clinical study was carried out in the Medical, Surgical 
and Gynaecological Wards at Groote Schuur and New Somerset 
Hospitals. Haematological studies were carried out in the 
Haematology Departments at these hospitals. 
2.3 Patient selection 
Patients belonging to either sex and any racial group, aged 
from 12 to 70 years, and anticipated to require intravenous 
infusions via a peripheral line for 48 hours or longer, were 
included in the study. Diabetic patients and patients 
receiving blcod, fat emulsion, 50% dextrose solutions er 
high molecular mass dextrans were excluded from the study. 
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2.4 Study design 
Patients were allocated at random to either the filter or 
control (filter not included in the access line) group by 
the trial sister prior to cannulation. The filter was 
attached to the distal end of the infusion set, immediately 
prior to cannulation, by the trial sister or the physician 
in-charge and primed with intravenous infusion fluid (see 
Appendix I). Cannulation was carried out according to the 
procedure normally used by the physician, no attempt being 
made to prevent variations due to personnel changes in order 
to evaluate the practical benefit of filters in everyday 
use, and the filter outlet was connected to the cannula. 
Tetrafluoroethylene cannulae of varying size, as specified 
in Table 2.1, were used. 
The filters were changed daily, using the aseptic technique 
detailed on page 65, by the trial sister and retained for 
microbiological evaluation. The infusion sets were changed 
in accordance with the normal procedure of the hospital 
concerned. Cannulation site changes were carried out as 
directed by the physician in-charge. The cannula was 
removed by the trial sister, except for inadvertent removal 
by ward staff or patients, using the procedure outlined on 
page 68, and retained for microbiological evaluation. 
Patients on prolonged intravenous therapy were included for 
more than one cannulation site. Subsequent allocation to 
the filter or control group was random. 
Patient details were recorded as specified in Appendix II. 
- 37 -
2.5 Patient assessment 
The trial was observer-blind. Patients were assessed daily 
for phlebitis, by the investigator, for the period of 
cannulation and upon removal of the cannula, using the 
following criteria based on those suggested by Maddox et al. 
( 2 0) : 
Severity Criteria 
0 No pain or tenderness at the intravenous site, no 
erythema, no swelling, no induration, no palpable 
venous cord 
l+ Painful or tender intravenous site, no erythema, 
no swelling, no induration, no palpable venous 
cord 
2+ Painful or tender intravenous site with erythema 
or some degree of swelling, or both, no palpable 
venous cord 
3+ Painful or tender intravenous site with erythema 
and swelling and with induration or a palpable 
venous cord less than 7 cm above the cannulation 
site 
4+ Pair1ful or tender intravenous site, erythema, 
swelling, induration and a palpable venous cord 
greater than 7 cm above the cannulation site 
5+ Frank vein thrombosis together with all the signs 
of 4+; the infusion may have stopped running due 
to thrombosis 
Phlebitis was considered to be present if a score of 2+ or 
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more was recorded. 
The following parameters were also monitored prior to the 
initiation of intravenous therapy and, thereafter, at daily 
intervals: 
1) Body temperature (sublingual) 
2) Pulse rate 
3) Respiratory rate 
4) Blood pressure 
5) Erythrocyte sedimentation rate 
6) White blood cell count 
7) Haemoglobin and haematocrit 
The length of infusion and time to the discovery of 
phlebitis was recorded to the nearest hour. The reason for 
termination of each infusion was recorded as being one or 
more of the following: 
a) elective 
b) development of phlebitis 
c) blockage 
d) infiltration into tissues 
e) inadvertent removal by patients or ward staff. 
2.6 Medication 
Full details of intravenous fluids and all medication were 
recorded, and these are given in Appendix 11. Intravenous 
antibiotics were administered over 30 minutes, using an 
Add-A-Line, piggy-back to the infusion fluid. The 
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preparation of antibiotics, 
normal saline, was carried 
in minibags containing 50 ml 
out by the ward sister. 
Intravenous potassium chloride and vitamins were added 
directly to the infusion fluid. 
Infusion fluids were supplied in plastic containers except 
for Plasmolyte Ff), which was supplied in glass bottles. 
Drugs administered in concentrations of less than 5 µg/ml, 
or in doses of less than 5 mg over a 24 hour period were not 
passed through the filter (103). 
2.7 Statistical analysis 
Preliminary statistical analysis was carried out using 
either the chi-square test or the Student's t test (104). 
The chi-square test or Fisher's two-tail test of exact 
probability (104) were used to determine the independence of 
concomitant variables which could possibly affect the 
incidence of phlebitis. 
Continuous variables were compared using the Student's t 
test. When an equivalent nonparametric method was required, 
either the Kruskal-Wallis one-way analysis of variance by 
ranks or the Wilcoxon two-sample test was used (105). 
The Kaplan-Meier estimate of survival function was used to 
compare the filter and control groups with regard to time 
for the development of phlebitis, because the data were 
censored, ie the infusions were not all continued until 
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phlebitis developed. The significance of the difference 
between the two groups was determined using Gehan's test 
(106). 
The null hypothesis was that there is no statistically 
significant difference in parameters between the filter and 
control groups. Significance was assigned to a probability 
value of less than 0,05; where an association is reported as 
not statistically significant, this indicates a probability 
value of greater than 0,05. 
Infusions discontinued prior to 30 hours due to blockage of 
the access line or infiltration into tissues were not 
included in the final statistical analysis (unless phlebitis 
had already developed), as studies have shown a low 
incidence of phlebitis under 30 hours (10,65). 
To test the randomization procedure and the comparability 
between the filter and control groups, the patient's age was 
examined by analysis of variance. 
Chi-square analysis of each of the following categorical 
variables versus treatment group was performed: sex, cannula 










medicines, smoking habits, alcohol intake, reason for 
discontinuation of the infusion, and whether the infusion 
was an initial or subsequent infusion. 
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2.8 Results 
Patient data and results are detailed in Appendix II. 
Patients included in the final statistical analysis were 
numbered consecutively from 001 and patients not included in 
the final statistical analysis were numbered consecutively 
from 101. Hence, the first 3 digits of each Trial Number 
refer to the patient number and the digit after the oblique 
indicates the Trial cannulation site number. 
One hundred and nine patients, aged 13 to 66 years, were 
included in the study which was conducted over a period of 
six months. Twenty eight patients were excluded from the 
final statistical analysis for the reasons given in Appendix 
III. The 81 remaining patients yielded results for 132 
infusions, 41 patients having more than one cannulation site 
included in the study. A total of 62 infusions was studied 
in the filter group and 70 in the control group. 
The filter and control groups were comparable with respect 
to all the parameters in Table 2.1. No significant 
difference was found between these parameters in the two 
groups. 
Other variables such as oral and intravenous medication, 
type of cannula, smoking habits, alcohol intake, surgical 
procedure and medical condition were also tested using the 
chi-square test and no significant differences between the 
groups were found. Table 2.2 lists the surgical procedures 
and medical conditions in the two groups and Tables 2.3 and 
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Table 2.1 
Comparison of patient data in the filter and control groups 
Parameter 





































































* More than one type of infusion fluid was used in 28/132 
infusions. 
Note: 
The Student's t test was used to compare age, and the 
chi-square test was used to compare all other parameters in 
the filter and control groups. No differences were found at 
the p=0,05 level of significance. 
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Table 2.2 
surgical procedures and medical conditions in the filter 




drainage of lung abscess 
repair of pneumothorax 





















































1) Surgical procedures and medical conditions were grouped 
together for statistical purposes. 
2) The patient details referred to in the various categories 
above are given in Appendix II. 
3) One patient in the filter group (Patient Number 001) and 
one in the control group (Patient Number 042) had both a 
surgical procedure and a medical condition. 
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2.4 the oral and intravenous medicines, respectively that 
were administered. 
The majority of patients had an infection, most commonly 
pneumonia, and therefore antimicrobial agents were the most 
common medicines administered intravenously, penicillin 
and/or a cephalosporin being the usual drugs of choice 
(Table 2.4). The most common oral medicines administered 
were analgesics, non-steroidal anti-inflammatory agents, and 
antimicrobial agents; metronidazole was the most frequently 
used antimicrobial agent (Table 2.3). 
Of the 132 infusions analysed, 74 (56%) resulted in the 
patient developing post-infusion phlebitis of grade 2+ or 
greater. In the filter group 29/62 infusions (47%) resulted 
in phlebitis, as compared to 45/70 (64%) in the control 
group (Table 2.5). This difference was significant at the 
5% level, using the chi-square test (p=0,0431). A 
significant reduction in the incidence of phlebitis, between 
the control and filter group, was also found at 48 hours 
(p=0,005) and 72 hours (p=0,0062), but not at 30 hours, 
using the chi-square test. 
The mean time to phlebitis was 77,1 hours for the filter 
group and 63,3 hours for the control group, and the mean 
duration of infusion was 75,9 hours for the filter group and 
85 hours for the control group. 
Due to the non-normal distributions of time to phlebitis and 
duration of infusion, the filter and control groups were 
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Table 2.3 
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Intravenous medicines administered 
Medicines Filter Control 
Group Group 
Antimicrobial agents 
Aminoglycosides 15 9 
Ampicillin 1 0 
Cefamandole 20 24 
Ceftazidime 8 7 
Chloramphenicol 3 3 
Erythromycin 0 1 
Metronidazole 3 1 
Penicillin 30 33 
Tetracyclines 1 3 
Others 
Aminophylline 0 4 
8 receptor stimulants 0 1 
Clothiapine 0 3 
Diazepam 0 1 
2'-Deoxycoformycin 0 1 
Furosemide 0 2 
He par in 0 l 
Hydrocortisone l 1 
Methylprednisolone 0 1 
Morphine 2 0 
Potassium Chloride 5 3 
Vitamin B Compound 2 1 
No. of medicines 
0 4 2 
1 32 43 
2 16 16 
3 8 3 
4 l 4 
5 0 0 
6 0 2 
7 l 0 
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Table 2.5 
Cumulative incidence of phlebitis over time in the filter 
and control groups 
Duration of Cumulative incidence of phlebitis 
infusion ( h) Filter group Control group p* 
n=62 n=70 
<30 3 ( 5%) 10 (14%) >0,05 
30-48 9 ( 15%) 25 ( 3 6 % ) 0,005 
48-72 15 (24%) 33 (47%) 0,0062 
>72 29 ( 4 7 % ) 45 (64%) 0,0431 
* Differences were tested using a chi-square analysis; 
significance was assigned to a probability value of 0,05. 
Table 2.6 
Severity of phlebitis in the filter and control groups 
Phlebitis Filter group Control group p* 
grade n=62 n=70 
0 21 (34%) 18 (26%) > 0, 05 
l+ 12 (19%) 7 (10 % ) > 0, 05 
2+ 18 (29%) 21 (30%) > 0, 05 
>3+ 11 (18%) 24 (34%) 0,0316 
Differences were tested using a chi-square analysis; 
significance was assigned to a probability value of 0,05. 
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compared with regard to these variables using a 
nonparametric method of analysis. The Kruskal-Wallis 
one-way analysis of variance showed no significant 
differences between the filter and control groups as regards 
mean time to phlebitis and mean duration of infusion. 
Table 2.5 and Figure 2.1 show that the incidence of 
phlebitis increased with time. 
The probability of not developing phlebitis as a function of 
time was compared for the filter and control groups. Since 
many of the observations were censored, the method of Kaplan 
and Meier (the K-M estimate of the survival function) was 
used. Figure 2.2 depicts these estimates for the filter and 
control groups and shows that the incidence of phlebitis was 
lower in the filter group between 25 and 130 hours. 
The significance of this difference was tested using Gehan's 
test which is a generalisation of Wilcoxon's rank test. The 
generalisation was necessary due to the use of censored 
data. A test statistic of 2,25 was obtained, which is 
significant at the 5% level. 
Gehan's test was also used to compare the incidence of 
phlebitis between initial and subsequent infusions. No 
significant difference was found. 
The chi-square test was used to investigate whether cannula 
size or site of cannulation affected the incidence of 
phlebitis. Neither of these parameters was found to exert a 
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Figure 2.1 
Cumulative incidence of phlebitis over time in the filter 
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significant effect on the incidence of 
Table 2.6 gives the severity of phlebitis in the filter and 
control groups. The difference between the filter and 
control groups, as 
phlebitis, was tested 
regards the overall severity of 
using a chi-square test with three 
degrees of freedom, and was not statistically significant. 
The overall incidence of grade 3+ and greater phlebitis was 
34% (24/70) and 18% (11/62) for the control and filter 
groups, respectively. This difference was statistically 
significant (p=0,0316) using the chi-square test. At 72 
hours the incidence of grade 3+ and greater phlebitis was 
24% (17/70) and 6% (4/62) in the control and filter groups, 
respectively. This was statistically significantly 
different using Fisher's two-tail exact test (p=0,0077); 
this test was used because, with the low numbers involved, 
it gives a more accurate statistic than the equivalent 
chi-square test. 
Antibiotics were included in 90% (118/132) of infusions. 
The incidence of phlebitis in patients receiving intravenous 
antibiotics and in patients receiving the cephalosporins, 
cephamandole and ceftazidime, and penicillin alone is given 
in Table 2.7. One infusion 
excluded from this analysis, as 
administered concomitantly. 
The incidence of phlebitis 
containing antibiotics was 
high doses of heparin were 
for infusions containing 
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Table 2.7 
Effect of intravenous antibiotic therapy on the incidence of 
phlebitis. 
Antibiotic Incidence of phlebitis 
therapy Filter group Control group p* 
All antibiotics 27/57 ( 4 7%) 41/61 (67%) 0,0293 
Cephalosporins 7/18 (39%) 18/23 (78%) 0,0103 
Penicillin 6/11 ( 5 5%) 10/14 ( 71 % ) > 0, 05 
* Differences were tested using a chi-square analysis; 
significance was assigned to a probability value of 0,05. 
Table 2.8 
Incidence of phlebitis and mean time to phlebitis with 
different infusion fluids 
Infusion Incidence of Mean time to Standard 
fluid phlebitis phlebitis (h) deviation 
Normal Saline 52/88 (59%) 69,3 44,6 
Other fluids 7/16 ( 4 3 % ) 48,4 31,2 
Combinations* 15/28 ( 5 3 % ) 76,4 38,6 
Note 
1) * Normal saline was used in combination with other 
intravenous infusion fluids. 
2) There were no significant differences 
phlebitis or mean time to phlebitis between 
tested, using the chi-square test and 
one-way analysis of variance, respectively. 
for incidence of 
the three groups 
Kruskal - Wallis 
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antibiotics was significantly greater in the control group 
than the filter group, at the 5% level using the chi-square 
test (p=0,0293). The difference was statistically 
significantly greater (p=0,0103) when the cephalosporins 
were tested separately, but no significant difference was 
found between the two groups for penicillin. 
The effect of other individual intravenous medicines on the 
incidence of phlebitis could not be tested, as insufficient 
numbers were available. 
Table 2.8 shows the incidence of phlebitis and mean time to 
phlebitis with different infusion fluids. The 
Kruskal-Wallis one-way analysis of 
used to compare the effect of 
variance procedure was 
normal saline with other 
intravenous infusion fluids, alone or combinations of 
infusion fluids, on the mean time to phlebitis. The 
chi-square test was used to compare the effects of infusion 
fluids on the incidence of phlebitis. No significant 
difference was found between the three groups for either 
parameter. 
The reasons for discontinuation of intravenous infusions are 
given in Table 2. 9. The percentages of infusions 
discontinued electively, and for infiltration into tissues 
and inadvertent removal, are approximately the same for both 
groups. Sixty three percent of infusions in the control 
group were discontinued due to phlebitis, as compared to 47% 
in the filter group. This difference was not statistically 




Reasons for discontinuation of intravenous infusion 
Reason for Filter group Control group 
discontinuation n=62 n=70 
Elective 14 (22%) 13 (19%) 
Phlebitis 0 29 (47%) 44 ( 6 3%) 
Blockage 13 (21%) 8 ( 11 % ) 
Other* 6 ( 10 % ) 5 ( 7 % ) 
Note 
1) 0 Blockage was also reported as present in 6 infusions in 
the filter group and 4 in the control group. 
2) * This includes infiltration into tissues and inadvertent 
removal by patients or ward staff. 
3) There was no significant difference between the two 
groups using chi-square analysis, as regards the reasons for 
discontinuation of infusions; significance was assigned to a 
probability value of 0,05. 
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however, p=0,06 and this difference may tend 
significance with a larger sample. 
towards 
The percentage of infusions discontinued due to blockage was 
approximately twice as great in the filter group as compared 
to the control group, being 21% (13/62) and 11% (8/70), 
respectively. The difference between the filter and control 
groups was tested using a 
statistically significant. 
present in 6 infusions 
chi-square analysis, and was not 
Blockage was also reported as 
in the filter group and 4 in the 
control group, when phlebitis necessitated discontinuation 
of the infusion. 
The preceeding statistical analyses showed that there were 
no overall statistical differences between the filter and 
control groups for the parameters 
incidence of phlebitis. It was 
tested, except for the 
therefore felt to be 
important to statistically 
phlebitis in the control 
elimination of any possible 
evaluate the incidence of 
and filter groups, after 
bias that may have been 
introduced by the higher incidence of blockage in the filter 
group. 
After the exclusion of infusions discontinued due to 
blockage, 49 infusions remained in the filter group and 62 





mean time of 77 hours, compared to 73% in 
in a mean time of 63 hours. The 
incidence of phlebitis was tested using the chi-square test 
and the time to phlebitis using a Kruskal-Wallis one-way 
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analysis of variance. No statistically significant 
difference was found between the two groups for either 
variable. 
In view of the high incidence of blockage, it was deemed 
necessary to investigate parameters that may have influenced 
the development of blockage. The chi-square test was used 
to compare the group in which blockage occurred, with the 
group which was blockage free, in terms of race, cannula 
size, site of cannulation, sex, intravenous fluids 
(categorized as normal saline alone or other intravenous 
fluids) and smoking, whilst age was compared using the 
Student's t test. No statistically significant differences 
were found between the two groups for the parameters tested. 
Summary of results 
The results indicate that the filter and control groups were 
comparable for the parameters tested, except for the overall 
incidence of phlebitis. There was a statistically 
significant reduction in the overall incidence of phlebitis 
when a filter was included in-line; this was especially 
marked when antibiotics were included in the intravenous 
infusion. 
This reduction in the incidence of phlebitis was not 
significant at the 5% level after the exclusion, from the 
statistical analysis, of infusions in which blockage of the 
access line had developed. 
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The overall severity of phlebitis was not statistically 
different when a filter was included in-line; however, the 
reduction in the incidence of grade 3+ and greater phlebitis 
in the filter group was statistically significant. 
This study also demonstrated that the incidence of phlebitis 
increased with the duration of infusion. 
Variables such as site of cannulation, size of cannula and 
infusion fluids used did not affect the incidence of 
phlebitis. 
2.9 Discussion 
No statistically significant differences were found between 
the filter and control groups, in the various variables 
tested, which included the incidence of phlebitis between an 
initial and subsequent infusion. This latter point was of 
particular importance to this study as many patients were 
used for more than one cannulation site, which reduced the 
variation between the groups. 
The inclusion of the 0,2 µm air venting filter in-line made 
a real contribution to the reduction in the incidence of 
phlebitis. However, the presence of the filter in-line did 
not affect the mean time to onset of phlebitis, the mean 
duration of infusion, or the overall severity of phlebitis. 
The overall incidence of phlebitis in the control group 
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(64%) was similar to that reported by DeLuca et al. (3), 
Evans et al. (22), Chamberland et al. (26) and Allcutt et al. 
(23), all of whom used similar criteria for phlebitis. 
Clinical trials suggesting the beneficial effects of in-line 
filters were first reported in 1973 and in all, except in 
the recent trial by Allcutt et al. (23), the infusions were 
discontinued after a specified time, ranging from 48-72 
hours. In this study and that of Allcutt et al. (23), 
infusions were allowed to run until no longer required, or 
until there was a reason for removal. 
In the first published clinical trial, by Ryan et al. (16), 
the reduction in the incidence of phlebitis between the 
control and filter group, from 45% to 2%, was much greater 
than was reported subsequently by other investigators. The 
great difference in the incidence of phlebitis between the 
control and filter groups reported by Ryan et al. (16) 
cannot be explained. The 45% incidence of phlebitis in 
their control group, after 72 hours infusion, was comparable 
with the 47% in this study, and the 51% in the study of 
Al 1 cut t et a 1 • ( 2 3) • 
Direct comparison between clinical studies is difficult, 
because the pore size 
and the criteria for 
of filters, the duration of infusion 
phlebitis varied widely between 
studies, as can be seen from Table 2.10. 
In three studies, which demonstrated an advantage for 
in-line filters, infusions were allowed to run for 72 hours 
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Table 2.10 
Clinical studies using in-line filters 
Reference Duration Filter Phlebitis Incidence of phlebitis 
of study size score Filter Control 
(h) ;.r:n Group Group 
This a) 30 0,2 2 3/62 ( 5%) 10/70 (14%) 
study b) 48 a,2 2 9/62 (15%) 25/70 ( 36%) # 
c) 72 0,2 2 15/62 (24%) 33/70 (47%) l 
d) >72 0,2 2 29/62 ( 4 7%) 45/70 (64%) j 
Ryan et al. 16 72 0,45 3 1/51 ( 2%) 22/49 ( 45%) # 
DeLuca et al. 3* 72 0,45 2 19/75 (25%) 44/71 (62%)# 
Evans et al. 22* 72 5 2 2/24 (18%) 14/25 ( 56%) # 
Maddox et al. 20* 48 0,22 l 4/20 (20%) 12/20 (60%) 
2 2/20 (10%) 7/20 (35%) 
Rusho & Bair 18* 60 0,45 4 N S ( 6%) N S (27%) i 
5 4 N s (22%) N S (27%) 
Allcutt et al. 23* a) 72 0,2 2 32/101(31%) 47/93 (51%) it 
b) >72 0,2 2 49/101(48%) 51/93 (55%) 
Collin et al. 24 NS 0,45 2 13/33 (39%) 12/27 (44%) 
Swift et al. 17 72 0,45 l 7/24 (29%) 6/26 (23%) 
O'Brien et al. 25 48 0,45 2 14/33 (42%) 6/15 (40%) 
Chamberland et al.26 48 0,45 l 72/107(67%) 53/84 ( 63%) 
Thayssen et al. 27* 72 0,45 2 27/57 ( 4 7%) 33/58 (57%) 
Maddox et al. 28 48 0,22 1-3 38/95 ( 40%) 39/100(39%) 
kev --
* denotes a double blind-trial 
j denotes a significant difference at the 5% level 
NS= not stated 
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and similar criteria for phlebitis were applied. DeLuca et 
al. (3) in 1975 reported a decrease in the incidence of 
phlebitis, from control to filter group of 62% to 25%, Evans 
et al. (22) in 1976 from 56% to 10%, and Allcutt et al. (23) 
in 1983 from 51% to 31%. 
From Table 2.10 it can be seen that after 72 hours the 
incidence of phlebitis in this study, when a filter was 
included in-line, is similar to that found by DeLuca et al. 
(3) and Allcutt et al. (23). 
Two studies, demonstrating an advantage for filters, used 
shorter infusion periods. Maddox et al. (20) reported a 
reduction in the incidence of phlebitis, over 48 hours, from 
35% to 10% when an in-line filter was included, which is 
comparable to the 36% and 15% of this study, over the same 
time period. Rusho and Bair (18) using more stringent 
criteria for phlebitis, equivalent to grade 3+ or greater, 
found no difference in the incidence of phlebitis when a 
5 µrn filter was included in-line; however, a reduction from 
27% to 6% was obtained with a 0, 45 µ m filter, over 
approximately 60 hours. In this study the overall incidence 
of grade 3+ and greater phlebitis was 34% and 18% for the 
control and filter groups, respectively and at 72 hours, 24% 
and 6%. 
Allcutt et al. (23) determined the survival time of 
intravenous infusions and found that the inclusion of a 
filter in-line was clinically advantageous for infusions 
lasting 72 hours and under, but not for infusions of over 72 
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hours. The incidence of phlebitis in the control and filter 
groups, respectively was 55% and 48% for infusions of over 
72 hours. They also reported that in-line filtration 
prolonged the phlebitis-free survival time of infusions; 
only 38 (41%) infusions in the control group were able to be 
continued until no longer required, compared to 63 (62%) in 
the filter group. 
In this study, the overall incidence of phlebitis was 
statistically significantly lower in the filter group for 
infusions of 25 to 130 hours duration. This difference in 
clinical advantage over time, when compared with the results 
of Allcutt et al. (23), could possibly be explained by the 
inclusion of antibiotics in a higher percentage of infusions 
in this study. This study, and those of Maki et al. (601 
and O'Brien et al. (25), demonstrate that antibiotics 
increase the incidence of phlebitis, however, Swift et al. 
(17) concluded from their study that phlebitis was not 
associated with any particular type of additive. 
Most of the studies conducted have included antibiotics 
and/or other additives in at least some of the infusions. 
However, the type of medicine infused and the number of 
infusions with additives cannot always be established from 
the published papers, except for the studies of Maddox et 
al. (20) and Rusho and Bair (18) in which a cephalosporin 
was included in all infusions. 
This study, as well as those of Allcutt et al. (23), Maddox 
et al. (20) and Rusho and Bair (18), found the inclusion of 
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an in-line filter to be beneficial when antibiotics were 
administered through the intravenous line. This was most 
pronounced when the antibiotic was 
comparison Chamberland et al. (26), 
a cephalosporin. In 
reported that filters 
exerted no protective effect when irritant solutions such as 
cephalothin sodium or potassium chloride were infused. 
A higher percentage of access lines in the filter group than 
the control group were discontinued in this study due to 
blockage. This was possibly due to an unwillingness, by 
ward staff, to manipulate an infusion line when a filter was 
included. 
When infusions in which blockage of the access line occurred 
were excluded from the statistical analysis, there was no 
significant difference between the incidence of phlebitis in 
the filter and control groups. The possible link between 
blockage of the access line and the development of phlebitis 
is not known, therefore, it is not possible to comment on 
whether discontinuing the infusion due to blockage might 
have biased the data. 
The studies showing an advantage for in-line filters 
reported no problems due to blockage, but the pore size of 
the filters was larger than 0,2 µm, except in the studies of 
Maddox et al. (20) and Allcutt et al. (23). 
In five of the studies showing no clinical advantage for 
in-line filters (17,24,25,26,27), a 0,45 µm filter was used. 
In the study by Collin et al. (24), filters were changed at 
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48-hour intervals or when the filter blocked, which occurred 
with 53% of the filters. Chamberland et al. (26) and 
Thayssen et al. ( 27) experienced problems with blockages. 
Chamberland et al. (26) replaced filters every 24 hours or 
sooner if blockage occurred and they state that it was not 
possible to conduct a double-blind study as the placebo 
filter would not become blocked. 
Previous studies utilised filters which were unable to 
release air entering the filter, and this caused blockage. 
The filters used in this study and those of Allcutt et al. 
(23) and Maddox et al. (28) contained a hydrophobic 
membrane, which eliminated air, as well as a large 
hydrophilic membrane for filtration of fluids, which allowed 
flow rates to be maintained. 
The published studies, except for the study by Rusho and 
Bair (18) and part of the study by DeLuca et al. (3), do not 
appear to have complied with present requirements that 
filters should be changed at daily intervals, to prevent the 
possibility of micro-organisms retained on the filter from 
liberating endotoxins (107). This procedure itself could 
increase the risk of microbial contamination. 
DeLuca et al. (3) found the incidence of phlebitis to be 
32%, when the filter and administration set were changed 
daily, as opposed to 12% when the filter was not changed 
over the 72 hours of the study. This difference could be 
due to trauma caused at the cannulation site when the filter 
and infusion set were changed, or to microbial 
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contamination. Rusho and Bair (18) did not investigate the 
effects of filter changes on the incidence of phlebitis. 
The incidence of phlebitis increased with time, for both the 
control and filter groups. This is in agreement with the 
study of Thayssen et al. (27), who stated that the 
cumulative risk of developing post-infusion phlebitis 
increased with the duration of infusion. They found that 






This section of the investigation included evaluation of 
microbial contamination of in-line filters, skin at the site 
of insertion of the cannula, and cannulae. The data 
collected were used to determine: 
a) if there is any correlation between the number of 
additives to the infusion system and microbial contamination 
of in-use filters 
b) if filters reduce microbial contamination of the cannula 
tips, and 




is any correlatfon 
of the skin, or the 
betweeri microbial 
cannula tip, and 
Microbiological evaluation of filters, swabs and cannulae 
was carried out in the laboratories of the Department of 
Medical Microbiology at Groote Schuur Hospital. 
3.3 Materials and methods 
3.3.l Sampling of filters 
Filters were replaced in the patient's access line daily, to 
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prevent the accumulation and proliferation, on the filter, 
of Gram-negative endotoxin-producing bacteria (107). 
The patient's skin surrounding the filter was cleansed with 
70% ethyl alcohol. The intravenous infusion was 
interrupted, using the clamp on the administration set, the 
used filter was disconnected and the filter inlet plugged 
with a sterile stopper. A new filter was attached to the 
access line, primed, and then connected to the cannula, in 
place of the used filter. The outlet of the used filter was 
plugged with a sterile stopper and labelled with the 
patient's name, trial number, date and time of removal. 
In the Department of Medical Microbiology the filters were 
washed with 50 ml of sterile normal saline, in an attempt to 
remov~ any residual inhibitory drug, and opened using a 50 
ml bolus of sterile air under pressure. The air was 
previously sterilized using a sterile Mille~ FG 0,2 µm 
filter (Batch No CIA 89203). 
The filter membranes were removed aseptically from the 
filter casing, using a flamed and cooled scalpel, and 
treated as follows: 
i) The central membrane was cultured: 
a) aerobically by placing the container side of the 
membrane onto the surface of a 2% blood agar plate, and 
allowing it to remain in contact with the surface for 
one minute prior to removal. 
b) anaerobically by placing it_in cooked meat medium. 
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ii) The container side of the two outer membranes was placed 
on 2% blood agar and allowed to remain in contact with 
the surface for one minute prior to removal. These 
membranes were not placed in cooked meat medium due to 
the possibility of contamination of the patient side of 
the membranes via the air venting apertures. 
After incubation at 37°C for 48 hours, micro-organisms from 
the blood agar plates and cooked meat medium were 
identified. The blood agar plates were incubated for a 
further 72 hours at 37°C and any fungal growth identified. 
3.3.2 Controls 
Positive and negative controls were prepared using 0,2 µm 
filters. 
Candida albicans and 8-haemolytic streptococci were used to 
prepare positive controls. 
Sterile normal saline was inoculated with Candida albicans, 
and then two 50 ml aliquots were drawn into 50 ml sterile 
syringes and passed through two 0,2 µm filters. 
This was repeated for 6-haemolytic streptococci. 
Negative controls were prepared similarly using sterile 
normal saline. 
The filters acting as positive and negative controls were 
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then processed in the same way as filters obtained from 
patients. 
3.3.3 Sampling of skin and cannula tips 
The skin was sampled for microbial contamination, at the 
site of insertion of the cannula, immediately before removal 
of the cannula. 
Swab 1 was taken from the site of insertion of the cannula, 
prior to cleansing of the skin, using a sterile Transwad]) 
MW 170 (Batch Number 01 1021) moistened with Amies clear 
transport medium (108,109). The swab was then inserted into 
Arnies medium in the Transtube. 
The skin surrounding the site of cannulation was then 
cleansed, using a centrifugal motion, with 70% ethyl alcohol 
and allowed to dry. 
Swab 2 was taken, in a similar manner to swab 1, after the 
skin had been cleansed. 
The cannula was then withdrawn from the patient's vein with 
sterile forceps, and the distal 2 cm cut off with sterile 
scissors and placed in the transport medium in a sterile 
Trans tube. 
The swabs and cannula tips were transferred aseptically into 
cooked meat medium, incubated for 48 hours at 37°C, and the 
cultured organisms identified. 
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3.4 Statistical analysis 
The effect of skin contamination on mean time to phlebitis 
was investigated using the Kruskal-Wallis one-way analysis 
of variance (105). For all other statistical analyses 
either the chi-square test or Fisher's two-tail exact test 
were used (104). 
The null hypothesis was that there is no statistically 
significant difference in the parameters tested between the 
two groups under investigation. Significance was assigned 
to a probability value of less than 0,05; where an 
association is reported as not significant, this means a 
probability value of greater than 0,05. 
3.5 Results 
results for each patient are given in Microbiological 
Appendix II. Where reference is made to Trial Numbers, the 
digits indicate the patient number, and the first three 
digit following the oblique indicates the Trial cannulation 
site number. 
Microbiological results were obtained for 209/216 filters 
from 62 infusions. Four filters 




could not be 
opened without contaminating the filter membranes. 
Cannula tips and swabs from 112/132 intravenous infusions, 
55 from the control group and 57 from the filter group, were 
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examined for microbial contamination. Twenty infusions were 
discontinued by ward staff or patients and, therefore, swabs 
and cannulae could not be collected. 
3.5.1 Filters 
The negative controls were all culture negative and the 
positive controls were all culture positive for the seeded 
organisms. 
Contaminated filters originated from 19/62 (31%) of infusion 
systems with filters in-line. 
From Table 3.1 it would appear that contamination of the 
infusion system was not affected by the number of 
intravenous medicines added. A chi-square analysis was 
performed using three categories, 0, 1 and 2 or more 
additives; no significant relationship was found between the 
number of additives and microbial contamination of in-use 
filters from infusion systems. 
Twenty eight of the 209 filters cultured (13%) were 
contaminated. Fifteen of the contaminated filters 
originated from 6 infusions and the remaining 13 originated 
from one infusion each. From Table 3.2 it would appear that 
there was no apparent association between the number of 
filters used per infusion, which reflects the number of days 
of infusion, and the presence of microbial contaminants. An 
analysis of the patient data in Appendix II indicates that 
there was no discernible pattern in the day to day sequence 
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Table 3.1 
Relationship between the number of intravenous (IV) 
additives and contamination of filters in infusion systems 

















































4/8 · 50 
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0/1 0 


















from each infusion 
0 1 2 3 4 
6 1 0 0 0 
9 4 0 0 0 
12 4 1 0 0 
5 0 2 0 1 
4 1 1 0 0 
4 3 0 l 0 
2 0 0 0 0 
l 0 0 0 0 
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of contaminated filters. 
Table 3.3 summarizes the organisms isolated from filters. 
Staphylococcus epidermidis was the most common 
micro-organism isolated from filters, accounting for 69% of 
all isolates. Two species of fungi, Aspergillus nidulans 
and a Cephalosporium species, were isolated from the same 
filter. 
A single species of bacterium was isolated from 21 filters 
and two species from 6 filters. 
3.5.2 Skin 
Microbiological results for skin contamination, at the site 
of insertion of the cannula prior to removal of the cannula, 
were obtained for 112 infusions. 
i) Microbial contamination of the skin prior to 
cleansing with 70% ethyl alcohol. 
Fifty seven of the 112 (51%) skin swabs taken prior to 
cleansing of the skin at the cannulation site (swab 1) 
yielded the micro-organisms listed in Table 3.4. 
Staphylococcus epidermidis was the most commonly 
cultured micro-organism; Bacillus, Corynebacteriurn, 
Enterococcus and Micrococcus species were isolated more 
than once. 
Forty nine swabs were culture-positive for a single 
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Table 3.3 































Micro-organisms cultured from the skin, at the site of 
insertion of the cannula, prior to cleansing 
Micro-organism Number of Swabs with 
isolates rnul tiple isolates 
Bacillus sp 7 3 
Bacillus rotans 2 1 
Corynebacterium sp 2 1 
Enterococcus sp 4 3 
Micrococcus sp 3 2 
Staphylococcus aureus 1 1 
Staphylococcus epiderrnidis 47 6 
Non-haemolytic streptococcus 1 1 
- 74 -
species of organism, 6 for two species and 2 for three 
species. 
Table 3.5 gives the incidence of skin contamination 
prior to cleansing of the skin and removal of the 
cannula. In the filter group 44% of infusions were 
associated with skin contamination at the site of 
insertion of the cannula, compared with 58% in the 
control group. No statistically significant difference 
was found, using a chi-square test, between the filter 
and control groups. 
From an analysis of the patient data in Appendix II it 
was found that in 9 of the 19 infusions with 
contaminated in-line filters, the same contaminants were 
cultured from the filters and the skin prior· to 
cleansing. 
ii) Microbial contamination of the skin after cleansing 
with 70% ethyl alcohol. 
Fifteen of the 112 (13%) skin swabs, taken after 
cleansing of the cannulation site with 70% ethyl alcohol 
(swab 2), were contaminated with the micro-organisms 
detailed in Table 3.6. Staphylococcus epidermidis was 
the most common contaminant; Staphylococcus aureus and 
Bacillus, Enterococcus, 
species were also isolated. 
Micrococcus and Penicillium 
A single species of micro-organism was isolated from 11 
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Table 3.5 
Incidence of skin contamination with micro-organisms, at the 














There was no statistically significant difference between 
the filter and control groups using a chi-square test. 
Table 3.6 
Micro-organisms cultured from the skin, at the site of 
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swabs and two species from 4 swabs. 
Twelve of 57 postcleansing swabs from the filter group, 
and 3/55 from the control group were contaminated. This 
difference was significant at the 5% level, using 
F i she r ' s exact t es t ( p= 0 , 0 2 4 2 ) • 
One infusion, Trial Number 033/1, was associated with a 
culture-positive postcleansing swab, but a culture-negative 
precleansing swab, and in 4 infusions, Trial Numbers 023/1, 
027/1, 066/1 and 068/1, the organisms on the two swabs 
differed. 
The incidence of phlebitis following infusion was 
approximately the same whether or not micro-organisms were 
isolated from the skin. Phlebitis ~eveloped in a mean time 
of 64 hours, in 61% (35/57) of the group with skin 
contamination, and 74 hours in 55% (30/35) of the group with 
no skin contamination at the site of insertion of the 
cannula. 
A chi-square analysis confirmed that microbial contamination 
of the skin had no significant effect on the incidence of 
phlebitis. Using the Kruskal-Wallis one-way analysis of 
variance, skin contamination was found to have no 
significant effect on the mean time to phlebitis. This 
nonparametric method of analysis was used to compare cases 
with or without skin contamination, since the time to 
phlebitis did not have a normal distribution. 
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3.5.3 Cannula tips 
Twelve of the 112 (10,7%) cannula tips cultured were 
contaminated with the organisms listed in Table 3.7. The 
micro-organism most frequently isolated was Staphylococcus 
epidermidis; four cannula tips were contaminated with 2 
species of micro-organism, and eight with a single species. 
There was no instance of septicaemia associated with a 
contaminated cannula. 
Micro-organisms were isolated from 8/57 (14%) cannula tips 
in the filter group, compared to 4/55 (7%) in the control 
group. This difference was not statistically significant 
using Fisher's exact test. 
The incidence of phlebitis' was 67% (8/12) when cannula tip 
contamination was present and 57% (57/100) when 
contamination was absent, see Table 3.8. The mean time to 
phlebitis was 70 hours and 68 hours, respectively. Fisher's 
exact test was used to compare the incidence of phlebitis, 
and the Kruskal-Wallis one-way analysis of variance was used 
to compare mean time to phlebitis, in the presence and the 
absence of cannula tip contamination; no statistically 
significant differences were found. 
The mean duration of cannulation for the 12 contaminated 
cannula tips was 78 hours as compared to 81 hours for the 
uncontaminated cannula tips. The Kruskal-Wallis one-way 
analysis of variance confirmed that microbial contamination 
of cannula tips had no significant effect on the mean 
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Table 3.7 

























Correlation between incidence of cannula tip contamination 
and phlebitis 
Phlebitis Contaminated Uncontaminated 
cannula tips cannula tips 
n=l2 n=l00 
Present 8 (67%) 57 (57%) 
Absent 4 ( 3 3 % ) 43 ( 4 3 % ) 
There was no statistically significant difference in the 
incidence of phlebitis, using the Fisher's exact probability 
test. 
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duration of infusion. 
Antibiotics were included in 7/12 (58%) of infusions in 
which cannula tip contamination was 
(93%) of infusions in which cannula 
present, and in 93/100 
tip contamination was 
absent. This difference was statistically significant using 
the Fisher's exact test (p=0,003). 
From Table 3.9 it can be seen that the same species of 
micro-organisms were isolated from the skin, prior to 
cleansing, and the cannula tips in 7/12 infusions. Filters 
were included in-line in 8/12 infusions with contaminated 
cannula tips (Table 3.9). In four of these 8 infusions, 
filters and cannula tips were contaminated; in 3 instances 
the same s~ecies of micro-organism, Staphylococcus 
epidermidis, was isolated from both the filters and cannula 
tips. 
Summary of results 
In this study there was no correlation between microbial 
contamination of the skin or cannula tips, and the 
occurrence of phlebitis or mean time to phlebitis. 
In addition, there were no significant differences between 
the filter and control groups, as regards contamination of 
the skin prior to cleansing or of the cannula tips. This 
indicates that skin and cannula tip contamination were not 
significant variables in the development of phlebitis and 
that in-line filters did not reduce the microbial 
- 80 -
Table 3.9 
Correlation between microbial contamination of swabs, cannula tips and filters, 
phlebitis and duration of cannulation 
Trial Number Micro-organisms isolated Phlebitis Antibiotic Duration 
Number contam. Swab l Swab 2 Cannula score included in of cann. 
filters infusion (d) 
011/2 1/2* H H 2+ N 2,4 
019/1 0/6 A+C 3+ y 5,8 
020 2/3* H H H 2+ N 2,9 
026/1 Control B+D+G D+G D+G 0 N 3 
/2 2/4* D E+H l+ N 3,1 
035/1 0/4 H 2+ y 3,5 
/2 Control H l+ y 2,5 
046/3 1/2 H H H l+ N 1,8 
050 Control H H 3+ y 4,8 
053 0/1 A A A 3+ y 1,5 
071/2 0/6 D+H 3+ y 5,7 
072/1 Control F+H H 2+ y 1,8 
* infusions in which the same mice-organisms were isolated from both the 
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Note: The criteria for phlebitis are given on page 37 
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contamination of cannula tips. The fact that the incidence 
of skin contamination, after cleansing the skin, was 
significantly greater in the filter group appears to be of 
little clinical importance. 
Contaminated filters were obtained from 19/62 infusions. In 
three infusions, the same species of micro-organism was 
isolated from the filters and cannula tips, which may 
indicate retrograde contamination of the filters from the 
cannulae. Infusions running for prolonged periods, with a 
consequent increase in the number of filter changes, did not 
demonstrate a greater incidence of contamination than 
infusions running for shorter periods. In addition, 
contamination of infusion systems was not increased by an 
increment in the number of intravenous medicines added. 
There was a low level of cannula tip contamination, which 
could possibly be explained by the high percentage of 
antibiotics administered. 
There was a significant reduction in the incidence of 
microbial contamination between the precleansing (51%) and 
postcleaning (13%) skin swabs, thus proving the efficacy of 
70% ethyl alcohol as a skin disinfectant. 
The principal micro-organism isolated from filters, swabs 
and cannula tips was Staphylococcus epiderrnidis; other 
common skin commensals such as Bacillus, Enterococcus, 
Micrococcus and Corynebacteriurn species were also isolated. 
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3.6 Discussion 
3.6.1 Contamination of cannula tips 
The incidence of cannula tip contamination in this study, 
10,7%, falls within the wide reported range of 3,8% to 57% 
( 3 2) • 
This study, like those of Fuchs (38), Cheney and Lincoln 
(34) and Band and Maki (37) demonstrated a low level of 
cannula contamination, even though the technique used was 
culture in broth and not the semiquantitative method 
recommended by Maki et al. (39). 
Maki et al. (39) claimed that the clinical interpretation of 
a positive broth culture was unclear, as a positive culture 
may result from very few organisms. This may account for 
the relatively poor reported correlation between phlebitis 
and cannula tip microbial contamination (32,41). They 
suggested that the semiquantitative method, utilising a 
plate culture, differentiates infection from contamination. 
In their study, 10% of cannula tips yielded significant 
growth on a plate culture and this was interpreted as 
contamination. 
In this study, using the broth culture technique, 12/112 
(10,7%) of cannula tips were culture-positive and 67% (8/12) 
of contaminated cannulae were associated with phlebitis. 
These figures are similar to the 10% (25/250) and 64% 
(16/25) respectively, reported by Maki et al. ---- ( 3 9) • 
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However, contrary to the findings of Maki et al., there was 
no significant difference between the number of 
culture-positive and culture-negative 
associated with phlebitis. 
cannula tips 
In this study the majority of cases of ~hlebitis were not 
associated with culture-positive cannula tips and, in fact, 
most studies have failed to demonstrate a relationship 
between phlebitis and a positive cannula tip culture 
(24,34,35,36,37,38,40,110). 
In contrast to the reports of Druskin and Siegel (35), 
Collins et al. (40) and Maki (5), there was no association 
in this study between duration of cannulation and 
culture-positive cannula tips. 
The inclusion of a filter in-line did 
incidence of cannula tip contamination. 
not reduce the 
This is in 
agreement with Collin et al. (24);_however, their cannula 
tip contamination rate, 58%, was much higher. 
Maki (30,31) stated that cannula related infections derived 
mainly from the patients own skin flora or from personnel 
inserting or handling the cannula. The most common isolates 
reported are Staphylococcus aureus, Staphylococcus 
epidermidis, Gram-negative bacilli, Enterococci and Candida 
(8,13,31,32,33,110). I~ this study similar contaminants 
were isolated, except for Candida. 
Maki et al. (32) pointed out that phlebitis may dispose to 
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an increased risk of cannula-related sepsis and that, whilst 
phlebitis is usually a physicochemical phenomenon, in its 
later stages secondary infection may occur and lead to 
sepsis. In this study no case of sepsis was associated with 
a contaminated cannula, but, if the sepsis rate of 0,5% as 
reported by Rhame et al. (41) is considered, there were 
insufficient numbers to demonstrate this association. 
3.6.2 Contamination of filters 
Contamination of in-line filters has been reported in the 
range of 2,8 to 27% (19,24,55,61,63). 
In this study, in which the infusion line was broken daily 
to change filters, contaminated 
of 62 (31%) infusions, and 13% 
filters orig~nated from 19 
(28/209) of the filters 
cultured were contaminated. This is similar to the 11% 
(7/65) contamination rate for filters reported by Rusmin et 
al. (63), but lower than the 21% and 27% reported by Collin 
et al. (24) and Newman et al. (61), respectively. In these 
studies (24,61,63) filters remained in-line for the duration 
of the infusion, unless blockage occurred, and the incidence 
of contamination of filters reflects the incidence of 
contamination for the infusion system. 
Newman et al. ( 61) stated that the main source of 
contaminacing microbes seemed to be the hands of personnel 
changing infusion containers, as Staphylococcus epiderrnidis 
was the most common contaminant. The common skin cornmensals 
were isolated from filters in this study, which does imply 
that the main source 







3.6.3 Contamination of infusion systems 
was the personnel 
administration of 
rather than the 
If contamination of filters reflects contamination of 
intravenous solutions, or additives, or administration sets, 
or contamination during use, rather than contamination due 
to daily filter changes or retrograde contamination from the 
cannula, it follows that 31% of infusion systems were 
contaminated in this study. 
This percentage of contamination is similar to the 27% 
reported by Newman et al. (61) but is considerably higher 
than the 11% reported by both Maki et al. (60) and Rusmin et 
al. (63), which could possibly be explained by the daily 
breaking of the infusion line when changing filters. In the 
study by Maki et al. (60) infusion fluid from 10/94 (11%) 
in-use systems contained micro-organisms, usua!ly 
staphylococci or bacilli. Contamination appeared to be 
related to the duration of continuous intravenous therapy as 
9/61 systems in-use for longer than 48 hours were 
contaminated, compared to 1/33 of those in-use for less . than 
48 hours. The occurrence oLphlebitis in 29/94 (32%) of 
cases did not correlate with contamination of the infusion 
system. 
The incidence of in-use contamination of intravenous 
- 86 -
infusions has been associated with increased duration of 
uninterrupted .infusion (2,49,54), 
appeared to be no correlation 
but in this study there 
between the duration of 
infusion and contamination of the infusion system. 
This study, in agreement with those of Letcher et al. (54), 
Hughes (57) and Hanson and Shelley (59), demonstrated little 
correlation between the addition of intravenous medicines 
and the contamination rate of intravenous infusions. In 
contrast, studies conducted by D'Arcy and Woodside (56) and 
Woodside et al. (62) indicate that drug additives may be a 




PARTICLE SIZE ANALYSIS 
4.1 Aim 
This study was undertaken in order to determine: 
a) the particulate load of intravenous infusion fluids, and 
medicines entering the patient's systemic circulation 
b) if the particle counts of the infusion fluids and 
medicines comply with the British Pharmacopoeia 1980 
specifications (101) 
c) if an in-line filter reduces the particle count of 
infusion fluids and medicines. 
4.2 BP 1980 Limit test for particulate matter 
According to the BP 1980 (101) specifications the average 
count for the undiluted infusion fluid, using an apparatus 
which operates on the electrical zone-sensing principle, eg 
the Coulter Counter, must not exceed 1000 particles/ml 
greater than 2 µm, and 100 particles/ml greater than 5 µm. 
At present, this test is only applicable when the volume of 
intravenous infusion fluid is 100 ml or more and is 
specified in the particular monograph; the test does not 
apply to small volume parenteral injections or to powders 
requiring reconstitution prior to injection. 
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4.3 Location 
Particle counts were carried out in the Department of 
Pharmacology, Medical School, University of Cape Town. 
4.4 Materials and methods 
Particle counts were performed using a Coulter Counte~ 
Model ZM, fitted with a 70 µm orifice tube. The Coulter 
Counter detects, counts, and measures the size of individual 
particles by changes in electrical resistance that occur 
when particles pass singly through a small orifice. The 
instrument measures particle volume, and the diameter of a 
particle is expressed as the diameter of a sphere, with the 
same votume as the particle. The results are obtained as 
numbers of particles equal to or larger than a specified 
size. 
The Coulter Counter was calibrated with a dispersion of 
latex spheres, of diameter 4,77 µm, in sterile normal saline 
filtered through a 0,2 µm air venting filter, using the half 
count technique (111). Particle counts were performed on 
intravenous infusion electrolyte solutions and on 
intravenous medicines to establish the number of particles 
of size 2 µm and greater, 5 µm and greater and 10 µm and 
greater. Sterile normal saline filtered through a 0,2 µm 
air-venting filter was used both as the diluent and as the 
electrolyte solution when preparing intravenous medicines 
for particle counting. 
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A minimum of two samples of each product was counted, each 
count being performed six times, and the mean value taken. 
Samples of 0,05 ml were counted; therefore, the mean value 
was multiplied by 20 to give the number of particles/ml. 
Prior to sampling, each container was inverted 20 times to 
suspend particles uniformly. Samples were transferred to a 
particle-free cuvette (washed with filtered sterile normal 
saline) and placed in an ultrasonic bath for 30 seconds 
prior to counting, in order to disperse aggregates of 
particles and minimize air bubbles. 
Special precautions were NOT taken to avoid the introduction 
of extraneous particulate matter during the preparation of 
medicines and all particle counts were made at room 
temperature, in order to approximate clinical conditions. 
4.4.1 Preparation of samples 
i) Intravenous infusion fluids 
Intravenous infusion fluids were transferred from the 
infusion container, via a Continu-Flo Solution 
Administration Set (Batch No 111 S 513) into a cuvette and 
counted. 
The counts were repeated following filtration of the 
infusion fluids through a 0,2 µm air venting filter. 
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ii) Intravenous medicines 
Intravenous medicines in solution were added to a 50 ml 
minibag of sterile normal saline (Baxter Batch No 203Vl41) 
via a sterile 10 ml Promex syringe (Batch No 2/119). 
Powdered intravenous medicines, requiring reconstitution 
prior to administration, were prepared by adding water for 
injection (see Table 4.3), via a sterile 10 ml Promex 
syringe. When the powder was dissolved, the resulting 
solution was transferred via the syringe to a 50 ml minibag 
of normal saline, as is done in the wards. Fifteen minutes 
after preparation the mixed solution was transferred via an 
Add-A-Line (Batch No 111 S 533) into a cuvette and counted. 
The counts were repeated, following filtration of the 
prep~red medicines through a 0,2 µm air venting filter. 
A particle size analysis was performed on the following 
medicines for intravenous administration both before and 












































The particulate content of intravenous infusion fluids and 
medicines is given in Tables 4.1, 4.2 and 4.3. 
The results of the particle size analysis show little 
corr~lation between samples from the same batch. All three 
minibags of normal saline, but only two of the ten samples 
of intravenous infusion fluids, complied with the BP 1980 
limit test for particulate matter, prior to filtration. All 
of the intravenous medicines failed to comply with the limit 
test. 
Particle counts for the majority of samples of powders to be 
reconstituted prior to use were greater than for .intravenous 
medicines supplied in solution. 
Filtration of intravenous infusion fluids and medicines, 
through the 0,2 Jm air venting filter, brought all samples 
to within the B . P limits for particulate matter, except for 
one sample of normal saline (Labethica Batch No 778LI) at 
the 2 µm level and one sample of normal saline (Baxter Batch 
No 202vll) at the 5 µm level, and one sample of ampicillin. 
Summary of results 
Infusion fluids as supplied by the manufacturer's are 
expected to comply · with the limit test for particulate 
matter specified in the 1980 BP. This study demonstrates 
that the majority of the intravenous fluids sampled, after 
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Table 4.1 
Particle size analysis of intravenous infusion fluids after 
passage through an administration set 
Sample Sample Mean particle count/ml 
Number Unfiltered solution Filtered solution 
~2 µm ~5 µm ~10 µ m ~2 µm >5 µm,>10 µm 
Normal Saline l 4673 173 0 70 0 
Baxter 200 ml 2 1643 46 0 83 0 
Batch No 202Vll 3 2256 90 0 220 143 
4 896 50 0 223 45 
Normal Saline 1 2510 226 0 1033 43 
Labethical000 ml 2 650 66 0 300 0 
Batch No 7748LI 3 1023 43 0 
Dextrose 5% in 1 1423 206 0 210 20 
Normal Saline 2 3026 53 0 143 0 
Baxter 200 ml 3 2216 60 0 403 10 
Batch No 111V670 
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TABLE 4.2 
Particle size analysis of 50 ml minibags of normal saline, and 
intravenous medicines in solution, in 50 ml minibags of normal 
saline after passage through an Add-A-Line 
Medicine Sample Mean particle count/ml 
Number Unfiltered solution Filtered solution 
~2 µm .;>5 µm 910 µm ~2 µm ~5 µm >10 µm 
Normal saline 1 563 60 0 63 0 
50 ml minibag 2 300 56 0 40 0 
3 456 30 0 56 0 
Amikacin 1 3790 222 0 113 0 0 
500 mg/2 ml 2 12546 1296 180 
3 9466 446 0 
Co-trimoxazole 1 2926 125 0 
480 mg/5ml 2 5426 346 0 
3 2566 230 0 
Gentamicin 1 2276 140 0 20 0 0 
80 mg/2 ml 2 2766 153 0 20 0 0 
3 1993 56 0 10 0 0 
Tobramycin 1 1696 80 0 
40 mg/2 ml 2 1293 160 0 
3 3460 180 0 
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TABLE 4.3 
Particle size analysis of reconstituted powders for intravenous 
administration, in 50 ml minibags of normal saline after passage 
through an Add-A-Line 
Medicine Sample Mean particle count/ml 
Number Unfiltered solution Filtered solution 
~2 µm >5 µm~l0 µm~2 µm~5 µm;;>l0 µm 
Ampicillin 1 10446 203 1900 126 
500 mg+3ml WI 2 4950 226 153 10 
3 13673 306 446 40 
Benzylpenicillin 1 2533 116 106 0 
sodium 600 mg 2 6010 193 70 0 
+3ml WI 3 4843 206 
Cefamandole lg 1 18170 1416 113 220 20 
+5ml WI 2 6486 440 0 50 0 
Ceftazidime lg 1 3920 233 0 46 0 
+3ml WI 2 9146 306 0 76 0 
Cloxacillin l 7083 346 0 160 0 
500 mg+3ml WI 2 18833 2140 0 193 20 
3 5143 393 0 32 0 
Chloramphenicol 1 41333 1516 103 73 0 
1 g+7,5ml WI 2 51473 1056 53 643 0 
3 46706 966 16 40 0 
Diethanolamine 1 47736 3660 316 213 36 
fusidate 500mg 2 70956 5050 570 376 33 
+50ml buffer* 3 39503 2806 176 560 30 
Erythromycin 1 9716 486 0 560 63 
300 mg+6ml WI 2 6436 343 0 86 0 
3 7960 380 0 133 i3 
Rolitetracycline 1 5333 500 0 153 0 
275 mg+l0ml WI 2 6356 333 0 550 0 
3 14576 936 0 666 0 
WI= water for injection 
* sterile phosphate buffer solution was supplied with the 
powder 
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passage through administration apparatus, did not comply 
with the BP limit test. 
Particle counts for intravenous medicines in 50 ml minibags 
of normal saline all failed to comply with the BP limit 
test for particulate matter. 
Filtration of infusion fluids and medicines reduced the 
particle counts to within BP specifications in the majority 
of samples tested. 
4.6 Discussion 
Myers (55) stated in 1972, that infusion bottles and giving 
sets are a source of particles and that micro-organisms can 
enter intravenous fluids. Logically, claims Myers, there 
should be a sterile bacteriological filter at the point 
where fluids enter the vein, so that micro-organisms and any 
particles from the rubber bung, glass bottle or plastic 
container, solution, giving set and tubing would be filtered 
out. 
Since then there has been an increase in the number of 
medicines administered intravenously and the particulate 
load of intravenous medicines is high, especially for 
powders requiring reconstitution. These microcrystalline 
drug particles, polymeric substances or degradation 
products, which are present in the subvisible range (96) and 
administered during intravenous therapy, may react with 
tissue proteins and thereby cause or contribute to the 
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complications of phlebitis. 
Traces of macromolecular proteins of peptide complexes 
possessing allergenic properties have been reported in the 
cephalosporins and penicillins (87,112), which were 
supposedly pure by pharmaceutical standards. In addition to 
the protein contaminants, polymers are formed in the beta 
lactam antibiotics either through internal rearrangement or 
degradation. These polymers may conjugate with tissue 
proteins after injection and may be involved in delayed 
allergic reactions. 
The presence of particulate matter in antibiotic 
preparations supplied as powders has been demonstrated in 
the past (95), but little information is available on the 
more recently introduced intravenous medicines. 
Rebagay et al. (96) commented that the medication added 
during intravenous fluid administration often contained more 
particles than the large volume parenteral itself. This was 
also found by Mehrkens et al. (68) and in this study. 
The considerable variation between particle counts for 
intravenous products within a batch could be partially 
explained by differences in the number of particles released 
by the administration sets or syringes. Studies are 
required, however, to determine the extent of inter-batch 
variation as well as the variation between manufacturers' 
products. Studies are also required to identify the 
particulate matter and determine its origin. 
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CHAPTER 5 
SUMMARY and CONCLUSION 
This study demonstrates that the incidence of phlebitis is 
significantly reduced by the inclusion of a 0,2 µ m 
air venting filter in-line. The efficacy of the filter in 
reducing phlebitis was most pronounced when intravenous 
antimicrobial agents, especially the cephalosporins, were 
administered. 
The inclusion of an in-line filter did not reduce the 
incidence of cannula tip contamination and a relationship 
was not found between phlebitis and microbial contamination 
of cannula tips or skin at the site of insertion of the 
cannula. 
The incidence of microbial contamination of infusion systems 
was high, 31%, as determined from the number of infusion 
systems with contaminated filters. A relationship could not 
be established, however, between microbial contamination of 
infusion systems, and the number of filters included, or the 
number of intravenous additives to the infusion system. 
Intravenous additives, and in particular the powders 
requiring reconstitution prior to administration, were 
heavily contaminated with particles and 
BP limit test for particulate matter 
would not pass the 
in large volume 
parenteral products. 
the majority of samples 
After filtration, particle counts of 
tested complied with the BP limit 
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test. 
It may be postulated that the reduction in the incidence of 
phlebitis was a result of the removal of particulate matter 
rather than the removal of micro-organisms from the 
intravenous system. 
The major deficiencies in this study were: 
a} the lack of data on microbial contamination of infusion 
systems 
establish 
in the control group. This made it impossible to 
whether the daily filter change - affected the 
incidence of contamination of infusion systems; 
b} the fact that very few patients received a single 
medicine for therapy. This made it impossible to establish 
a relationship between the particulate load of additives and 
phlebitis; 
c} the large number of variables between patients. This was 
overcome partially by using patients for more than one 
infusion period, which resulted in the filter and control 
groups being comparable as regards the parameters tested; 
and 
d} that some cases of phlebitis may have been missed as many 
patients were discharged immediately 
infusion was discontinued with the 
after the intravenous 
result that the 
intravenous sites could not be inspected the day after 
removal of the cannulae. 
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This study, in contrast to 
clinical reports, confirmed 
including a filter in-line. 
six of the twelve published 
the clinical advantage of 
The other six papers reported 
on the clinical advantage of using in-line filters. One of 
these six studies (20) failed to show a significant decrease 
in the incidence of phlebitis in the filter group, when the 
criteria used in this study are applied; one (18) failed to 
report on the number of patients in the control and filter 
groups; and one was not blinded (16). In another study (22) 
a 5 µm pore size filter was used, which indicates that 
removal of micro-organisms 
reduction in the incidence of 
was not responsible for the 
phlebitis. The remaining two 
studies (3,23) showing a clinical advantage for filters were 
double-blinded and used larger sample sizes than in the 
other four. 
This study demonstrates the need for a filter which is 
capable of adsorbing microbial endotoxins, but not 
intravenous additives, thus relieving ward staff of the 
necessity of a daily filter change and preventing possible 
microbial contamination of the infusion system during this 
procedure. It also emphasizes the need for a limit test for 
particulate matter in small volume parenteral injections and 
for powders requiring reconstitution prior to injection. 
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APPENDIX I 
Instructions for use of filter 
1) Insert needle adapter of administration set into filter 
inlet. 
2) Holding the filter below the level of the infusion 
container, open the clamp of the IV administration set, and 
ensure the back (flat side) of the filter is completely 
filled. 
3) Close administration set clamp. 
4) Rotate the filter to observe the · front of the filter. 
5) Remove the protective cap from the filter outlet and open 
the administration set clamp to prime filter and entire 
pathway, and ensure that air bubbles are absent. 
6) Attach the filter outlet to the cannula. 
Diagram of filter 
Filter 
Filter outlet 
Patient data collected 
Hospital and ward 
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APPENDIX II 
Patient's name and hospital number 
Trial number 
Infusion number 






Site of cannulation, where inserted and by whom 
Type and size of cannula 
• Length of infusion in hours and reason for discontinuation 
Daily phlebitis score 
Time to phlebitis in hours 
Time, date and reason for infusion set change 
Time and date of filter change 
Length of hospital stay 
Oral medicines administered 
Intravenous medicines administered 
Intramuscular medicines administered 
Intravenous fluids administered 
Microbial contaminants isolated from skin 
Microbial contaminants isolated from filters 
Microbial contaminants isolated from cannula tips 
Dressing over cannula 
Alcohol intake 
Smoking habits 
PAT I ENT - OOL Coloured Fema le Age 16 years 
DIAGNOSIS Pulmonary tuberculos i s 
Empyema 
Drainage of lung al:>scess 
ALCOHOL INTAKE Ci] 
SMOKlNG DJ 


















BLOOD PRESSURE """Hg 
mrn.h 
xlO'I . ( 
120/ 80 120/ 80 130/ 90 
E S R 











. ?eni cillin 2mu MEDICINES -----. ?4 •• __ ;:;__:..::.;.::a;:;.:.:='-> IV .6h 
?d + Gentamicin 80mg IV .Sh 
+ Metronidazole 400mg po ----- • ?4 - __ _..;~=====a::...===-...i.:.; 
f'lorohine 2mgIV. h ! 
INTRAVENOUS FLUIDS I RF D5! RF 
TOTAL DURATION OF INFUSION 
Final phlebitis score 
Days to phlebitis 
• Elective removal of IV line. 
PATI!NT 002 - Coloured Male 

















Aortic incompetence secondary to bacterial endocarditis 




ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S':'UDY 
CANNULAT!ON SITE 
















Renal failure - acute 
Left ventricular failure 
Microbiology 
1st Cannulation. site 
Filter l i Ceohalosporium species 
ii Asperg1l lus nidulans 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 







FILTER/ CONTROL PERIOD V//////J I///////IJ!////J [ ='·::-:::. ·:.-: :·.::~::: :·:'.': ·.: ·.: : ·.':-': r.:,:: :.::: . .-: :·· :·:-:::::· >.: ::.: ·:·:,\::: .... ,: .. ::·:·:=I 
PHLEBITIS SCOR£ 0 0 0 - 0 0 1:.3 0 l+ l+ 2+ TEMPERATURE •c 35, 9 36.3 36,1 36,l 36 36,2 36, 5 36,4 36,3 36 
PULSE RATE .m 88 84 90 88 80 90 
J ao 80 88 92 80 
RESPIRATORY RATE . m 28 24 24 20 22 24 24 28 24 24 20 
BLOOD PRESStJRE IMI Hg 130/ 80 130/80 140/80 140 / 70 130/60 130/70 130 / 60 140 / 60 130/ 80 120/ 80 130/ 50 
E s R mm . h 108 - - 100 97 79 87 - 66 - 128 
w 8 C COUNT xlO~ . e 9 7,5 - - 7, l 8 7, 3 - 5,9 - 6,3 
HAEMATOCRIT , 240 , 279 - - , 295 ,350 ,344 - , 286 - , 296 
HADIOGLOBIN " · dt 9 9, l - - 9,7 ll ,6 10 ,2 - 9 ,2 - 9,9 
IIIED ICIN ES L_ __ 5.,1. _ ---·~"',:.:·o::.:b::.:r.::am~y-:'c..:.i:.:.n..;80m,,:::::::S:....,:I,.:V......,; . ,:d------------------------------
L__ _ _ 21,q _ --".".·:::?:-'e.,.n,...1'-:c::'.i:-°l-:l""i :.:.n_?,.,<m"'u"-:-'I:-"V'-:.':6.,_,h ___ ,----------------------------
! 20mg rv 1,urosemide 30mg oo .d 
l___ . -~q_. ---·..aD;.:i:.:c:.:l:.:o..:.oc;,;n..:.e:.:.n:ac=-S::Oacm:::g'---"o:.:oc....::t :d:,.s ____________________________ _ 
INTRAVENOUS FWIOS '------'-N..:.S;..... ____ ....j 
TOTAL DURATION OF INFUSION 
~ Final phlebitis score 
Days to phlebitis 
• Elective removal of rv line . 















PATIENT 003 - Co loured Male Age 57 years Mass 68kg 
DIAGNOSIS Lo bar pneumonia - Streotococcus oneumoniae 
Urethral str icture 
ALCOHO L INTAKE Ci] 
SMOKING [I] 




FILTER/r.ONTROL PERIOD ... :~ -~ ::·.:.·.: ~- :··.::~ ::.- :. : .: .: : ::···:·:.·.:·:.: ·. :.· ·.:: ..... 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E S R mm.h 
W a C CCUNT xlO'I. t 
HAEMATOCRIT 
HAEMOGLOBIN o: . dt 
MEDICINES I - ~d- -
INTRAVENOUS FLUIDS 
TOTAL DVRATION OF INFUSION 
0 0 3+ 
36 36,4 36 
74 74 80 
20 24 20 




11 8 11,8 -
+ Cefamandole l . Sg 
NS 
Final phlebitis score 















PATIENT - 004 Black Male Age 31 years Mass 57kg 
DIAGNOS IS Lobar pneumonia - Klebsiel l a pneumcniae 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF STUDY 
CANNULAT!ON SITE 
FILTER/ CONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE °C 
PULSE RATE .m 















E S R 
mm Hg 
mm.h 
xlOq . t 
120/70 120 /70 110/70 






TOTAL DURATION OF IN FUSION 
26 32 39 
11 5 5,2 
1,464 ,390 , 398 
I 1s. s 14 13 .4 
jCeftazidime l g IV .ah 
!Paracetamol l g; 00 .6h 
NS 
Final phlebitis score 
Days co phlebitis 









Filter l NG 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 
PATIENT 005 - Coloured Male 
114 
Age 23 years Mass 60kg 
DIAGNOSIS Suspected pneumonia - final diagnosis not established 
ALCOHOL INTAKE [f] 
SMOKING [I] 




2 I 3 4 
2nd 
5 0 
FILTER/~ONTROL PERIOD I I I I I I /!I I ii l//,I II II l!L:i/ :·::·.,::>:->.:-'-:\::-_::::-:·;:-.=.: ?I 
PHLEBITIS SCORE 0 
I :6.6 
l+ 0 0 2+ 
TEMPERATURE •c 36 36, 7 36,6 36,2 36,5 
PULSE RATE .m 60 58 70 70 76 70 
I 
I RESPIRATORY RATE . m 20 22 20 20 20 20 
BLOOD PRESSURE !Ml Hg 120/70 130/ 80 130/70 130/70 120 110 I 120no I 
E S R mm.h 12 lO 12 ll -
W B C COUNT x1o'I . t 
HAEMATOCRIT 
HAEMOGLOBIN q . dt 
MED IC INES 
1:-ITRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
-
4,2 4,7 7,0 - 6,9 -
,434 ,407 ,520 - ,440 -
15,l 14,9 16,4 - 4,9 -
jCefamandole 1 . sg IV .Sh 
IIndom~thac ;n 2Smg no tds 
~ Pethidine 50mg IM 
Final phlebitis score 
Days to phlebitis 
NS 




• Infusion discontinued due to local pain 
PATENT 006 - Coloured Male Age 32 years 
DIAGNOSIS Lobar pneumonia - Stre~~ococcus pneumoniae 
ALCOHOL !NTAKE GJ 
SMOKING [!] 








FILTER/ ~ONTROL PERIOD ·:;<,\:!: :·::;::.JI I I, Ill/!//, 111111111/A 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY ~ATE .m 
BLOOD PRESSURE mm Hg 
E S R mm . h 





TOTAL DURATION OF INFUSION 
OUTCOME 
0 3+ 0 
38,2 37 36, 7 
80 80 76 
20 20 20 
140/100 130/ 80 130/ 90 
- - 46 
14,8 - 6,4 
, 563 - ,391 
16,8 - 13,2 
(Cefamandole l,5s tV .Sh 
!Indomethacin 25mg oo t ds 
NS 
final phlebitis score 
Days to phlebitis 
• Elective ~emoval of rv line . 
0 0 
36, 7 36,6 
70 80 
28 28 
140/80 140/ 80 
35 52 
6,4 8 , 5 
,366 ,375 
12,8 12,8 





1st Cannulation site 
filter l NG 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 
2nd Cannulation site 
Cannula ) Discar ded by 
Swabs ) ·•ard staff 





1st Cannulation site 
Cannula NG 
Swab l Stachylococcus ecider!'lidis 
Swab 2 NG 
2nd Cannulation site 
F"il ter 1 NG 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 





?ATIENT 007 Black Male Age 40 years Mass 67kg -
DIAGNOSIS Lobar pneumonia - Klebsiella species 
?ancreatitis 
Chronic alcoholism 
ALCOHOL INTAKE [i] 
SMOKING (}] 
DAY OF S':"JllY 
CANNULA! !Q,; SITE 
FILTER/r.ONTROL PERIOD 
PHLEBITIS SCO RE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E S R mm.h 
'ii B C COUNT xlOq . t 
HAEMATOCRIT 
HAEMOGLOBIN a .dt 
I l 2 3 
- lst--2nd-
l//////1 :.:·-:·:·:::· .... -.:-.::?.:·::~:·.··.:·; 
3+ 3+ 4+ 
38,5 37,4 38,8 
112 108 120 
28 24 30 
130/80 160 / 80 140/90 
95 - 88 
19,8 - 21,4 
,313 - ,253 
10,8 - 8 ,5 
MED I CINES L___ . _ 5il _ • __ ._.C:;;ec,:f.:::am=an::;d,:;o::..l:.:e::....:l:.,,..:5:.o"i...:.IV~.:.;· 6::.:h~-
L___ __ Sj ____ +;_.;.M.:.:e:..;t:.:.ro=nc::i c::da=z::.o;:.;l;;.;e:;._40..:.;:0"'m_,g...o:.o=-t=.:d;;.;s=--. 
INTRAVENOUS ,LUIDS 
TOTAL DURAT~ON OF INFUSION 
1st Cannulation site 
ld 
PATIENT 008 -
Fina l phlebitis score 
Days t o phlebitis 




DIAGNOSIS Lobar pneumonia - bactericiogical diagnosis not establis hed 
ALCOHOL INTAKE (1) 
SMOKING ~ 
DAY OF S'!"UUY 
CANNULAT!Qt; SITE 




1st Cannulation site 
Filter l NG 
Cannula NG 
Swabs NG 
2nd Cannulation site 
Cannula NG 
Swabs NG 






Swabs NG FILTER/ .ONTROL PERIOD :':. :,.:-:::: •: .... :.:: ·: ··:.: ;:.-:·::::: .. : :• :' :.': ·: ...... ; : .=: '.: .. :.:;,::, :·: ... ;: :.:·. :·. :· .: .::::.'·-:I 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSC: RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E s R mm.h 
'ii 3 C COUNT xlOq . t 
HAEMATOC!UT 
HAEMOGLOBIN ". dt 
i'!EDICINES 
lNTRAVENOUS ftuIOS 
TOTAL DURATION OF INF'TJS!ON 
OUTCOME 
0 I l+ I ~6.3 0 39 36,8 36,4 
96 70 84 76 
38 28 24 28 
130/80 140/ 80 150 / 80 130/ 90 
- 123 ' 112 100 
- 10,8 7 9,3 
- ,383 ,361 ,330 
- 12,3 11,9 11, 5 
I Cefamando le l,S<>: rv .Sh 
I indomet;iacin 25mg oo tds 
I Hexoorenaline Neb . .lh 
Final phlebitis score 





2+ 3+ 3+ 
36,2 36, 5 37 
70 88 80 
24 24 J 20 
130/60 130/ 80 i 120 / 80 
- as 72 
- 9,9 10, l 
- ,399 ,384 
- 13,4 13,l 
1 16 
PATIENT - 009 Coloured Male Age 26 years Mass 55kg 
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
ALCOHOL INTAKE ~ 
SMOKING (2) 





PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R mm.h 





TOTAL DURATION OF INFUSION 
l 2 3 I 4 5 
1st 
~/::: :"-:.?·:-:·: :::.·;: :· .: .:·:: ?:-:·: .: ·: .=:-:-::, .':,::, ·: . .'·.::,: 1 
0 0 0 
36,4 36,4 36 ,6 
96 70 88 
30 30 40 
110/60 120 / 80 100/70 
- 100 101 
- 14,9 14, 7 
- ,412 ,331 
- 12,5 10,8 
I Ceftazidime lg rv . Sh 
NS 
Final phlebiti s scor e 
























PATIENT 010 Coloured Female Age 22 years -
DIAGNOSIS 3ila~eral pyosa l pinx - bacteriological diagnosis no~ es tablished 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S':'UDY 
CANNUL;l,T!Otl SITE 
FILTER/ rDNTROL PERIOD 
PHLEBITlS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY :!A!E . m 
BLOOD PRESSURE mm Hg 
E s R mm.h 
\j/ B C COUNT x10" . t 
HAEMATOCRIT 
HAEMOGLOBIN 11 . dt 
MEDICINES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF ~NFUSICN 
l i 2 
t-- lst-
_:_::.:: ;-i;: .' :·:.: :~.'-1 






1 10, l -
,309 -
10,4 -
IEblitem,cycline I 275mg IV . 12h 
I ?s 
Final phlebitis score 






Swab l Staphylococcus epidermidis 





) ward staff 
PATIENT 011 - Coloured Male 
DIAGNOSIS Duodenal ulcer 
Vagotomy 
Gastro- jejunostomy 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S':'UOY 
117 
Age 27 years 









E S R 










xlOq . t 
,,,d( 
':'OTAL DURATION OF INFUSION 














































1st Cannulation site 
2,4d 
Final phlebitis score 





PATIENT 012 Coloured Male Age 45 years -
DIAGNOSIS Myocardial infarction 
Angina pectoris 
ALCOHOL INTAKE ~ . 
SMOKING ~ 
DAY OF S':' 1.JDY l 2 
CANNULAT!Q;; SITS ~ lst-7. 
3 4 I 5 6 
2nd 
FILTER/r.'.lNTROL PERIOD '///////////}.t/\:':::/::; ·._: :· :·-:::·:{; ,:·::,:.··.\:~·:::·\:\:~:.:: 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R :nm.h 
"' 3 C COUNT xl01 . ! 
HAEMATOCRIT 
H AEMOG LOB IN 12 .dt 
MEDICINES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
l+ 11 · 0 0 0 0 
36 37,5 35,9 36,4 36,1 36,9 
100 112 90 82 78 90 
24 26 20 18 20 20 
120/90 110/iO 120/ 90 110/60 110/70 I 100/ 60 
30 32 32 38 - ! 40 
15,5 13,4 14,1 16,4 i0,2 9,4 
,509 , 520 ,515 ,470 
I 
,487 ,461 
17 16,6 18 16,6 16 15,3 
I !sosorb1de dinitrate 20mg oo gid 
1 'Moduretic 1 po ?.d 
JParacetamol lg po . 6h prn 
fMe toprolol 50mg po tds 
I D iazepam 5mg po tds 
I Mori:,hine 2mg J IV prn 
NS 
1st Cannulation site 
l,5d* 
Final phlebitis score 
Days to phlebitis 
Discontinued due co i nfiltration in~o tissues 
l+ 
N/ A 
• Elective removal of IV line 
Microbiology 




l Staohylococcus eoiden:1idis 
2 NG 
2nd Cannulation site 
Filter 1 NG 
;11 ter 2 Staehyloccccus eoidermidis 
Cannula Staph:t:lococcus eEiderm1dis 
Swab l Staphyiococcus eoidermidis 
Swab 2 NG 












i -. haemolytic streptococcus 















PATIENT 013 - Coloured Male 
118 
Age 30 years Mass 55kg 
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S':'UDY 
CANNULAT!ON SITE 






E S R 














130/90 120 /70 
129 120 
27, 1 19 , 4 
,342 , 290 
11,8 10,6 
I Ceftazidime lg; 
0 0 0 
36,4 36 ,a 37 
80 90 84 
28 30 28 
140/90 140/100 160/100 
136 139 
18,2 15,9 17,6 
,338 ,320 ,316 
11, 2 10 10,3 
IV .Sh 
~ Po1:assium chloride 1,5g rv 
INTRAVENOUS FLUIDS NS M 
TOTAL DURATION OF INFUSION 
OUTCOME Final phlebitis score 
Days to phlebitis 
• ~lective removal of IV line. 
PATIENT 014 - Coloured Male 
DIAGNOSIS Fractured femur - compound 
Sepsis -~ mirabilis 
ALCOHOL INTAKE ~ 
SMOKING ~ 








E S R 







































• Gentamicin 100mg IV .Sh MEDI CIN ES L_ __ 9g ____ -=:.=====-= =......:..;._.:.=.:..---' 
+ '?anadeine' ? 00 .6h om .6t, L__ _ 5_2~ _ -----'-'~==-"--'---------------L.__ _6_2£ _ ------'~~;;.;;.;;'"""".=;...;;.;c=;.;;.-...;;.;;.;..;.;,;a......;_.;.. 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
OUTCOME 
• Dext~oorouoxYPnene 
! D5inNS l NS 
Fina l phlebitis score 
Days 1:0 phlebitis 












:'il 1:er l NG 
Filter 2. NG 
Filter 3 NG 
Filter 4 NG 
Filter 5 NG 
Cannula NG 
Swa b l Staphylococcus eoidermidis 
Swab 2 NG 
!-licrobiolog;y 
Filter l NG 
Filter 2 NG 
Filter 3 NG 




PATIENT 015 Coloured Male Age 38 years -
DIAGNOSIS Lung abscess - bacteriological diagnosis not established 
Epilepsy 
Chronic alcofio l ism 
ALCOHO L INTAKE ~ 
SMOKING ~ 
DAY Of S':'Ullf 
CANNULAT!ON SITE 
I l 
4- l s t -1-
I ? I 3 I 4 5 
2nd 
I 6 I 7 I 8 9 
3rd 
f'ILTER/ ."ONTROL PERIOD :.:.:::::=·'.-."VI//////, 1///////J I////////// I //.I·:.::;-.:·.:.::-:::'-:::'.·.::;· .. ::·.-·=·.'·.~.·::·:>:-:::':: :.:I 
I 2+ 0 
. 
l+ 0 l+ 3+ 3+ PHLEBITIS SCORE l+ l+ 
TEMPERATURE •c 38 38,2 38,2 37 37,8 37,7 37 36,9 36,3 
PULSE RATE .m 100 90 100 80 88 92 88 ,: 60 RESPIRATORY RATE .m 32 24 28 20 32 24 20 20 
BLOOD PRESSURE mm Hg 100/70 110/70 130/90 130/80 120/80 120/80 110/70 il20 / 80 110/70 
E S R mm . h - 114 118 106 107 100 110 i95 98 
W B C COUNT xlOq . t 17,4 14,5 17,2 17,9 15,3 15 10,9 I 8,6 19,9 
HAEMATOCRIT ,352 ,358 ,338 , 336 
I 
,326 , 343 - I· 316 ,339 
HAEMOGLOBIN :z.d( 11 , 6 11,5 ll ,4 11 , 2 11 11,8 11,9 10, 5 11,3 
MEDICINES I Penicillin lOmu IV .6h Smu IV .6h 
I Metronidazole 400mg oo . 8h 
I Indomethac in 25mg po t ds 
---------C..:P~h~e~n~y~t:::o~i~n.....::::.300:::::..~~~g>-,-l:o~o~a~t~n::.1~g~h~c=---------------------~ 
- • __ . ____ c..:Pc..:h.:.::e::.n:::o:::b:::ar::..;:o.:_i t;;o::n.:;e:......:30=.m~gc..a::p:::.o~. 8::hc:._ ____________________ -+ 
t~TRAVENOUS fLUIDS 
TOTAL DURATION Of INFUSION 
OUTCOME Final phlebitis score 
Days to phlebitis 
• Discontinued due to ~lockage of access line. 
' 
PATIENT 016 - Coloured Male Age 35 years 
NS 





DtAG.'40SIS Lobar pneumonia - bacteriological diagnosis not es tablished 
ALCOHOL INTAKE [jJ 
SMOKING ~ 





1st Cannulation site 
Cannula NG 
Swabs NG 
2nd Cannulation site 
Filter l NG 
Filter 2 NG 
Filter 3 NG 
Filter 4 NG 
Filter 5 NG 
Filter 6 NG 
Cannula NG 
Swabs Stao hr lococcus 
eoidermidis 
3rd Cannulation site 
Cannula NG 
Swabs NG 




DAY Of S':'lJlJY Microbiolos,y 
CANNULAT!ON SITE 
FILTER/ ."ONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R mm.h 





TOTAL DURATION OF CNFUSION 
0 0 0 0 
37,2 36,6 37,9 38,2 
110 84 80 100 
32 30 32 36 
100 / 60 100/ 60 130/90 130 / 80 
86 101 91 105 
13,2 7,5 l0,3 lO, 7 
,408 ,367 ,366 ,346 
14,2 11, 9 12,5 11 ,8 
I Cefta:zidime lg IV .Sh 
I Indomethacin 25mg oo tds 
I Paracetamol 1!1j 
Final phlebitis score 




• Discontinued due to blockage of access line and local pain . 
Filter l NG 
Filter 2 NG 
Filter 3 NG 
filter 4 NG 
filter 5 NG 
0 l+ l+ 
filter 6 Staoh:i: lococcus eoide~ i C:. : 
Cannula NG 
Swabs Staoh:z:lococcus ~oi::ier'7ni::i: ~ 
36 ,6 36,8 36,5 
92 100 I so I 
32 30 : 28 
140 / 80 140 / 90 : 130 / 80 
32 105 j 108 
I 
10, l 6,7 16, 32 
,385 ~38°9 . ,-
13,4 13, 7 13,5 
po tds om • 
120 
PATIENT 017 Coloured Male Age 31 years :.lass 60kg -
DIAG.'IOSIS Lobar pneumonia - bacteriological diagnosis not establ ished 
Brown ~quard syndrome 
ALCOHO L INTAKE ~ 
SMOKING ~ 
DAY OF STUDY 
CANNULAT!O,; SITE 






E S R 

















































MEDICINES I.__. ~<! - ___ +_c,..e_r,..am_a.,.n.,..d_o_le.,.._1.., • ..,s,.g.._I_v_ ._8..,.hj 
t__ _ ~d- .. ---"-' _I:;.:c.:.::d:.:ao::.:m:.::e""tc:..:ha.::.c.:;in:.o...;2::.:Sm=g'-"o.::.o-=.td;:.s;:._ _ 
!NTRAVEllOUS FLUIDS 
TOTAL DURATION OF INFUSION 
OUTCOME 
NS 
Fina l phlebitis score 
Days t o phlebitis 
• Elective ,re~oval of rv line. 
PATIENT 018 Coloured Ma l e Age 63 years -
DIAGNOSIS Cho l eli thias i s 
Choi ecystectomy 
Hypertension 
.U.COHOL INTAKE [i] 
SMOKING ~ 













E S R 










x10" . ~ 



















9 , 8 
, 369 
12 ,S 




I CeX't:"':O!"CCOxvot-eie l Dng oo . 41 cm 
I ?areve:-erun 155 ;;.1. ~hi 
?9 M 
Final phlebitis score 
Da ys to phlebiti s 
3,9d 
2• 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































- " 0. 













PATIENT 020 Black Ma l e Age 48 years -
DIAGNOSIS ?ancreatitis - alcoholic 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S,UDY 
CANNULAT!O:, SITE 






E S R 








xlOq . l 































filter l NG 
tilter 2 Stae h:z:lococcus eo idermidis 
Filter 3 Staoh:z:lococcas eoiderm1dl's 
Cannula Staohylococcus eoidermidis 
Swabs S t ao h:z: lo coccus eoidenn1d.is 
)IEDICINES I ?apaveretum 1Sm;t ( i:M .Sh prn 
iNTRAVENOUS FLUIDS 
TOTAL DURAT ION OF INFUSION 
RF I 
!"inal phlebitis 3core 
Days ::0 phlebit i s 




Mass 72 kg 
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not esi:ablished 
ALCOHOL :NTAKE Ci] 
5:~0KING W 
DAY OF' 5".'UDY Microbiology i l 2 3 
A:lNULAT!O:, SITE l s,: Cannulation site - 1st- ,-2."ld ~ 






E S R 










xl01 . l 
z.dt 
TOTAL DURATION OF IN FUSION 
_:.-::: ... :.::-_-":·.:.::,::::·:: l·:·:·.\' .. <}I 
0 12+ 1 2+ 
37 l 36, l 36,3 
92 62 60 
18 20 18 
ll0/70 130/90 100/ 70 
11 5 105 98 
15 ,5 7,2 7 , 7 
- ,339 ,355 
ll. 5 ll,6 12.l 
I Cef':azidime ls rv . Sh I 
I Hexoo rena line )l eb . ah • 
I NS 
Final phlebitis 3Core 













1st Cannulation site 
l, 7d 




PATIENT 022 - Coloured Male Age 62 years 
123 
Mass 50kg 
OIAG.'lOSIS ~obar onecunonia - bacteriological diagnosis not established 
Chroni~ obstructive airways di sease 
ALCOHOL INTAKE Ci] 
SMOKING [}] 
DAY OF STUIJY 1 ' , 4 5 I 6 7 I 3 Microbiology CANNULAT!O:l SITE 






E S R 


































































MEDICINES ld ~ Penicill i n 2mu Pl .6h 
I Cefamandole lg IV .6h 
ld • Indomethac in 25-50mg oo tds 
I Hexoprenaline Neb .4h 
Thiamine 100mg oo .d 
INTRAVENOUS FLUIDS pt NS j 55 j 








11 , l 
,321 
10 
















TOTAL DURATION OF INFUSION 
1st Cannulation site 
4,8d· 
2nd Cannulation site 
2,8d• 
Final phlebitis score 
Days to phlebitis 
0 
N/ A 
•£lective ~emoval of IV line. 
PAT I ENT -
D!AG.'lOSIS 
023 3lack Male Age 44 years Mass 58 kg 
Pnecunonia, necrotising - bacteriological diagnosis not established 
Microbiology 
1st Cannulation site 
Filter l,2,3,5,6 NG 
0 
NIA 
Filter 4 Staphylococcus eoidermidis 
ALCOHOL INTAKE 
SMOKING 
DAY OF S".'l/lJY ? 
CANNULAT!O:l SIT:: 
FILTER/ -ONTROL P~RIOD 
0 0 
Cannula NG· 
Swab l Staphylococcus eoider:nidis 
Swab 2 i Bacillus species 
ii ?~nicillium species 
4 7 
l+ 2+ 2+ 0 















0 l+ 3+ 3~ 
1? l< 





38, l 38 37, 7 37 37 37 36, 3 37, S 37, 6 37 37 37, 5 36 , 7 
E S R 
'II B C COUNT 
HAEMATOCRIT 









TOTAL DURATION Or :NFUSION 
OUTCOME 
118 110 108 lOO 110 80 76 90 100 
32 32 30 24 32 30 32 30 30 
130180 130170 140170 130190 120180 120 / 80 110170 120180 130180 
150 150 130 125 1-







!Penicillin Smu !V .6h 




9 , 7 
,300 
9,4 
I Mecron~dazo le 4C0mg oo . 3h 
I Parace tame l lg po tds 
Final phlebitis score 
Days co phlebitis 
lsc Cannulac ion sice 
5,9d 
NS 




• Discontinued due t:o i nfi l tra'Cion into tissues 
96 92 96 100 
30 28 28 30 
110160 130170 120170 100/70 
148 150 150 











PATIENT - 024 Black Male 
124 
Age 18 years Mass 46kg 
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not estab l ished 
Previous pulmonary ~ubercu!osis 
ALCOHOL INTAKE ~ 
SMOKING 0 
2 3 4 s 6 7 a -;JAY OF S':'UlJY Microbiology 
1st - 2nd -CA.'INUI.AT!m; SIT?:: 1st Cannulation site 
FILTER/CONTROL PERIOD 





E S R 










xlOq . t 
.d( 
TOTAL DURATION OF INFUSION 
0 lo 0 
36, 3 I 36,4 37, l 
52 1: 52 24 24 
120/ 80 1 110/ 60 120 / 70 
92 79 62 




, 4 . ', 0 
I Cefamandole l , Sg 
Final phlebitis score 
Days to phlebitis 
4 
IV .Sh 
• Elec~ive removal of IV line. 
PATIENT 025 - Coloured Female Age 24 years 
·: ::: : ... : : . .-:::·.: :.-:: :~."-.:~ Filter l NG 
Filte~ 2 Staohylococcus epiderr.,idis 
Filter 3 NG 0 0 3+ 0 0 
36,8 36,2 36, 7 36 36,2 Filter 
4 i ~ species 
ii Staohylococc~s ep1dermid i ! 
54 50 50 58 72 Filter 5 NG 
20 20 20 20 20 
Filter 6 i Bacillus species 
110/70 110/ 60 110/ 60 J 110 / 60 120/ 70 
i i Staohv l ococcus epide!"ffl1di £ 
Cannula NG 
Swabs Staphylococcus epiderm1dis 67 62 57 
5,8 5 , 5 7,2 
,409 ,401 ,438 
., ~ , 4 
NS 








2nd Cannulation s ite 
Cannula NG 
Swab Staohylococcus epidermid i s 
Swab 2 NG 
2nd Cannula~ion site 
l , 9c!• 
0 
N/A 
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
Bronchial asthma 
Drug allergy - cefamandole 
ALCOHOL INTAKE [iJ 
SMOKING [D 
~AV OF S':'UlJY 
Co<.NNULAT!Ql; SITE 
FILTER/ CONTROL PERIOD 
PHI.EBIT IS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hi 
E s R mm.h 
... B C COUNT xlOq . t 
HAEMATOCRIT 
HAEMOGLOBIN . d( 
MEDICINES 
!NTRAV?::NOUS FLUIDS 
TOTAL DURATION OF INFUSION 
~ 
2 3 
0 0 2+ 
38,4 36,2 37,l 
120 92 100 
28 24 30 
110/ 60 130/ 80 130/70 
78 78 
10,4 10,4 9,8 
, 377 ,427 ,390 
13,2 14, 3 12,5 
I r;;:r~mandole 1,5g IV J ,Sh 
l l ndomethacin 25m~ po 
jHexoorenal ine Neb 
D5 ! 
Final phlebitis score 
Days to phlebitis 
.4h 
• Discon~inued due to infiltra~ion i n~o tissues 
tds• 





1st CannulaLion site 
Filter l NG 
Cannula NG 
Swab 1 ~ species 
Swab 2 NG 
2nd Cannulation site 
Filter l NG 
Cannula NG 
Swab 1 Staohylococcus eoide:-midis 
s .. ab 2 NG 




PATIENT 026 - Age 58 years 
DIAGNOSIS Sezary syndrome - T cell tumour 
ALCOHOL INTAKE W 
SMOKING [I] 
DAY OF STUDY 
CANNULAT!ON SIT!i: 
l 2 I 3 
125 
Mass 61kg 
II l I 2 I 3 I 4 Micro bio logy 
1st Cannulation site 1st I 2nd 
F!LTER/~ONTRO L PERIOD I::·::·::.·:.::::,:.:>::·:·'.: ;_::_.::.\..:' 11//////////////1 1////////A Cannula Staohylococcus ~ ii Enterococcus 5pecies 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hi 
E s R mm.h 










84 80 80 
18 20 18 
150/ 60 150/70 120/70 
6 5 -
14, 7 10,8 -
,368 ,331 -
12,2 ll, 5 -
l2' 0CF 30mg IV .d 
NS 
Final phlebitis score 
Days to phlebitis 
• Elecciv~ ~emoval of IV line 
PATIENT 027 - Coloured Male Age 38 years 
0 0 l+ 
36,4 36,3 36,2 
80 76 leo 
- 20 lie 
I 




















ii Encerococcus species 
iiiCorynebac t erium species 
Swab 2 i Staphylococcus~ 
ii Encerococcus species 
2nd Cannulation site 
Filter l Staphylococcus eoidennidis 
Filter 2 NG 
Filter 3 S taoh:i: lococcus ~ 
ii Staohylococcus eoidermidis 
filter 4 NG 
Cannula i Staph;i:lococcus eoidennidis 
ii M.icrococcus ~ 
Swab l Enterococcus species 
Swab 2 NG 




DIAG.~OSIS Lobar pneumonia, bilateral - bacteriological diagnosis not es tablished 
Chronic alcoholism 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF STUD'!' 
CANNULAT!ON SIT!i: 






E S R 









TOTAL DURATION Of INFUSION 
2 3 
- 1s t -
0 0 0 
39 38,3 37,4 
100 104 100 
24 20 28 
130/80 120/75 130 / 80 
84 120 123 







ICefamandole 1,5g IV .ah
0 
1Clothiaoine <Ors 'N . §tj 
!Vitamin 8 Co 2ml !V .d l 
I :isl os i " Nsj NS I 
:inal phlebitis score 




• Discontinued due to blockage of access line. 
Microbiolo3y 
Filter l NG 
Filter 2 NG 
filter 3 NG 
Cannula NG 
Swab l Corvnebacterium species 







·--i~ ·- ., .• __ "'"" 
?AT:ENT 028 - Coloured female 
126 
Age 39 years 
DIAGNOSIS Pelvic inflammatory disease - bacteriological diagnosis not established 
ALCOHOL INTAKE [§] 
SMOKING m 





PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hi 
E S R mm.h 


















14, 7 13,9 
I J Penicillin 5mu IV . 6h 
1 JRolitetracycline 275mg IV . 12h 
!Co- trimoxazole 2 oo bd• 
IASoirin '500mg oo . 4h orn , 
)I 
Final phlebitis score 




• Discontinued due to blockage of access line . 
PATIENT -
DIAGNOSIS 
029 Coloured Male Age 41 years 
Lobar pneumonia - Streotococcus oneumoniae 
Chronic obstructive airways disease 




Filter l NG 









PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E S R mm.h 
w a C COUNT xlO 1 . t 
HAEMATOCR!T 
HAE:'IOGLOBill JZ . dl 
MEDICINES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
~ 
0 0 l+ l+ 
36, 7 37,8 37,8 37 
90 100 110 96 
24 32 32 24 
110/70 120/70 120/ BC 110/60 
87 94 110 BC 
18,9 15,3 16,4 17,l 
,371 ,364 ,367 ,360 
12 11 . 7 ,,., 1 ll " 
IP~nicillin 2..-nu IV ,i:ib 
I Aminoohy ll ine 250mg !V . 6h 
JHexoo~enaline Neb .6h 
!Dextroorcooxzehene 130mg 00 eds 
Final phlebitis score 




l+ l+ 0 0 2+ 
36, 5 37,4 37 37,1 36,9 
88 90 100 90 100 
24 28 28 30 30 
130/BC 130/ 60 110/ 60 120/70 120/ 65 
75 65 67 62 ss 
16,l 13,6 13,6 15,4 12,7 
1 · 365 ,400 ,396 ,380 ,363 
~ 1 =; J 1 R ,, 1' 'i 1? 7 
I 
JCo-tr imo xazo l e ? 00 bd 
or-:, 
NS 
[Metronidazole 400 mg oo eds 
Cannula 
Swabs 
) Discarded by 
) ward sta1'f 
127 
PATIENT 030 ,Hack Male Age 30 years -
DIAGNOSIS Lung abscess - bacteriological diagnosis not established 
ALCOHOL INTAKE [&] 
SMOKING ~ 










3 4 5 6 7 
2nd 
,;: ·:_:_:_.·:·· _-:.:·. ·_:. :.-. ·>:: :."· ::··.: :"· ·: .-::;" : ....... :·.-":·.-:._::: ::1 
0 2+ 3+ 3+ 
36.4 36,2 36 
Microbiology 



















RESPIRATORY RATE .m 24 20 24 20 20 20 24 2nd Cannulation site 
BLOOD PRESSURE mm Hg 110/70 - 100/50 80 / 50 100/60 100/50 100/50 Cannula NG 
E s R mm.h - 148 
xl01 . ( 
- - - - - Swab 1 Staohylococcus eoider.nidis S"ab 2 NG 
"' B C COUNT 10,3 7,5 - - - -
HAEMATOCRIT ,314 ,297 - - - -
HAEMOGLOBIN ll.dt 10 3 9 3 - - - -
MEDICINES !Penicillin Smu !V .6h 
JMetronidazole 400mg oo .3h 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
final phlebitis score 
Days to phlebitis 
• Discontinued due to blockage of access line 
?ATIENT 031 Black Male Age 38 years -
DIAGNOSIS Pneumonia - Klebsiella pneumoniae 
Renal failure, acu~e 
ALCOHOL INTAKE ~ 
SMOKING ~ 
NS 












DAY Of S"!'UD Y Microbiology 1 2 3 4 5 6 
CANNULAT!Ot/ SI!E 1st Cannulation site 1st +--2nd -
FILTER/ t:ONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE 
E S R 







x1o'I . e 
.dt 
TOTAL DURATION Gr !NFUSION 
OUTCOME 
0 l+ l+ 
36 , 4 36 36,2 
80 88 80 
32 24 28 
140/80 140/90 150/90 
141 148 140 
19,5 14,8 15,6 
,275 ,285 ,282 
8,9 8,9 9,2 
I Cefarnandole 1,5g; rv 
!Thi.amine lOOm!il po .d 
!Vitam i n a Co po 2bd 
NS 
Final phlebitis score 
Days to phlebitis 
.8 
::·::-: -:: /:··:::.:_:::.:· Filter 1 NG 
,ilter 2 NG 
1+ 2+ 2+ l+ 2+ filter 3 NG 
36,9 36, 7 36,4 36,2 36 Filter 
4 NG 
filter 5 NG 
80 84 80 80 60 Cannula NG 
32 20 24 20 20 
Swab 1 Staohylococcus 
Swab 2 NG 
180/110 160/110 170/100 140/80 160/100 
I 2nd Cannulation site 
148 145 
25,2 25,9 













I Methyldopa 2S0m3 po bd: 
D5 









) ·•ard staif 
eoidermidi3 
PATIENT 03~ - Coloured Male 
128 
Age 66 years Mass 55kg 
DIAGNOSIS Lobar pneumonia - bact.,r·iological diagnosis not established 
Chronic obstructive airways diseas e 
Myocardial i nfarction 
Septic lesion in groi~ - Staphylococcus aureus 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S':'UDY 
CANNULAT !ON SIT!: 
1 2 3 4 
1st 
5 6 
FILTER/r.ONTROL PERIOD ::-;::::-.:-:· ,: .<:<· :·:": _::-.'<_'.:: .' -: ... : .:.: : :. ; ·.:-:.: ·: ·.:\ ,;.:- .: ;:_ :-:: .  =,;-, 
PHLEBITIS SCORE 
TEMPe:'RATURE •c 
PULSE RATE , a, 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R mm.h 
w B C COUNT x1oi . t 
HAEMATOCRIT 




TOTAL DURATION OF INFUSION 
OIJ1'COME 
0 0 3+ 
37,4 37,2 36,8 
70 84 88 
20 24 24 
120/ 60 140/80 120/ 60 
35 50 60 
9,4 8,8 9, 7 
,299 - ,302 
9 4 9,3 9 4 
+ Penicillin 2 , 5mu IV .6h 
+ Sa lbutamo l Ne b .4h 
l 'Kloref' l co bd 
Fina l phlebitis s core 














PATIENT 033 - Black Male Mas s 43kg 
DIAGNOSIS Lung abscess - Bac~eroides species isolated 
ALCOHOL INTAKE [§:] 
SMOKING [I] 









10 8 11,4 
5 6 7 
Microbiology 
Cannula 
Swa b 1 






CANNULAT!ON SITE +--1st~ 2nd -3rd - 1st Cannulation site 
FILTER/r.ONTROL PERIOD r1111111, '!11111,.::: ': . ._.: ...-; ::· i :· ;- .: .-.::·::\· .. :t::·.:·.: :.:· :=_·:_:;:/·:r/ 
PHLEBITIS SCORE l+ l+ 0 3+ 3+ 3+ 
TEMPERATURE •c 38,8 38 38 38,4 37,8 37 
PULSE RATE .m 100 92 90 100 92 100 
RESPIRATORY :lATE . m 32 36 36 36 32 36 
BLOOD PRESSURE mm Hg 120 / 7C 110/70 130/7C 130/ 80 125/ 80 150/ 100 
E S R mm . h :> 1so > 150 > 1'50 - - -
W B C COUNT xlO 1 . t 17,7 18,5 21,l - - 16,4 
HAEMATOCRIT , 325 ,365 ,343 - [ 
,358 
HAEMOGLOBIN " . dt 10, 7 ll, l 11,4 - 11. 2 
MEDICINES !Penicillin 5mu !V .6h 






120/ 90 130 /75 
146 > 150 
19,l 17, 9 
,324 ,324 
10 ,6 10, 7 
Filter 1 NG 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swab 1 NG 
Swab 2 Enterococcus 
2nd Cannulation site 
Cannula NG 
Swa bs NG 
3rd Cannulacion site 
Filter 1 NG 




!Metronidazole 800rg po . 8h 
INTRAVENOUS FLUIDS 
TOTAL DURATION Of IN FUSION 
Fcnal phlebitis score 
Days to phlebitis 
• Discontinued due to blockage of access line 
NS 












PATIENT 034 - Black ,emale 
129 
Age 15 years Mass 47kg 
DIAGNOSIS Lobar pneumonia - bacteriolog ical diagnosis not established 
ALCOHOL INTAKE Ci] 
SMOKING ~ 
DAY OF S"." U!JY 




PULS E RATE 
RESPIRATORY RATE 
BLOOD PRESSURE 
E S R 









xio" . t 
.dt 
TOTAL DURATION OF INFUSION 
2 3 
84 72 
.c4 20 32 
130/80 110/ 60 100/ 60 
86 82 
13.5 8,9 8,4 
,326 ,312 ,330 
!Penicillin 2mu IV .6h 
1Metronidazole 500mg IV 
JGentamicin 40mg IV 
Final phlebitis score 
Days to phlebitis 
.8h 






















DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
Pleural effusion 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF STU!JY l 2 3 4 5 6 
7 8 Microbiolo3;t 
f"il ter l NG 
filter 2 NG 
Filter 3 N<; 
Filter 4 NG 
Filter 5 NG 
Filter 6 NG 
84 Filter 7 NG 
Filter 8 NG 
20 Cannula NG 




7 8 Microbiolog;t 
CANNULAT!O:, SITE 
FILTER/,~NTROL PERIOD 






E S R 









l<lO q . e 
. d! 
0 l+ 2+ 
39,2 37,7 38 
100 96 92 
30 28 24 
120/ 70 110/ 50 90/ 50 
65 72 69 
8,3 9, l 7,4 
,349 ,319 ,310 
11 , 8 11.1 10,5 
JGentamicin 40mg IV .Sh 
JPenicil li n 2mu IV .oh 
:;\.";:::·-:-- ::: ::_:.:~·.:. :. · .. :..:·: :' ;_:_:.: .: 
2+ l+ 1~ 
38,5 37,7 37 ,4 
100 110 100 
30 28 28 
100/ 60 110/70 110/70 
73 70 65 
10,3 8 14,3 
,348 , ,352 ,330 
11 , 11.9 10,4 
jMetronidazole SOOm3 IV . 3h 
INTRAVENOUS :~UIDS 
TOTAL DURATION OF IN FUSION 
OUTCOME Final phlebitis score 
Days to phlebitis 
• Discontinued due to blockage of access line 
NS 







110/70 20 / 70 
79 9 













Staph;tlococcus eoidermi d i 
NG 
2nd Cannulation 3ite 
Cannula 
Swabs 
Staohylococcus e ide!"::lid , _ 
NG 
3rd Cannulation si te 






2nd Cannulation site 
2,Sd• 
3rd Cannulation site 
1,3d 
l+ 2+ 






?AT!ENT 036 Coloured :.tale Age 13 years -
DIAGNOSIS '.~eningi tis - probably viral 
ALCOHOL INTAKE Ci] 
SMOKING IT] 
DAY OF S,UDY 
CANNULAT!O:, SITE 






E S R 










xlO'I . t 
a.d( 
TOTAL DURATION OF INFUSION 
l 2 3 
._------- 1st~------~, 
38 36,6 36,8 
80 80 88 
20 18 20 
100/60 110/60 110/60 
18 17 19 







IP'!nicillin 2.'llu IV .6h J 
I Q,.J.oraTDherocol :C95 DJ • oo 1 
"IS 
Fina l phlebitis s cor e 
Days"~ phlebitis 









Swa bs NG 
DIAGNOSIS !..obar pneumonia - bacteriological diagnos is not e s tablished 
ALCOHOL INTAKE GJ 
SMOKING GJ 
DAY OF S,UDY Microbiology l 2 3 4 5 6 







RESPIRATORY RATE . m 
BLOOD PRESSURE 
E S R 








TOTAL DURATION OF INFUSION 
VIII/II, ·;II I I I I I I I I / 't: . . . .. . . . . . . . . . .. ·.-1 :-.::-;-:·:·::: :.~:·: :: :: ,·. ·: ::::·. ~:/· .. _:_. 
I::, 
l+ 12+ 
137, s 36,4 
92 84 
24 20 20 
110/60 100/50 110/70 
122 - 103 
10,2 - 7,8 
,280 - ,336 
9 , 7 - 10, 9 
jPenici llin 2mu IV .6h 
jParac,otamol lg po .4h 
I NS 
Final phlebitis scor e 
Days to phlebitis 
2+ 2+ 2+ 
36,7 37 36, 7 
92 96 104 
24 20 24 
120/70 130/ 9<J 110/ 60 
108 123 114 
10 14 8,2 
,351 ,340 298 
ll,S 11,2 9 ,8 
pm 
I 














Staphylococcus ep idermidis 
NG 
2nd Cannulation site 
Cannula 
Swabs 






PAT I ENT 038 - Coloured Male Age 29 years 
DIAGNOSIS Meningitis - probably viral 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF STUDY 
CANNULAT!ON SITE 
I l ! 2 
...._ 1st---. 
I 3 I 
131 
Mass 58kg 
4 5 I 6 7 8 I 9 Micr-obiology 
2nd ~3rd- 1st Cannulation site 
FILTER/r'ONTROL PERIOD '///////////I/A.:.:·_.·_.\:: :_ .: :"::::·: .:-::-:·::-.:·:. :;_.::.·.:_:.:-.··. : '://:.~,~·.::·:·::J;, '/////// '//IA Filter NG 
PHLEBITIS SCORE 0 
1:. 7 
0 0 l+ l+ 
TEMPERATURE •c 37,5 36,6 36,2 35,9 36 
PULSE RATE .m 72 72 80 96 90 72 
RESPIRATORY RATE . m 18 20 24 24 20 28 
BLOOD PRESSURE mm Hg 130/ 90 120/70 120/80 120/70 120/70 120/70 
E S R mm.h 7 8 9 5 7 5 
w B C COUNT x101 . i 7, l 8 21,3 14,9 7 8,9 
HAEMATOCRIT ,448 ,465 ,699 ,460 ,434 ,463 
HAEMOGLOBIN :z.dt 15 7 15,l 16,4 15 . 9 15 15 6 ' 
MEDICINES ' Penicill i n 2,5mu IV .6h 
tChloramohenicol 500mg IV .6h 
I Paracetamol lg oo .6h pm 
INT RAVENOUS ,LUIDS 
TOTAL DURATION OF INFUSION 
NS RF 
Final phlebitis score 
Days to phlebitis 
• Discont i nued due to blockage of access line 
• ~lective removal of rv line 
PATI ENT 039 Coloured Male Age 52 years -
DIAGNOSIS Lung abscess - Staphylococcus aureus 
ALCOHOL INTAKE [jJ 
SMOKING [I] 
DAY OF S, UDY 
CANNULAT!O.; SITE 
FI LTER/r'ONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE . m 
RESPIRATORY RATE . :n 
BLOOD PRESSURE mm Hg 
E s R :nm.h 
'JI B C COUNT xlOq . t 
HAEMATOCRIT 
HAEMOGLO BIN g: .d t 
l 2 3 
- 1st -




92 88 96 
18 20 28 
120/ 80 140/ 100 130/ 90 
- - 145 
- - 12,2 
- - ,334 
,_ - 11 .2 
NS 

















[ 10. 9 
l,(ED ICINES L___ . ~d- _ --·-?~~~n~i"'c"'i ~ll:.1:.;· n ..... S'-m~ua-aI ... ·r ........ 6h'----------• 
L__ - ~d. - __ +.;.....a~ .. e~,:._.r_.o~n~i=d=a:.ZO:.l:.;e::.....:ao=o"'m"'g'"""'o.:.O....;..• 8"'h"-------'' 
L__ . ':d. • __ ._ r:.:n.::d::oc:.cm:.::ec.::t;..:ha=c:::i n'"-'2=-=5111=g'-"oc::o.....;t :ds::.... _____ __, 
[NTRAVENOUS FLUIDS 
TOTAL DURATION OF !NFUStON 
OUT CQl,(E 
NS 
Final phlebiti s score 
Days to ~hlebitis 
• Di scont i nued due to blockage of access l ine 
RF 






















Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 
2nd Cannulation site 
Cannula NG 
Swab l Staphylococcus 
~01dermia i s 
Swab 2 NG 
3rd Cannulation s i te 
Filter l NG 





2nd Cannulation site 
4,9d 0 







1st Cannulation site 
Cannula 
Swabs 
) Discarded by 
) ward staff 
2nd Cannulat i on site 
Fi leer l NG 
Filter 2 NG 
Filter 3 ) Disc&rded 
Cannula ) by 
Swabs ) ward staff 





PAT I ENT 040 coloured Ma le Age 60 years Mass 49kg -
DIAGNOSIS Lo bar pneumonia - bacteriological diagnosis not estab l i shed 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S:'UlJY 
CA.'INULAT!O:; SITE 
FILTER/ ·-ONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE . m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E S R mm. h 
'II B C COUNT xlO~ . t 
HAEMATOC!IIT 
HAEMOGLOBIN . d t 
MEDICINES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
OUTCOME 
2 3 
2+ 2+ 3+ 
37,6 137,6 37 , 6 
100 88 92 
30 28 32 




, 318 ,329 
10 10,4 10.5 
!t;eftazidime lg IV .Sh 
!Paracetamol l g po . 6h 
rinal phlebitis score 
Days to phlebitis 
PATIENT 041 Co loured Fe!:lale Age 18 years -
DIAGNOSIS Mitral valve disease - rheumatic fever 
Previous nitral valve replacement 
4 5 6 
3+ 
36,7 37 
80 68 l:!2 
28 24 28 
130/70 120/70 120/ 80 
122 120 119 
15,2 12 12,3 
,318 1,298 ,298 
10 ~.5 9.7 
orn 
NS 







~: 2 4 
~30/70 20 / 70 20/70 
10 2 18 
0,5 ,9 2 
, 293 340 297 
.2 ,6 




;l!ic r:-o biology 






eoidenn i di s 
NG 
2nd Cannulation s i te 
Filter l NG 
Filter 2 NG 
Filter 3 NG 
Filter 4 NG 
Filter 5 NG 
Cannula NG 
Swab l i Staphylococcus 
eo i dermi <iis 
i i Enterococcus 
species 
Swab 2 i Staehylococcus 
eEidermid i s 
ii Enterococcu~ 
species 
Bacterial endocarditis - bacteriological diagnos i s not established 
ALCOHOL INTAKE W 
SMOKING ~ 
DAY OF S:'UDY 
CANNULAT!Q:; SITE 




RESP I RATORY RATE 
BLOOD PRESSURE 
E S R 










xio" . t 
. dt 
TOT AL DURAT ION OF !NFUSION 
.::·. ·:.::-:-.- :_:: ·: .. .: ; :· ... : ... · · ·: .. 
0 0 0 
37,4 36 ,8 36,4 
120 108 80 
128 
32 28 
100 / 60 U0/70 120/ 60 
20 
11,a 12,2 9,6 
,334 ,334 ,276 
10 10 , 3 8,9 
jPenic illin 4mu rv .4h 
!Tobramyc1n 80mg rv . ah 
I ' Moduret i c ' 2 ~o .d 
!D i gox i n 0 , 25mg 00 
Final phleb i tis score 
Days t o ~hlebitis 
.d 
• Discon t i nued due to blocka~e of access line 
0 0 0 







100/ 60 ~20 / 60 
NS 





1st Cannulation site 
Cannula NG 
2+ Swabs NG 
37 2nd Cannulation site 
120 Filter l NG 
Filter 2 NG 
30 Filter 3 NG 
lZ0 / 60 Filter 4 NG 
Filter 5 Staphylococcus 
Cannula NG 
Swab l Staehylococcus 
Swab 2 NG 




e2 idennid i s 





PATIENT 042 Coloured Male Age 49 years -
DIAGNOSIS Chronic obstructive airways disease 
Pulmonary emphysema •.i th bullae 
Pneumo thorax 
ALCOHOL INTAKE ~ 
SMOKING ~ 
133 





PULS E RATE 
RESPIRATORY RATE 
BLOOD PRESSURE 
E S R 









xlOq . ! 
<Z.d! 
































!Aminophylline 250 - S00m2 rv .12h 
jAmoxycil l in 250mg co .Sh 
l'Modur~tic' 2 po bd 
lHexoorenaline Neb . 4h 
I NS 
Final phlebitis score 




PATI ENT - 043 Coloured Male Age 41 years Mass 50kg 
I 
DIAGNOSIS Bacterial endocardit i s - bacteriological diaif\OSis not established 
Mitra! incompetence 
Hypertension with renal impairment 
ALCOHOL INTAKE 0 
S140KING [TI 
DAY OF S':'UllY l 
, 
! 2 I 
1st 




Swab 1 i Staphylococcus epidermidis 
ii Bacillus species 
Swab ~ NG 
7 8 9 Microbio log:z: 
1st Cannulation CANNULAT!ON SITE 
FILTER/CONTROL PERIOD VIII/II 1/////////// ///~ ~:·:.:· :=.~ .:·/·:.; ::\~ -: -~ ;:-. ~: :::::_::;_-_:: .::.:t:.:-:::·: ::· ~ :·=.:-:. ;,.~-:~~ -:~=~ ::·.=:·~.:::.J Filter l NG Filter 2 NG 
PHL?:B IT rs SCORE 
TEMPERATURE •c 
PULS E RATE .m 
RESPIRATORY RATE .m 
K) r, 0 0 l+ l+ b 12• 2• Filter 3 NG 36,5 36, 3 36,9 36 .2 36, l 36 36,4 - Cannula NG Swabs NG 
92 100 82 80 84 88 80 72 - 2nd Cannulation 
24 28 24 24 20 24 24 !2o -
Cannula NG 
BLOOD PRESSURE mm Hg 160/ 90 140/ 80 160 /100 160/ 110 160/100 150/80 140/80 1170/100 - Swabs NG 
E S R mm.h 95 102 105 106 102 112 110 t74 -




HAEMATOCRIT , 231 ,240 , 254 ,253 ,239 , 269 ,256 ,239 -
HAEMOGLOBIN <Z. d! 7 5 17 5 .8 S-,3 7 ,6 8 3 8,2 t7' 8 -
MED IC.N ES L_ __ 29q -----..,P.en_ ic __ 1~· 1~1~i .... n- 5~m~u- I1_1_ .6 __ h-----------------------.... 
L_ _ .?9<; . ___ .., __ -ur=o .. s __ e""m~i"'d"'e-"80-"-m"'g"---o"-o'--'.-'d ------------- ----------- .. , 
L_ _ ?(2'1. ----P'-cr:ca:"z::..:o:..:s','1:"n'-::6- - ...:;;9m;.;;S'!-'P:..:O;_,;·..::dc._ _____________________ _., 
t___ --~ .. ---•-' _S_lo_w_ K_'_ 2__._p_o_ t _ds _______________________ _ _ .. 
INTRAVENOUS FLUIDS l D5 l NS l 
TOTAL DURATION OF INFUSION 
~ Final phlebitis score 
Days ~o phlebitis 
• Discont inued due to blockage of access line 
05 









PATIENT 044 Black Male Age 36 years -
DIAGNOSIS Pancreatit1s, chronic relapsing 
Chronic alcoholism 
Delirium tremens 
ALCOHOL INTAKE ~ 
SMOKING ~ 






- lst_._ ___ 2nd -
PHLEBITIS SCORE 0 0 
TEMPERATURE •c 35,S 36,2 36 
PULSE RATE .m 72 •76 60 
5 Microbiology 









2nd Cannulation site 
NG RESP!RATORY RATE .m 28 
BLOOD PRESSURE mm Hi 150/90 
32 20 24 








E S R mm .h 





TOTAL DURATION OF INFUSION 
115 90 100 
9,6 8 8,5 
,387 ,318 ,321 
12 6 10 1 10,4 
!Penicillin 2mu IV . 6h 
!Tobramycin 8Qr.,g IV .Sh 
I Clothiapine 40mg IV .6h f <10ms po tds , 
fVitamin 3 Co 2ml IV .d ! 
IAsoirin 2 po .6h 
NS j :,t NS j 
Final phlebitis score 
Days to phlebitis 




• Discontinued due to patient non-compliance 
0 Discontinued due to infiltration into tissues 




PATIENT 045 Black Male Age 56 years Mass 50kg :.licrobiolo1tY - 1st Cannulation site 2nd i.:annulation 
DIAGNOSIS Lung abscess - bacteriological diagnosis not established 
Bronchiectasis 
ALCOHOL INTAKE [:;J 
SMOKING ~ 










































































1<10 / 90 
;cs ;co 20 
E S R 







xlO 'I. l 













!P~nicillin 2mu IV .6h 










8, 5 8, 5 
r~etronidazole dOOmg po . Sh 
Aspirin 500mg po .6h 
Final phlebitis score 
Days co phlebicis 












130 / 90 1120/80 ~30 / 80 
':il 90 188 
7,1 6,9 ,3 
,260 ,265 , 266 
7,7 
,290 
8,9 7,9 8,3 





6 5, 7 
b 2 4 
I 
1<10/90 d() / _ 
5 
PATIENT 046 Blacl< Male -
DIAGNOSIS Tuberculous meningitis 
ALCOHOL INTAKE C!J 
SMOKING ~ 
DAY OF S':'UDY I l 




3 4 I 5 6 7 Microbiology 
CANNULAT!ON SITE - 1st~ 2n" - 3rd- 1st Cannulation site Filter NG 
Cannula NG 
FILTER/rONTROL PERIOD 'I I Ill I I I l;h :::: ::···. \:-:_.,_::.=.<:.:. :,·:: :'/:- ':·:·.: _::\:<_: VIII///, 
PHLEBITIS SCORE 0 
1:7 
l+ l+ l+ l+ 0 
TEMPERATURE •c :J7,8 36,3 35,5 36 35,9 
PULSE RATE .m 62 60 68 72 80 64 
RESPIRATORY RATE .m 20 20 20 18 18 20 
BLOOD PRESSURE mm Hg 110/70 120/80 130/90 110 / 70 115/75 120/90 
E S R mm.h 75 87 - 72 116 95 
"' B C COUNT x10
1 . t 10,2 9 - 7,4 7 6,5 
HAEMATOCRIT ,342 , 364 - ,368 ,368 ,400 
HAEMOGLC BIN :;z . dt 11, 7 12 - 12,2 12,5 12,6 
p>enici-- in "11\U .v .on I 
MEDICINES JChloramohenicol lg IV .6h 
I~TRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
OU'l'COME 
!Streotomycin lg IM .d 
1rsoniazid 400 mg oo .d 
jPyrazinamide 1,2g po .d 
jRifamoicin 450mg po . d 
NS 
Final phlebitis score 
Days to phlebitis 
• Discontinued due to blockage of access line 
• Elective removal of IV line 
PAT!ENT 047 ,!lack Male Age 35 years -
! P•rridoxine 25m5 
I M 
















00 . d ! 1 
Swabs NG 
2nd Cannulation site 
Cannula 
Swabs 
/ Discarded by 
J • ard ,ataff 









2nd Cannulation site 
3, 7d * 
3rd Cannulation site 
l , 8d 0 
1+ l+ 
N/A N/A 
~hronic alcoholism with peripheral neuropathy, proximal myopathy and cirrhos i,a 
Delirium tremens 
Pellagra 
ALCOHOL INTAKE ~ 
SMOKING [}J 





PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E S R mm.h 





TOTAL DURATION OF INFUSION 
I 1 ~ 3 4 ! 5 6 
1st- ~- d 
v I//// I I I/// I I /1 1// ;i=,::.-._:/,:!:::;: :.: :_:·:/:.:,_-:_:-:,:; ; _:- ;-::.j 
0 , , + 3+ 0 
1:6,2 
0 
38,2 36, 3 37,3 37,5 37,7 
152 92 120 ~ 100 120 
40 :J2 40 40 42 40 
130/ 80 130/ 90 150/90 120/75 120/70 110/70 
60 70 68 95 104 1,3 
Y,2 11,6 17,7 23,4 22 14,3 
,248 ,271 ,284 ,262 1 ,250 ,247 
R 1 9 9 l B 5 7 7 7 A 
JCefamandole 1 1 Sg !V . 8h ! 
jTobramycin 00mg; IV . Sh 
I Penicillin 2,nu rv . Sh 
!V i tam in B Co 2ml IV . 12!1 
!Potassium chloride 3g IV . 12h 
!lndomethacin 25mg po tdsj 
I' Klo r'ef' 200 aid 
Final phlebitis score 
Days to phlebitis 
M 




• Discont i nued due to i !'\filtrat:1.on into tissuf!s 
Microbiology 
l,at Cannulation site 
Filter l Bacillus species 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 




) ward staf!' 





PATIENT 048 ~lack Male Age 17 years Mass 60k.;: -
DIAGNOSIS Lobar pneumonia - bacter iolog i cal diagnosis not establisned 
ALCOHO L INTAKE [1J 
SMOKING [I] 
DAY OF S':'UOY 
CANNULAT!O:l SITE 




4 I 5 I 6 
"-d 
FILTE R/~ONTROL PERIOD '/////// '//////J 1///l :<::: ::::·:·,) :"·::::·.:::.::.:\-:.:.:\//,1 
PHLEBITIS SCORE l+ 0 l+ 
TEMPERATURE •c 36, °I 37 36, 2 
PULSE RATE .m 64 80 60 
RESPIRATORY RATE .m 24 20 24 
BLOOD PRESSURE mm Hg 110/70 ll0/70 120 / 70 
E S R mm.h 93 90 92 
W BC COUNT xlOq . t 8 ,8 9,9 7,2 
HAEMATOCRIT ,410 ,400 ,386 
HAEMOGLOBIN ~.d( 13.3 13,2 13,l 
MEDICINES ICeftazidime lg IV . 8h 
INTRAVENOUS FLUIDS NS 
TOTAL DURAT ION OF INFUSION 
Final phlebitis score 
Days to phlebitis 
• ! lective r-emoval o r IV line 





Age 58 years 
Chronic obs truc~ive a ir•ays disease 
ALCOHOL INTAKE [!] 
SMOKING ~ 
DAY OF S,UOY 
CANNULAT !Oil SITE 











BLOOD PRESSURE mm Hg 130/90 160/ 100 180/100 
E S R 






TOTAL DURATION OF IN FUSION 
110 93 98 
6,4 7 7,4 
,300 ,313 ,334 
9,7 9 , 9 10,4 
!Penicillin 2 - 2 1 5mu 
,inal phlebitis score 
Days co phlebitis 
rv 
2+ 3+ 4+ 
36,4 36,2 36 
72 60 72 
20 24 20 
100/80 115/70 130/80 
72 58 75 
6,5 6,6 7,4 
, 397 ,417 ,438 
12,9 13. 7 14,7 














150/ 100 140/90 
85 92 
6,6 6,6 




1st Cannulation si t e 
Filter l NG 
Filter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs Nu 






ii Staphylococcus epidermidis 
NG 



















PATIENT 050 Black Ma le Age 47 years -
DIAGNOSIS Perforated gastric ulcer 
Carcinoma of stomach 
Gastrectomy 
ALCOHOL INTAKE ~ 
SMOKING ~ 
137 
Y Microbiology 1 2 3 4 5 
CANNULAT!ON SITE 






E S R 









1st Cannula Staphylococcus epidermidis 
Swab l Stapnyloc~ccus epidermidis 
Swab 2 NG ::.:-:-=.-:.:::·;~· :::):;·(:~·?\/--:.:\?: ·:~·:·.: _:; ::,. ·."·.\il 
l+ , 1 ... l+ 2+ 3+ 
37,7 38,4 37,3 36,8 36 
88 <;4 84 80 80 
20 20 24 20 24 
170/80 130/80 120/70 130/70 120 /80 
11 35 90 102 98 
14,5 20,l 15,4 10. 'l 9,4 
,466 ,4!:13 ,410 ,372 1,376 
15,4 16 13,7 11,8 12,5 
I fhli tetracycline p;,ng N. 1.ai I 
I Papaver-erun ~-Shi 
rretracycline 500mg io .6h 
1Dextropropoxyphene 130mg po .Sh prn 
I 
'.NT.RAVENOUS FLUIDS 
TOTAL DURAT!ON OF INFUSION 
IPBI 
Final phlebitis score 





PATIENT 051 Coloured Male Age 20 years Mass 47kg -
DIAGNOSIS Pneumonia - oacteriological diagnosis not established 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S".'lJDY 
CANNULAT!ON SITE 






E S R 










x10" . ! 
2 3 I 4 I 5 











92 72 80 · 64 58 
30 20 30. 24 18 









jCefamandole 1,5g !V .ah 
16 
6 , 9 
,393 
13 
I Indomethacin 25mg po tds 





TOTAL ilURATION OF INFUSION 
1st Cannul ation si~e 
1, 7d 
Final phlebitis gcore 
Days to phl~bi~is 










2nd Cannulation site 
Filter l ~ 
filter 2 NG 
Filter 3 NG 
Cannula NG 
Swab l ~acillus 
Swab 2 NG 
- -










PATIENT 052 - !:!lack Male 
DIAGNOSIS Lung aoscess 
Carc!.noma of oesophagus 
ALCOHOL INTAKE ~ 
SMOKING ~ 
138 
Age 46 years Mass 46kg 






0 2+ 3+ 3+ 3+ 
37 37,2 36,3 36,2 36,6 
100 88 80 72 80 





BLOOD PRESSURE mm Hg 
mm . h 
xlO ,_ t 
120/80 110/70 120/ 80 130/70 110/70 
E S R 










12 2 - -
! Penicillin 2,Smu IV 
ll~etronidazole 400mg 
I NS 
~ Final phlebitis score 
Days to phlebitis 



















Chronic obstructive air,..ays disease •dth bilateral lung fibrosis 
Cardiomyopathy 
Allergy to penicillin 
ALCOHOL INTAKE 
SMOKING 



















E S ~ 









:<lOq . t 
"· dt 




30 I 32 
110/70 1120/ 90 
83 49 
7 ,3 5,6 
, 395 , 356 
13,l 11 , 9 
t?enicl.l.lin 2.1Tlu iV 
1 Hydrocort i sone ~OOmg IV 




Final phlebitis score 











PATIENT 054 Coloured Male Age 61 years Mass 46kg -
DIAGNOSIS Lung aoscess 
Pneumonia - bacteriological diagnosis not established 
Previous pulmonary tuberculosis 
ALCOHOL !NTAKE ~ 
SMOKING [§] 
DA'! OF S".'Utl'! 
CANNULAT!ON SITO: 




RESP IRATOR'! RATE 
BLOOD PRESSURE 
E S R 





xlOq . ( 











10 5 11 4 
3 4 5 
1st 
1///////, 1///////, f/////li 
l• l• l• 
35,7 36,3 36,3 
72 80 80 
24 24 20 
120/80 120/ 90 120/ 80 
- 38 45 
- 5,1 5,8 
- ,490 , .344 
- 11 5 11 l 
+?enici 11 in 2,Smu !V .Sh MEDICINES L__ . \4.d. --~=----===--"-'-"-=-~~~----
+Metronidazole 400mg oo tds 
I' Moduretic' 1 eo .d L.___. ~ - ------'-----------,---
t NTRAVENOUS FLUIDS I NS 
6 7 Microbiolo!!il 
~d- 1st Cannulation 
.:_:.::::··.:::,_::.:-'.::l Filter l NG 
Filter 2 NG 
2• 2• Filter 3 NG 
36,2 36,2 Filter 4 NG 
Filter 5 NG 
80 80 Cannula NG 
28 24 Swabs NG 
110/50 - 2nd Cannula1:ion 
33 - Cannula NG Swabs NG 
5,2 -
,360 -





".'OTAL DURAT!ON OF INFUSION 
1st Cannulation site 
Sd• 
2nd Cannulation site 
1,2d 
Flnal phlebitis score 
Days to phlebitis 
• Elective removal o f IV line 
Black Male Age 43 years 
CIAC.'IOSIS Systemic lupus erythematosus (active) 
ALCOHO L INTAKE ~ 
SMOKING [I] 




4 I 5 
2• 
l 











RESPIRATORY RATE .m 
BLOOD PRESSURE 
E S R 






xlO~ . e 




36 , 2 35 ,5 
80 74 72 
32 32 30 
130/80 110/70 100/70 
i- - -- - -
- - -
- - -











!Indomethacin 50m !!i oo tds 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF IN FUSION 
Flnal phlebi1: i s score 
Days to phlebitis 
• Disconti~ued due t o infiltration i nto tissues 
l• 
ri / A 
NS 
Swab 2 NG 
0 0 0 
36,4 35 , 8 35, 6 
80 88 80 
30 128 2S 






PAT!ENT 056 - Coloured Male Age 18 years 
DIAGNOSIS Looar pneumonia - streotococcus oneumoniae 




DAY OF S':' ti\l Y 2 3 4 5 Microbiology 
CANNULAT!ON SITE 
FILTER/ r ONTROL PERIOD 
PHLE3ITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESP I RATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R mm.h 





TOTAL DURATION OF !NFUSION 
0 0 
35,8 36, l 
68 58 72 
24 20 20 
110/ 70 110 /70 120/60 
95 69 55 
4,7 4,7 6,8 
,362 ,344 ,396 
1 :> 4 
ld +Cer-tazidime lg IV .8h 
Final phlebitis s core 
Days to phlebitis 
• El ect i ve removal of IV line 
PATIENT 057 - Black Male Age 34 years 
DIAGNOSIS Pneumonia - Klebsiella oneumoniae 
Lung aoscess 
C!"'.ronic obstructive airways disease 
ALCOHOL INTAKE ~ 
SMOKING ~ 






RESP I RATORY RATS 
BLOOD !'~SSURE 
E S R 





mm . h 
xlO 1 . l 













36 36 ,2 
72 80 
30 28 































100/ 60 100/60 
76 86 
6,8 6,2 
,332 I ,3S9 
















9,3 7 ,3 
, 371 
11 . 5 11. 7 
-Peniccllin 2 1 5mu IV .6h MEDICINES t.__ _ _l_l,i ____ .;..;a====-===--=---=-------------_. 
~~e~ronidazole 400mg co tds l.__ . .1!~- ----'--'--'-"-'-'-'~-""-'----'--....... -----------~ •Paracetamo l l g 00 q i d l.__ - _lC?~- __ _;;_=.;=.;;;..;.;:;;;.;;..;;.....;=...;;..;;.....a..~------------' 
INTRAVENOUS , LU IDS 
TOTAL ~URATION OF :NFUSION 
Final phlebieis score 





l t Staohylococcus 
ii Nonhaemoly,:ic 









filter l NG 
Filter 2 NG 
Filter 3 NG 
Filter 4 NG 
Filter 5 NG 
Filter 6 NG 








PATIENT 058 Coloured Male Age 33 years -
DIAGNOSIS Mitral stenosis 
Rneumatic neart: disease, chronic 
Atrial fiorillation 
cnronic alconolism 
ALCOHOL INTAKE C1J 
SMOKING ~ 
DAY OF S':'UllY r 2 
CANNULA! rm: SITS: 1st 
3 I 
FILTER! iONTROL PERIOD ::_.\" ~· :: :::-::~·::·.~:-.:~: .::.·:'} :·:: :·: .: -:: .. ·:-:.:"/. 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY ilATE .m 
BLOOD PRESSURE mm Hg 
E s R mm.h 
w a C COUNT xlO~ . t 
HAEMATOCRIT 
H AEMOGLO 8 IN C>.dt 
!o!EDIC!NES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF !NFUSION 
OUTCOME 
l+ 2+ 3+ 
35,6 36,l 36,:J 
l:lO 84 72 
20 24 20 
100/ 70 115/70 110/70 
8 6 8 
3 3,6 3,6 
,462 ,472 -
15,9 15.3 15,9 
LJciothiapine 60mg IV 
1b iazepam 10mg rv 
!Digoxin O, 25mi3 po . d 
I' Moduretic' 2 oo . d 
05 NS 
Final phlebitis score 
Days to phlebitis 
PAT IE IT - 059 Black Female Age 19 years 
DIAGNOSIS Pyelonephrit:is - Klebsiella species 
ALCOHOL INTAKE [L] 
SMOKING ~ 
DAY OF STUDY 
CANNULAT!O.l SITS 
FILTER/ i'.)NTROL ?ERIOD 
l 2 
- 1st -
































7 8 Mic:-ooiolosY 
1st: Cannulat:ion site 
Cannula NG 
Swab l i Staphylococcus 
3+ ii Nonnaemolyt:ic 
eoidermid1s 







35,4 35 36 35, 7 35,3 35, l :;5,a iii Bacillus species 
E S R 









xlO~ . t 
TOTAL DURATION OF rNFUSION 
OUTCOME 
Swab 2 NG 
100 92 84 92 84 84 68 84 
2nd Cannulacion 
24 26 24 24 20 20 18 24 
Filter l NG 
100/50 90 / 50 110/10 100/ 50 90 / 60 -00 / 50 120/ 70 110/ 60 filter 2 NG 
114 113 136 115 83 109 99 >150 filter 3 NG 
Filter 4 NG 
·, . a 9,4 10 l:l,4 9,4 7,4 7,2 8, l Filcer 5 NG 
,263 ,271 ,249 ,284 ,267 ,290 ,295 Filter 6 NG Cannula ~G 
7 , 9 2 8 7 8 4 8 9 7 Swabs NG 
ICefamandole 2g rv .6h 
tMetronidazole 400mg po tds 
I Nalidixic acid Lg po aid 
(Slow K' 2 po gid 
NS 
Final phlebitis score 
Days t o phlebi~is 
DS 










PATIENT 060 Black Ma le Age 64 years Mass 60kg -
DIAGNOSIS Cardiomyopathy, restrictive 
Congestive cardiac failure 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S'!'Ull 'f I l I 
CANNULAT !O.i SITE 
2 3 
l s t 
fILTER/ ,~ONTROL PERIOD I:>).-·;':.\:\·::-:·.> '.·.a.j /·::.J 
PHLEBIT IS SCORE 0 l• l• 
TEMPERATURE •c 35,5 36 , 3 36,l 
?ULSE RATE .m 76 76 80 
RESPIRATORY RAT E .m 24 20 28 
BLOOD PRESSURE mm Hg 110/70 115/65 110/60 
E s R mm.h 5 - 7 
"' a C COUNT x10
1
.i 5 ,5 - 5,2 
HAEMATOCRIT ,415 - -
HAEMOGLOBIN ,:,.d( 13,2 - 13, 4 
MEDICINES 1.______2g _____ •~F~uraa..ao~s~e~m~i~d~e'"="'80'-'-"m~g._.o~o-,_;;b~d_.! 
I._____ .. ~g .. ___ •_l'_r __ a_z __ o __ s_i_n_ l_O_m.,.g._.o_o_b_d_..,..,. .. , 
L._______- ~~ -- +Isos orbide dinitr ate 10mg po qid 
L-. ~~ . . ___ •_'_S_l_o_w_K_'_ J_ o_o_ b_d ___ ..... 
INTRAVENOUS FLUIDS NS 
TOTAL DURATION CF INFUSION 
Final phlebi tis score 
Days to phlebitis 
• Elec~ive removal of IV line 
PATIENT - 061 Coloured Ma le 
DIAGNOSIS Chronic duodenal ulcer 
Acute antra l eros ions 
Vagotomy and ant r ec tomy 
ALCOHOL INTAKE [gJ 
SMOKING ~ 
DAY OF S'!'UllY 1 
Age 31 years 
2 I 3 
CANNULAT!O,i SIT!: - lst--2nd-
FILTER/ <"ONTROL ?ERIOD r111111111;.(·/:·:.::-=;1-:.'.-:_::-::-i: 
PHLEBITIS SCORE 0 
1: 
l• 3+ 
TEMP!:RATURE •c 37,2 37 
PULSE RATE .m 96 88 
RESP!RATORY RATE .m 20 24 28 
BLOOD PRESSURE mm H&: 130/90 140/80 130 / 90 
E S R mm . h 77 100 77 
W 3 C COUNT xlO ~ . t 10,2 7,9 7,9 
HAEMATOCRIT - ,408 ,402 
HAEMOGLOBIN ,z . dt 13.3 13.5 13 
MEDICINES 2d • Cefata"d:)le lg IV. 6h I 
INTRAVENOUS FLUIDS iRF1 M !RF! M 





















i Staohylococcus eoidennidis 
ii En~erococcus species 







70TAL DURATION OF !NFUSION 
1st Cannulation site 
l, 2d " 
2nd Cannulation site 
1,8d 
~ Final phlebitis score l+ 3+ 
Da ys to phlebitis N/ A l, 7 
• Discontinued due to blockage of access line and local pain 
153 
PATIENT 081 Coloured ma le Age SO years -
DIAGNOSIS Superficial burns 
Cellulitis - f3 haemolytic streptococci and Staohylococcus ~ 
Skin graft 
ALCOHOL INTAKE ~ 
SMOKING ~ 
DAY OF S,\ffiY 
CANNULAT!O;; SITE 
FILTER/ rONTRO L PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E S R mm.h 
W B C COUNT xlO~ . t 
HAEMATOCRIT 
HAEMOGLOBIN a .dt 
MEDICINES 
INTRAVENOUS FLUIDS 













!Erythromvcin 30qmg IV .6h 
1Dextroorooox7Phine 130mg po .6h 
NS 
Final phlebitis score 











Summary account of incompleted studies not included in the 
final statistical analysis 
Code 
Patient numbers beginning 
also have cannulation 
with zero refer to patients who 
sites included in the final 
statistical analysis; patient numbers beginning with one 
refer to patients with only incompleted studies. 
Group 
F = Filter included in-line 
C = Control - no filter in-line 
Sex 
M = Male 
F = Female 
Reason for exclusion from statistical analysis 
1 Blood administered 
2 Elective removal of access line prior to 30 hours 
3 Blockage of access line prior to 30 hours 
4 Infiltration of infusion fluid into tissues prior to 
30 hours 
5 Patient non-compliance 
6 Patient not examined after infusion discontinued 
7 Patient deceased 
PATIENT - 062 Coloured Male Age 58 years 
DIAGNOSIS Cholecystitis due to cholelithiasis 
Cholecystectomy 
ALCOHOL INTAKE [I] 
SMOKING ~ 








E S R 
































1 Paoaver-e,:im 1~ rM .€hi 
IP9 ! 
Final phlebitis score 
Days to phlebitis 













ilIAGNOSIS Lobar pneumonia - bacteriolo~ical diagnosis not established 
Oulmonary tuberculosis 
Syphilis 
ALCOHOL INTAKE [I] 
SMOKING ~ 
DAY OF S,UlJY 
CANNULAT!ON SITE 
FILTER/ rONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULS E «ATE .m 
RESPIRATORY RAT! .m 
BLOOD PRESSURE mm Hg 
E S R mm.h 





TOTAL DURATION OF INFUSION 











,405 , 388 
1.3 5 12.5 
JCe.fana-xi:lle 2g IV 
f Penicillin 411.J rv 
I Prroxycillin ~ 00 eds I 
f.t'mlrcphylline ~ r. 
~de<Org IV 
M 
Final phlebitis 3core 
Days to phlebitis 
• Elective removal of IV line 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PATIENT 065 Coloured Male Age 40 years -
DIAGNOSIS Pleural effusion 
Chronic alcoholism 
Chronic obstructive airways disease 
Chronic pancreatitis 
ALCOHOL INTAKE Ci] 
SMOKING ~ 
DAY OF S:'lJlJY ! l I 2 3 
145 
Mass 47kg 
4 5 6 
CANNULAT!ON SITE - lst--2nd--3rd-
FIL!ER/ m NTROL PERIOD · 'f///////////l/Y 1 /////II/ I// I IJ.:·\:\~:·::-: .=::~/:'.: /1 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD ?RESSURE mm Hg 
E S R mm.h 






TOTAL DURAT!ON OF INFUSION 
0 12+ 0 
36,9 36,6 36 , 7 
00 70 74 
24 24 24 
120 / 80 120/70 120/80 
125 :> 150 -
12,1 10,6 9,6 
,366 ,:388 ,360 
12 12 9 12 
+Cefamandole lg IV . Sh 
•Penicillin 3mu IV .6h 
Final phlebitis score 
Days to phlebitis 
NS 
066 Black Male Age 25 years 
2+ 2+ 3+ 
36, 9 36, 7 36,4 
84 78 80 
20 24 20 
1:.:0/ 80 100/60 110/70 
138 - 105 
10,3 - 8,3 
,361 - ,361 
11 8 - 11 4 





DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
ALCOHOL INTAKE [}J 
SMOKING [!] 
DAY Of 5-:' lJlJY 
CANNULAT!ON SITE 
I l I 2 3 4 I s 
1st 
FILTER/ C:O NTROL PERIOD :::·.:.~\":':~:-:·-~:_::: \·~:::_:·~:.: :!·:.:..: : :· ;:: .. :.: :::::~ = .. \ ... ~-.: :· .: : J 
PHLEBITIS SCORE 0 0 lo 0 
TEMPERATURE •c 36,4 36,5 135,6 36,2 
PULSE RATE . m 72 80 72 76 
RESPIRATORY RATE . m 28 24 24 20 
BLOOD PRESSURE mm Hg 105/ 60 110 / 70 100/70 110/ 70 
E s R mm.h 116 121 135 91 
vi B C COUNT xlO~ . t 18,4 l3, 7 9,2 11, 5 
HAEMATOCRIT - ,400 ,418 ,377 
HAEMOGLCB IN <> . dt 13.5 13 13,4 12 ,6 
MED ICINES jCeftazidime l g I V . Sh 
jParacetamol lg 20 tds om 
INTRAVENOUS FLUIDS 
TOTAL DURATION f INFUSION 
~ Final phlebitis score 
Days to phlebitis 
















filter l NG 
















3rd Cannulation site 
Cannula NG 
Swab l i Staph:z:lococcus eoidermidis 
ii Bacillus ~ 
Swab 2 NG 















PATIENT - 067 Coloured Female 
DIAGNOSIS Pleural effusion 
Pulmonary tuberculos is 
ALCOHOL INTAKE [I] 
SMOKING ~ 
DAY OF S":'U\J:' 
CANNULATION SITE 
FILTER/ rONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD ?RESSURE mm Hg 
E s R mm.h 
















110 /70 130 / 90 
140 111 
6 5,4 
• ::r,2 ,377 
12 1 12 2 
MEDICINES !Penicillin 2mu IV .6h 
146 







6,3 6 , 7 
,:366 , 357 
12 4 12 
Mic:-obiology 
1st Cannulation site 
r"il ter l NG 
Filter 2 NG 
c;annula NG 































3rd Cannulation site 
NG 
ep iderm id is 
eoidermidis 
(;annula 













80 88 84 
20 22 24 
120/80 120/70 110/60 
115 90 102 
5,4 5,8 5,8 
,4~9 ,407 , 375 
13 6 13 2 2,9 
}Paracetamol lg po .6h 9rn 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
Final phlebitis score 
Days to phlebitis 
• !1ective removal of IV line 
068 'alack Female Age 47 years 
DIAGNOSIS ?yelonephri tis 
Renal failure, chronic end stage 
Hypertension 
ALCOHOL INTAKE [I] 
SMOKING [LI 
NS 




2nd Cannulat ion site 
3,7d 
3+ 
2 , 5 




~D~A~Y;....;C~F_;;S~":'~U1~0~Y---------'---l=--'----'2~__,---..:3.___. _ _;;4'--_.--"'--'---"---'---7'---..._--'8.___.._~.._--; Microbiology 
CANNULATION SITE +--------- lst---------••------2nd-----,t 1st Cannulation site 
\:_::°:-°:-:\·:_:_:.::_.::.:: ./\<·:::>: ·. Filter 1 NG 







E S R 











0 0 l• l+ l+ 2+ 0 + 
38 36,6 36 , 4 36,9 37,3 37 37 6,5 
64 68 60 72 64 60 84 4 
ka 24 20 20 20 24 20 24 
140/100 150/100 160/90 150/100 150/80 160/90 190/120 l1so/ 90 
> 150 > 150 :;,i50 ") 150 130 _ I> 150 
15 11 9,3 7 6,7 , 2 
,278 ,297 .286 ,228 ,289 ,292 
8 9 9 4 9 2 6 S 9 8,3 
iCe tamandole 0mg V h 
1 Fetassiun cnlorice 1. :g r-1 • d I 








L-__3.9__ •Furosemide 40mg oo .d 
t____t4j __ ---·~P~r~a~Z~O~S~l~n...,.4m~g...:.OO;:...b~d;:.....,.... ____________________________ • 
L__~~<!- ---,.,,·-A_t.,.e_n_o_1_0_1_ ..o_o_m_g.._p"-o ~. d=- --~--------------------
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
~ 
IDextropropoxyt,hene 130mg po .6h 
Final phlebitis score 
Days to ~hlebitis 








Filter :l Stapnyloaxc..s eoi.dernud:s 
Filter 4 NG 
Filter 5 NG 
Filte r 6 NG 
Cannula NG 
Swa b . l Bacillus species 
Swab 2 Micrococcus species 
2nd Cannulation si~e 
Cannula NG 
Swab 1 Sta;,oyl.ocoa:ts eoicernu.d:s 
Swab 2 NG 
147 
PATIENT 069 ~lack Female Age 25 years -
DIAGNOSIS Pelvic i nflammatory disease - bacteriological diagnosis not established 
ALCOHOL INTAKE CI] 
SMOKING ~ 








E S R 










xlOq . ! 
.dt 
TOTAL DURATION OF :NFUSION 
-1st-









iAmoicillin 500mg ttv .6h 
1Papaveretum lOmgjIM .4h 
tMei:ronidazole 400mg po .82 
tMef~namic acid 500mg co ~ 
1
s 
05 ! NS I M 
Final phlebitis score 




• Disconi:inued due to blockage of access line 
PATIENT 070 l!lack tllale Age ~4 years Mass 46kg -
DIAGNOSIS Pneumonia - oossibly due to Enterobacter ~ 
Renal failure, acute 
Myositis 
ALCOHOL INTAKE CI] 
SMOKING [I} 
Filter l Staphylococcus epidennidis 
Hlter 2 NG 
Filter 3 NG 
Cannula NG 
Swabs NG 
DAY OF S'!'UDY l 2 Microbiology 
CANNULAT!O,l SITE 
FILTER/ ~ONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE 'C 
PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E s R mm.h 
w B C COUNT xlO~ . t 
HAEMATOCR!T 
HAEMOGLOBIN ". dt 
MEDICINES 
INTRAVENOUS FLUIDS 












tCefamandole lg rv .Sh
1 ?aracei:amol lg po .6h 
I 
NS 
final phlebitis score 






J Discarded by 
) patient 
148 
PATIENT - 071 Coloured Male Age 49 years Mass 57kg 
DIAGNOSIS Pneumonia - Klebsiella oneumoniae 
ALCOHOL INTAKE ~ 
SMOKING c:;] 
DAY Of S,UDY 
CANNULAT!Ol, SITE 
fILTER /CONTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE . m 
RESPIRATORY RATE . m 
BLOOD PRESSURE 
E S R 









2 3 4 
120/70 130/80 120/ 80 120/80 
100 120 103 75 
11,3 9,3 10 8 
,329 ,330 ,267 ,343 
10, 9 10,9 8,7 11 
1cefamandole lg IV .8h 
[Tobramycin 80mg IV . Sh 
LJ Potassium chloride l, 5g IV 














TOTAL DURATION OF INFUSION 
OU'!'COME 
1st Cannulation site 
3,ld 
PATIENT - 072 
Final phlebitis score 
Days to phlebitis 




7 8 9 
150/100 140/90 120/ 70 
132 > 150 140 
7,9 8,4 8,4 
,322 ,337 ,309 
10, 7 11,1 10,3 





1st Cannulation site 
Filter NG 
Filter 2 NG 
Filter 3 Discarded 
Filter 4 NG 
Cannula NG 
Swabs NG 
2nd Cannulation site 
Filter l NG 
Filter 2 NG 
filter 3 NG 
Filter 4 NG 
Filter s NG 
Filter 6 NG 
Cannula i Staphyloo:x:o..s eoi.dernli. ' 
ii Ehterococc.5 spe::ies 
Swabs NG 
DIAG,iOSIS aacterial endocarditis - bacteriological diagnosis not established 
ALCOHOL INTAKE CI] 
SMOKING [2J 








E S R 















TOTAL DURAT:ON OF INFUSION 
l 2 3 
- 1st -
~-::_::._·.-.: .. _::.: i -;·~· :·: ::·,; ... 
l+ 2+ 
36 35,3 
72 74 70 
30 24 20 
140/10 130/0 130 / 30 
48 25 37 
7,6 6,7 7,6 
,413 ,41~ ,375 
12 9 13 11, 9 
IP~nicillin Smu !V .6h 
•Furosemide 80mg oo .d 
•Digoxin 0,25mg po .d 
• 'Slow K' 2 po tds 
F:nal phlebitis score 
Days to phlebitis 
NS 
4 5 6 
82 76 88 
20 24 28 
140/ 0 130/ 30 140/40 
32 38 31 
6,8 7,l 6,8 
,395 
12 
, . 366 , 369 
ll,9 11,9 






1st Cannulation site 
Cannula Staohylococcus epidermidis 
Swab 1 i Micrococcus species 
ii Staphylococcus eoidermidis 
Swab 2 NG 
2nd Cannulation site 
filter 1 Discarded 
Filter 2 IIG 
Filter 3 NG 
Filter 4 NG 
Cannula NG 
S1o1ab Staohylococcus eoider.n1di~ 
Swab 2 NG 





P.~TIENT - 073 Coloured Female Age 63 years Hass tl3kg 
DIAGNOSIS Septicaemia - Escherichi a coli 
Pleural errusion 
ALCOHOL INTAKE [I] 
SMOKING ~ 
DAY OF STUllY l I 2 I 3 I 4 
CANNULATIOtl SITE .-lst--2nd-
fILTER/r.ONTROL PERIOD :;.:.;·.=r:.::::,_·.:\/Y!l/1 ///////////J 
PHLEBITIS SCORE 0 2· 0 2+ 
TEMPERATURE •c . 39,5 38,9 38,4 37,8 
PULSE RATE .m 126 104 110 96 
RESP !RATORY RATE .m 36 30 32 36 
BLOOD PRESSURE mm Hi 140/90 130/90 150/80 160/80 
E s R mm.h 38 - 137 ) 150 
W B C COUNT xlOq. t 18 19,l 16, 3 12,6 
HAEMATOCRIT - ,383 ,360 ,332 
HAEHOGLOB IN sz .dt 12 12,3 11,5 10,9 
MEDICINES 
Microbiology 
1st Cannulation site 
C.:annula NG 
S1"abs NG 











tCefamandole lg IV .Sh 
1 
( Dextroprcpoxypnene 130mg po tds prn 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
H 
Final phlebitis score 




074 Coloured Female Age 49 years 
?yelonepnritis, acute, recurrent 
r-lephroli thiasis 
Congestive cardiac failure 
Angina pectoris 
Hypertension 
ALCOHO L INTAKE [I] 
SMOKING (2) 









DAY Of STUDY l 2 3 4 5 6 7 Micrcbiology 




PULSE RATE .m 
RESPIRATORY RATE . m 
BLOOD PRESSURE mm Hg 
E s R mm . h 
"' a C COUNT xlOq . l 
HAEMATOCR!T 
HA.EMOGLOB IN Sl,dt 
MEDICINES 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
1st 2nd 1st Cannulation site 
:_:_'-,\:\'·-"='·~-< .;:··.:: :::::':;.;:·:).J::,';-~.: ·.-::_: ··,-:-:,.=::.-:-:·:::;:-:::-.-'./;'. ~-.. :.-.1 Cannula Swabs 
) Discarded by 
) ward staff 
0 
1:7 
0 0 0 0 
37,l 37 37,3 36,6 36 
90 92 88 % 108 90 
28 30 30 32 28 30 
100/ 60 125/80 120/70 110/70 160/ 90 150/90 
61 88 79 - - 115 
19,4 13,6 - - - 9,4 
,393 ,406 - - [ ,426 
12 3 12 6 - - 13 5 
jCefamandole l g !V . 6h 
1Paracetamo l l g po . 61'1 
jFurosem i de 40mg oo .d 
D5 
final ?hlebitis score 
Days to phlebitis 
'IS 
1st Cannulation s ite 




















l ..,ard staff 




PATIENT - 075 Coloured Female Age 46 years 
DIAGNOSIS Bronchopneumoni a - Klebs iella spec i es 
Chronic obs t ruc t ive airways disease 
:.!alnutrition 
Anaemia 
ALCOHOL INTAKE 0 
SMOKING 0 
DAY OF STUDY 1 2 
CANNULAT!O:l SITE - 1st___. 
FILTER/ CONTROL PERIOD l/////////ll!/1, 
PHLEBITIS SCORE l+ 13+ 
TEMPERATURE •c 36,6 36,2 
PULS E RATE .m 76 76 
RESPIRATORY RATE .m 24 20 
BLOOD PRESSURE mm Hg 110/70 110/ 60 
E S R mm.h 104 109 
W B C COUNT x10\ t 7,3 6,9 
HAEMATOCRIT ,310 ,288 
HAEMOGLOBIN c, . dt 9,5 9,6 
MED ICINES L- .lZ<! ';_Penicillin !nu w .6hf 
L- _lJ~+l'1!1:rt:nic!azole '°?"3 co tos, 
I Sd+ 'Slow K' 2 co tds 
I i?d .sal.rutarel Neb .6h 
I !7 ~ ~Thianine l.COng CO • d 
INTRAVENOUS FLUIDS NS 
TOTAL DURAT ION OF INFUSION 
PATIENT 076 -
Final phlebitis score 
Days to phlebitis 




Filter l NG 







DIAGNOSIS l.Obar pneumonia - Streotococcus pneumoniae 
ALCOHOL INTAKE 0 
SMOKING [!] 
DAY Of STUDY 
CANNULAT!O:i SITE 




RESP IRATORY RATE 
BLOOD PRESSURE 
E S R 









xlOq . t 
". d t 
TOTAL DURATION OF IN FUSION 
I 2 3 
~-:,_=: :?/:) .. \;:.: ::·;: :::,::-::I 
0 l+ l+ 
36 36 37,2 
110 112 110 
32 32 28 
110/70 100/70 120 /80 
63 84 118 
17,7 9,8 7 
,414 , 380 ,375 
13,6 13,7 12,B 
!Penic i ll i n 2mu IV . 5h 
t' Codis ' 2no .6h 
I 
Final phlebitis score 
Days to phlebi ti s 
I 
I 
• Discontinued due to blockage o t· access line 







PATIENT 077 Coloured Male Age 15 years Mass 32kg -
DIAGNOSIS Lobar pneumonia - bacteriological diagnosis not established 
ALCOHOL INTAKE GJ 
SMOKING ~ 
DAY OF S7UDY 
CANNULAT!ON SITE 
FILTER/<":O NTROL PERIOD 
PHLEBITIS SCORE 
TEMPERATURE •c 
PULSE RATE .m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E s R mm . h 





TOTAL DURATION OF INFUSION 
l 2 3 4 
1st 
;-:-:-::,::::?.·:··:-,,:~::ii/\:::\::-.·:-:::.:··:::! 
0 0 0 
36 36,4 36,1 
90 84 88 
24 24 24 
110/70 110/60 110/70 
> 150 139 83 
10,4 6,1 6,7 
,336 ,324 ,360 
12,2 11,3 11,8 
tPenicillin 2mu IV .6h 
J'Codis ' 2 po .6h 
NS 
Final phlebitis score 













• Elective removal of IV line 
PATIENT 078 Coloured Male Age 42 years Mass 57kg -
DIAGNOSIS Lobar pneumonia - Streptococcus pneumoniae 
Gou, 
ALCOHOL INTAKE ~ 
SMOKING ~ 





CANNULAT!m; SITE - lst--2nd--3rd-
FILTER/ ,ONTROL PERIOD /::/,·\·\,:;il·?l/ '!!///// l////1// 1/////// /;1 
PHLEBITIS SCORE 0 2+ 0 0 0 0 
TEMPERATURE •c 40,3 35.9 36, 3 37,2 37,5 36,l 
PULSE RATE .m 98 80 76 72 64 70 
RESPIRATORY RATE .m 28 28 28 24 24 20 
BLOOD PRESSURE mm Hg 110/ 55 110/60 110/60 130/90 120/ 80 110/60 
E s R mm.h > 150 146 112 > 150 > 150 > 150 
w a C COUNT xlOq . t 27,8 16 11,l 7,3 8,8 6,7 
HAEMATOCRIT ,399 ,427 ,3SO ,366 
1'358 ,297 
HAEMOGLOBIN lZ.dt 14 2 14,5 12.l 12.3 11,8 il 
MEDICINES ICeftazidime lg IV .Sh 
1Asp1r in 600mg ~o .6h prn 
Microbiology 












3nd giving set used ~or 3rd cannula"icr 
site 
) Discarded by ,,.ard staff 
3rd Cannulation site 
filter 2 Staehvlococcus eoidermidis 
filter 3 S taoh:i: iococcus eoidermidis 
Filter 4 Staohzlococcus eotdermidi~ 
filter 5 Staohvlococcus eo 1dermidis 
Cannula NG 
Swabs NG 
!Indomethac in 25mg oo cds 1 
LJPotassium chloride l,Sg IV 
[ Klor,ef' l ~o tds 
INTRAVENOUS FLUIDS 
TOTAL DURATION OF INFUSION 
Final phlebitis score 
Days to phlebieis 
• Disconeinued due to blockage of access line 
0 Elective removal of IV line 








3rd Cannulation site 
l, 9d 0 
0 
N/A 
079 Coloured :.!ale Age 25 :rears 
DIAGNOSIS ?newnonia - vi ral 
ALCOHOL INTAKE ~ 
SMOKING ~ 





c:annula NG CANNULAT !O:, SITS 







E S R 







x101 . ! 
HAEMOGLOBIN 11.d! 








13 3 13,4 
MEDICINES tCefararl:>le l,3t l'l) .6h 
1 fffll.cillin aru r,; pi 
I ?aracet:aml 13 oo .5h • 
INTRAVENOUS FLUIDS ~ 
TOTAL DURATION Of INFUSION 
Final phlebitis score 
Days to phlebitis 




• Discontinued due to blockage of acces s line and local pa in 
PATIENT 080 Black female Age 30 years Mass 62kg -
DIAGNOSIS Bronchial asthma 
Chronic bronchitis 
ALCOHOL INTAKE ~ 
SMOKING [[] 





PULSE RATE . m 
RESPIRATORY RATE .m 
BLOOD PRESSURE mm Hg 
E S R mm.h 





TOTAL DURATION OF !NFUSION 
1 2 
.,__ ls 1: ---. 
;-:::~ :.\,::-:_:·:•?J 
0 0 








1Hydrocort1sone 200mg rv 




L....JHexoprenaline 5µg rv 
.._~~~~_. Amoxycillin 250mg po tds 
~~~~~- Hexoprenaline 0, 5mg subling . 6h 
~~~~~- Salbutamol ~eb .4h 
05 
F~nal phlebitis score 








8 FEB 5 
Patient Diagnosis Age in Sex Group Duration of Reason for 
number years F/C rv therapy i:-emoval 
h from stud 
003 Pneumonia 57 M C 13 4 
017 31 M C 10 4 
C 24 3 
C 29 3 
C 18 3 
021 31 F ? 24 2 
022 62 M C 26 2 
027 38 M F 21 3 
F 19 3 
C 11 5 
029 41 M C 18 3 
030 Lung abscess 30 M F 28 3 
F 22 3 
056 Pneumonia 18 M F 20 3 
057 Lung abscess 34 M F 5 3 
061 Vagotomy and antrectomy 31 M C 22 3 
C 25 4 
070 Pneumonia 24 M F 15 5 
073 Septicaemia 63 F C 24 4 
101 Total abdominal hysterectomy 44 F C 12 l 
102 41 F C 24 2 
103 42 F F 25 2 
104 65 F F 24 4 
F 24 4 
105 27 F C 15 4 
C 15 4 
106 47 F C 20 4 
C 18 2 
107 Pelvic inflamma tory disease 31 F C 12 2 
108 Total abdominal hysterectomy 33 F C 24 6 
109 42 F C 24 6 
110 42 F F 24 2 
111 Pneumonia 41 M F 24 2 
112 19 M F 24 4 
F 24 4 
F 24 4 
F 24 3 
C 18 4 
113 Laparotomy, tube-ovarian abscess 24 F F 24 6 
114 Pneumonia 29 F C 12 2 
115 44 M F 4 5 
116 Caesarian section and laparotomy 27 F F 24 3 
Peritonitis 
117 Pancreatitis 41 M C 20 4 
Septicaemia C 21 4 
C 17 3 
C 26 3 
118 Cholecystectomy 60 F f 23 4 
F 23 3 
119 Lung abscess 23 F C 28 3 
C 14 2 
120 Diarrhoea and vomiting 72 F F 18 3 
121 ?elvic inflammator y disease 56 F C 29 2 
122 Cerebrovascular accident - 51 F C 24 2 
arteriovenous malformation 
123 Pneumonia 51 M F 3 3 
F 3 3 
F 24 3 
124 52 M F 19 3 
125 'Mound sepsis - resistant 27 M ' 22 3 Staohylococcus aureus 9 3 
126 Congestive cardiac~e 60 F C 29 4 
Celluli tis 
127 Bronchitis 55 M F 14 2 
128 Pneumonia 43 F C 25 l 
